Small molecule inhibitors of KRAS G12C mutations
Heteroaryl compounds are developed to selectively inhibit KRAS(G12C) protein, addressing the lack of effective treatments for cancers with KRAS G12C mutations, demonstrating high potency and potential for treating non-small cell lung cancer and other KRAS-related malignancies.
Patent Information
- Application Number
- JP2023137630
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-05-26
- Filing Date
- 2023-08-25
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2040-10-27
AI Technical Summary
Current treatments for cancers with KRAS G12C mutations, such as non-small cell lung cancer, lack effective compounds to inhibit the KRAS G12C variant, necessitating the development of improved therapeutic agents.
Development of heteroaryl compounds and their pharmaceutically acceptable salts that selectively inhibit the KRAS(G12C) protein, modulating its activity and affecting signal transduction pathways associated with cell growth and proliferation.
The compounds demonstrate high intracellular potency with IC50 < 100 nM and potential for effective treatment of cancers with KRAS G12C mutations, including non-small cell lung cancer, pancreatic cancer, and other KRAS-related malignancies.
Smart Images

Figure 0007595127000001 
Figure 0007595127000002 
Figure 0007595127000003
Abstract
Description
[Technical Field]
[0001] This application is a continuation of U.S. Provisional Patent Application No. 62 / 926,87, filed October 28, 2019. No. 9 and U.S. Provisional Patent Application No. 63 / 030,014, filed May 26, 2020 and US Provisional Patent Application Publication No. 2006 / 0110299, each of which is incorporated herein by reference in its entirety. .
[0002] The present disclosure provides a method for inhibiting the G12C mutant form of the Kirsten rat sarcoma (KRAS) protein, Certain particular compounds are expected to have utility as therapeutic agents, for example for the treatment of cancer. This application also relates to certain heteroaryl compounds and pharmaceutically acceptable salts thereof. , pharmaceutical compounds containing such compounds, and the use of such compounds to treat cancer - Patents.com Regarding the method. [Background technology]
[0003] RAS proteins are membrane-bound guanine nucleotide-binding proteins that function as molecular switches RAS proteins mediate cell proliferation, survival, and differentiation from cell surface receptors. RAS functions as a component of signal transduction pathways that transmit signals to regulate oxidization. The protein cycles between an inactive GDP-bound state and an active GTP-bound state.
[0004] The most notable members of the RAS subfamily are HRAS, KRAS, and NRAS. It is primarily involved in many types of cancer. However, there are many other members DIRAS1;DIRAS2;DIRAS3;ERAS;GEM;MRAS ;KIRAS1;KIRAS2;NRAS;RALA;RALB;RAPIA;RAPI B;RAP2A;RAP2B;RAP2C;RASD1;RASD2;RASL10A; RASL10B;RASL11A;RASL11B;RASL12;REM1;REM2 ;RERG;RERGL;RRAD;RRAS and RRAS2.
[0005] Among these, the three major isoforms of RAS (HRAS, NRAS, or KRAS) Mutations in any one of these genes are the most common event in human tumorigenesis. KRAS mutations are detected in 25-30% of tumors. In comparison, NRAS and much lower rates of oncogenic mutations occur in HRAS family members (8 and 9, respectively). % and 3%).
[0006] The exchange of the 12th residue of RAS, glycine, for cysteine (G12C mutation) It is caused by a common mutation in the gene. A large-scale cancer sequencing study found that the G12C mutation The most frequent abnormalities were found in lung, colorectal, and pancreatic cancers. Histological analysis of two types of cancer revealed that non-small cell lung cancer harbors the KRAS G12C mutation It has been shown to be the largest contributor to 70-75% of cancer cases. .R.,et al.,Br J Cancer 121,197-198(2019) reference.
[0007] Thus, while progress has been made in this field, there are still many advances in the art, e.g., in mutant KRAs. S, HRAS, or NRAS proteins (e.g., KRAS G12C) There remains a need for improved compounds and methods for the treatment of cancer. The disclosed embodiments fulfill this need and provide further related advantages. [Prior art documents] [Non-patent literature]
[0008] [Non-Patent Document 1] Lindsay,CR,et al.,Br J Cancer 121,197-198(2019) Summary of the Invention
[0009] The present disclosure provides a method for the preparation of mutant KRAS, HRAS and / or NRAS proteins. The present invention provides compounds that can be valuable pharmaceutically active compounds for the treatment of cancer. In embodiments, the compounds of the present disclosure selectively inhibit the KRAS(G12C) protein. Compounds of formula (I) [ka]
[0010] and pharmaceutically acceptable salts thereof, which inhibit the activity of KRAS, HRAS and / or NR Modulation of AS activity, thereby inhibiting cell growth, differentiation, and proliferation associated with oncological disorders. In certain embodiments, the compound of formula The compound of formula (I) can inhibit the KRAS(G12C) protein. , methods for preparing compounds of formula (I), methods for using such compounds to treat oncological disorders The present invention also provides methods for use in treating rheumatoid arthritis and pharmaceutical compositions comprising compounds of formula (I). DETAILED DESCRIPTION OF THE INVENTION
[0011] Compounds of the Disclosure In embodiment no. 1, the present disclosure provides a compound of structural formula (I) as shown above. During the ceremony: Y is N or C(H); Z is N or C(R 5 ) and; M is C or N; The dotted line in the depicted ring containing M indicates an optional double bond; L is C1-C7 alkylene or C1-C7 heteroalkylene; wherein the alkylene or heteroalkylene is unsubstituted or oxo , fluoro, C1-C3 alkyl, C1-C3 fluoroalkyl, amino and hydroxy is substituted with 1 to 5 substituents independently selected from ; Alternatively, two geminal or vicinal alkylenes or heteroalkylenes may be Or hominal substituents may be bonded together with the carbon atom to which they are attached. Nattekan C L wherein the ring C L is a C3-C6 cycloalkyl wherein the ring C L is unsubstituted or substituted with 1 to 3 fluoro; R 1 is halo, H, C1-C4 alkyl, C1-C4 fluoroalkyl or C1-C 4 hydroxyalkyl; R 2 is H, CH3 or halo; Each R 3 are independently: (a) C1-C4 alkyl, C1-C4 cyanoalkyl, C1-C4 fluoroalkyl , C1-C4 hydroxyalkyl, C1-C4 alkylphenyl, oxo or carboxy Is it si; (b) Alternatively, two R 3 The substituents are integral with the carbon atoms to which they are attached. to form a 3-6 membered bicyclo or spirocyclic ring system having the ring shown containing M. It's okay to have it; W 1 is -C(O)- or -S(O)2-; W 2 is the expression: [ka]
[0012] is the basis of; During the ceremony W 2a is H, CH3, F, cyano, CH2OH, CH2CH2OH or CH2Br and; W 2b is CH3, CH2NH2, CH2N(H)CH3, CH2N(CH3)2, C H2-NH-cyclopropyl, [ka]
[0013] and; R 4 is H, C1-C4 alkyl or C3-C5 cycloalkyl; R 5 is H or halo; Ring C y teeth: (a) phenyl, (b) a 5- to 6-membered monocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S; heteroaryl; or (c) a 9- to 10-membered bicyclic ring containing 1 to 4 heteroatoms selected from N, O, and S; Heteroaryl of and; Each R y are independently selected from halo, hydroxy, C1-C3 alkyl, C1-C3 fluoro alkyl, C1-C3 alkoxy, cyano, hydroxy or C1-C3 hydroxyalkyl It is; Ring C z teeth: (a) phenyl, or (b) a 5- to 6-membered heteroaromatic group containing 1 to 3 heteroatoms selected from N, O, and S; reel and; Each R z are independently selected from halo, hydroxy, C1-C3 alkyl, C1-C3 fluoro alkyl, C1-C3 alkoxy, cyano, or C1-C3 hydroxyalkyl; The subscript m is 0, 1, 2, or 3; The subscript n is 0, 1, 2, 3, or 4; The subscript q is 0, 1, 2, 3, or 4; The subscript r is either 0 or 1 or a pharmaceutically acceptable salt thereof.
[0014] In embodiment number 2, [ka] The basis of [ka]
[0015] and; Each R 3 are independently: (a) C1-C4 alkyl, C1-C4 cyanoalkyl, C1-C4 fluoroalkyl , C1-C4 hydroxyalkyl, C1-C4 alkylphenyl, oxo or carboxy Is it si; (b) Alternatively, two R 3 The substituents are integral with the carbon atoms to which they are attached. to form a 3-6 membered bicyclo or spirocyclic ring system having the ring shown containing M. It's okay to have it; Each R y are independently selected from halo, hydroxy, C1-C3 alkyl, C1-C3 fluoro alkyl, C1-C3 alkoxy, cyano, hydroxy or C1-C3 hydroxyalkyl It is. The remaining variables are as shown in embodiment number 1.
[0016] In embodiment number 3, the present disclosure provides a compound in which L is -X 1 -X 2 -X 5 -X 4 -X 3 - a group where: X 1 and X 3 are independently -CH2-, -O-, -S-, -C(O)-, -C(H) (CH3)- or -N(H)-; X 2 are -CH2-, -CF2-, -C(H)(F)-, -C(H)(OH)-, -C (H)(CH3)-, -O-, -S-, -N(H)-, or -C(O)-; X 4 is absent or -CF2-, -C(H)(F)-, -C(H)(OH)-, - C(H)(CH3)-, -CH2-, -O-, -S-, -N(H)- or -C(O)- and; X 5 is absent or -CH2-, -CF2-, -C(H)(F)-, -O-, -S -, -N(H)-, -CH2CH2-, -CH2CH2CH2-, -O-CH2-, -C H2-O-; where: X 1 is -O-, -S- or -N(H)-, X 2 is -CH2- or -C( O)- and; X 2 is -O-, -S- or -N(H)-, X 1 is -CH2- or -C( O)- and X 5If present, -CH2-, -CF2-, -CH2CH2- or or -CH2CH2CH2-; X 3 is -O-, -S- or -N(H)-, X 4 is -CH2- or -C( O)- and; X 4 is -O-, -S- or -N(H)-, X 3 is -CH2- and X 5 If present, is -CH2-, -CH2CH2- or -CH2CH2CH2- the law of nature; X 5 is -O-, -S- or -N(H)-, X 2 and X 4 Both are -CH 2- and; and the remaining variables are as set forth in embodiment number 1 or 2. Embodiment No. 3 and L are -X 1 -X 2 -X 5 -X 4 -X 3 -Other bases In some embodiments, X 1 is ring C y is bonded to X 3 is ring C z is bonded to.
[0017] In embodiment number 4, the present disclosure provides a compound wherein L is: -O-CH2CH2CH2-O-; -CH2CH2CH2-O-; -O-CH2CH2CH2-; -OC(H)(CH3)CH2CH2-; -O-CH2CH2CH2CH2-; -O-CH2CF2CH2CH2-; -CH2CH2CH2CH2-O-; -CH2CH2CH2CH2-; -CH2CH2CH2-; -CH2CH2C(H)(OH)CH2-; -CH2C(H)(OH)CH2CH2-; -O-CH2CH2-; -CH2CH2-O-; -O-CH2CH2-O-; -O-CH2C(H)(CH3)-O-; -OC(H)(CH3)CH2-O-; -O-CH2CF2CH2-O-; -CH2CH2-O-CH2CH2-; -O-CH2CH2-O-CH2CH2-O-; -CH2-O-CH2CH2-; -CH2CH2-O-CH2-; -N(H)-CH2CH2CH2-; -O-CH2CH2-O-CH2-; -C(O)-N(H)-CH2CH2CH2-; -CH2CH2CH2-N(H)-C(O)-; -N(H)-CH2CH2-O-CH2-; [ka] or [ka]
[0018] and the remaining variables are as set forth in embodiment number 1 or 2. In these groups, the leftmost linking atom is the ring C. y is bound to The rightmost connecting chain atom is ring C z is bonded to.
[0019] In embodiment number 5, the present disclosure provides a compound wherein L is: -O-CH2CH2CH2-O-; -CH2CH2CH2-O-; -O-CH2CH2CH2-; -O-CH2CH2CH2CH2-; -CH2CH2CH2CH2-; -O-CH2CH2-; -O-CH2CH2-O-; -O-CH2CF2CH2-O-; -CH2CH2-O-CH2CH2-; -C(O)-N(H)-CH2CH2CH2-; or -CH2-O-CH2CH2- and the remaining variables are as set forth in embodiment nos. 1 or 2. to provide.
[0020] In embodiment number 6, the present disclosure provides a compound having -X 1 -X 2 -X 5 -X 4 -X 3 -of Based on: -O-CH2CH2CH2-; -O-CH2CH2CH2CH2-; -O-CH2CH2-O-; or -O-CH2CF2CH2CH2- and the remaining variables are as set forth in embodiment nos. 1 or 2. to provide.
[0021] In embodiment number 7, the present disclosure provides a compound in which R 1 is fluoro, and the remaining variables provides a compound of formula (I) as shown in any one of embodiment numbers 1 to 6. .
[0022] In embodiment no. 8, the present disclosure provides a compound in which R 2 is fluoro or chloro, The remaining variables are as set forth in any one of embodiment numbers 1 to 7. Provide something.
[0023] In embodiment number 9, the present disclosure provides a compound in which R 4 is H or isopropyl, The remaining variables are as set forth in any one of embodiments 1 to 8. Provide something.
[0024] In embodiment number 10, the present disclosure provides a compound according to the present invention, wherein the subscript m is 0, 1, or 2. and the remaining variables are as set forth in any one of embodiments 1 to 9. A compound is provided.
[0025] In embodiment number 11, the present disclosure provides a compound according to the present invention, wherein the subscript m is 0 or 1, The remaining variables are as set forth in any one of embodiment numbers 1 to 9. Provide something.
[0026] In embodiment no. 12, the subscript m is 0 and the remaining variables are the same as in embodiment no. 1. As shown in any one of the above.
[0027] In embodiment no. 13, the subscript m is 1 and the remaining variables are those of embodiment no. 1. As shown in any one of the above.
[0028] In embodiment no. 14, the subscript m is 2 and the remaining variables are the same as in embodiment no. 1. As shown in any one of the above.
[0029] In embodiment number 15, the present disclosure provides 3 is methyl or -CH2-CN The remaining variable parts are as shown in any one of embodiment numbers 1 to 9. Compounds of formula (I) as shown in Figure 10, 11, 13 or 14 are provided.
[0030] In embodiment no. 16, the present disclosure provides a method for preparing a compound having the formula: Provided is a compound of formula (I) as shown in any one of Form Nos. 1 to 15.
[0031] In embodiment number 17, the present disclosure provides a compound having the formula [ka]
[0032] In the group, there is no double bond, M is N, and the remaining variables are 5.
[0033] In embodiment number 18, the present disclosure provides a compound having the formula [ka] The basis of [ka]
[0034] and the remaining variables are as set forth in embodiment no. 1. do.
[0035] In embodiment 19, the present disclosure provides a compound having the formula [ka] The basis of [ka]
[0036] and; wherein there is no double bond, M is N, and the remaining variables are any of Embodiments 1 to 15. As shown in one A compound of formula (I) is provided.
[0037] In embodiment number 20, the present disclosure provides a compound having the formula [ka] The basis of [ka]
[0038] The remaining variable parts are as shown in any one of the first to fifteenth embodiments.
[0039] Compounds of formula (I) are provided as shown in embodiment number 19.
[0040] In embodiment number 21, the present disclosure provides a compound having the formula [ka] The basis of [ka]
[0041] and the remaining variable parts are as shown in any one of the embodiments 1 to 15. Compounds of formula (I) as shown in embodiment no. 19 are provided.
[0042] In embodiment No. 22, the present disclosure provides a compound in which C y is phenyl or N 5-6 membered monocyclic heteroaryl rings containing 1-3 heteroatoms selected from O and S the remaining variables are as shown in any one of embodiments 1 to 21. A compound of formula (I) is provided.
[0043] In embodiment number 23, C y is phenyl, and the remaining variables are embodiment numbers 1 to As shown in any one of 22.
[0044] In embodiment number 24, the present disclosure provides a compound having the formula [ka] The basis of [ka]
[0045] The remaining variable parts are those shown in any one of embodiment numbers 1 to 6 and 8 to 21. The present invention provides a compound of formula (I):
[0046] In embodiment number 25, the present disclosure provides a compound having the formula [ka] The basis of [ka]
[0047] The remaining variable parts are those shown in any one of embodiment numbers 1 to 6 and 8 to 21. The present invention provides a compound of formula (I):
[0048] In embodiment number 26, the present disclosure provides a compound in which C z is phenyl or N 5-6 membered monocyclic heteroaryl rings containing 1-3 heteroatoms selected from O and S the remaining variables are as set forth in any one of embodiments 1 to 25. A compound of formula (I) is provided.
[0049] In embodiment number 27, C z is phenyl or pyridine, and the remaining variables are real This is as shown in any one of embodiment numbers 1 to 26.
[0050] In embodiment number 28, the present disclosure provides a compound having the formula [ka] The basis of [ka]
[0051] and the remaining variables are as set forth in any one of embodiments 1 to 25. (I)
[0052] In embodiment number 29, [ka] The basis of [ka]
[0053] and the remaining variable parts are as shown in any one of the embodiments 1 to 25.
[0054] In embodiment number 30, the present disclosure provides a method for preparing a compound having the formula: Provided is a compound of formula (I) as shown in any one of Form Nos. 1 to 29.
[0055] In embodiment number 31, the present disclosure provides a method for preparing a compound having the formula: Provided is a compound of formula (I) as shown in any one of Form Nos. 1 to 30.
[0056] In embodiment number 32, the present disclosure provides a compound having the formula [ka] The basis of [ka]
[0057] and The remaining variables are as shown in any one of embodiments 1 to 29. A compound of formula (I) is provided.
[0058] In embodiment number 33, the present disclosure provides: In the formula [ka] The basis of [ka]
[0059] and The remaining variables are as shown in any one of embodiments 1 to 29. A compound of formula (I) is provided.
[0060] In embodiment number 34, the present disclosure provides a method for producing a compound according to the present invention, wherein the subscript r in the formula is 0 and the remaining possible The variable parts are as shown in any one of the embodiments 1 to 27 and 30 to 33. I)
[0061] In embodiment number 35, the present disclosure provides a compound in which the subscript r is 1 and the remaining possible The variable parts are as shown in any one of the embodiments 1 to 27 and 30 to 33. I)
[0062] In embodiment number 36, the compound of formula (I) is of formula (IA) [ka]
[0063] and In the formula, -X1 -X 2 -X 5 -X 4 -X 3 The - group is as shown in embodiment number 3. ; Each R 3 and each R y is as shown in embodiment number 2; R 1 , R 2 , R 4 , R z , Y, Z, Ring C y , ring C z and the subscripts m, n and q is as shown in embodiment number 1.
[0064] In the compound of embodiment number 37 having formula (IA), -X 1 -X 2 -X 5 -X 4 - X 3 The - group is as shown in embodiment number 5.
[0065] In embodiment number 38, the present disclosure provides a compound comprising: [ka]
[0066] The group is as shown in embodiment number 21, [ka]
[0067] The group is as shown in embodiment number 32, [ka]
[0068] The group is as shown in embodiment number 28, [ka]
[0069] The group is as shown in embodiment number 25, L is as shown in embodiment number 5 A compound of formula (IA) is provided:
[0070] In embodiment number 39, the present disclosure provides a compound of formula (IB) [ka]
[0071] and During the ceremony: C y is phenyl; C z is pyridyl; X 3 is -CH2- or -O-; X 5 is absent, -CH2-, -CF2- or -C(H)(F)-; R 1 is fluoro or chloro; R 2 is fluoro or chloro; R 4 is C1-C4 alkyl; The remaining variables are as shown in embodiment number 1. A compound of formula (I) is provided.
[0072] In embodiment No. 40, the compound has the formula (IB) -O-CH2-X 5 -CH 2-X 3 -The group is: -O-CH2CH2CH2-; -O-CH2CH2CH2CH2-; -O-CH2CH2-O-; or -O-CH2CF2CH2CH2- and; The remaining variables are as shown in embodiment number 39.
[0073] In embodiment No. 41, the compound has the formula (IB) -O-CH2-X 5 -CH 2-X 3 The - group is -O-CH2CH2CH2-.
[0074] In embodiment No. 42, the compound has the formula (IB) -O-CH2-X 5 -CH 2-X 3 The - group is -O-CH2CH2CH2CH2-.
[0075] In embodiment No. 43, the compound has the formula (IB) -O-CH2-X 5 -CH 2-X 3 The - group is -O-CH2CH2-O-.
[0076] In embodiment No. 44, the compound has the formula (IB) -O-CH2-X 5 -CH 2-X 3 The - group is -O-CH2CF2CH2CH2-.
[0077] In embodiment No. 45, the compound has the formula [ka]
[0078] The basis of [ka]
[0079] and; -O-CH2-X 5 -CH2-X 3 - group in any one of embodiments 39 to 44 the remaining variables are as shown in embodiment number 39. It has the formula (IB).
[0080] In embodiment No. 46, the compound has the formula [ka] The basis of [ka]
[0081] and; [ka]
[0082] is as shown in embodiment number 39 or 45; -O-CH2-X 5 -CH2-X 3 - group in any one of embodiments 39 to 44 the remaining variables are as shown in embodiment number 39. It has the formula (IB).
[0083] In embodiment No. 47, the compound has the formula [ka] The basis of [ka]
[0084] and having formula (IB) as shown in embodiment number 39 or 46, wherein
[0085] In embodiment 48, the present disclosure provides examples 1 to 20, 50 to 60 as shown below. 52, 54 to 68, 70 and 73 to 126, or Pharmaceutically acceptable salts thereof are provided.
[0086] In some embodiments, the present disclosure provides compounds with high intracellular potency (e.g., phospho-ERK The assay yielded an IC50 <100 nM with a 2-hour incubation time. A low estimated human oral dose (e.g., <500 mg orally once daily, preferred) <200 mg), and excellent preclinical pharmacokinetic and stability properties (e.g., Measurement of compound concentrations in rat and dog plasma and in plasma clearance studies The present invention provides a compound having the formula (I).
[0087] The present disclosure also provides pharmaceutically acceptable salts of the compounds defined herein, e.g., Pharmaceutically acceptable salts of any of the structural formulas, embodiments and classes defined in the document are also included. Reference to compounds of structural formula (I) includes compounds of other general structural formulas, such as formula (IA) and (IB) as well as embodiments within the scope of formula (I).
[0088] definition Unless otherwise defined, all technical and scientific terms used herein refer to the art to which this invention belongs. It has the same meaning as commonly understood by those skilled in the art.
[0089] As used throughout this disclosure, "a compound of formula (I)" means "a compound of formula (I) or It is to be understood that the term "compounds of formula (I)" encompasses "compounds of formula (I) or pharmaceutically acceptable salts thereof." "Compound" refers to "a compound of formula (IA)" and "a compound of formula (IB)" (as well as a compound of formula (IA) ) and pharmaceutically acceptable salts of the compounds of formula (IB). .
[0090] "Alkyl" as well as other groups having the prefix "alk", such as alkoxy, are defined in Table 1. means a carbon chain which may be linear or branched or a combination thereof, containing the number of carbon atoms indicated. In certain embodiments, straight chain alkyl groups have 1 to 6 carbon atoms, and branched chain alkyl groups have 1 to 6 carbon atoms. The group has 3 to 7 carbon atoms. Examples of alkyl groups are methyl, ethyl, and propyl. , isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl Examples of alkyl groups include ethyl, octyl, and nonyl.
[0091] "Alkylene" refers to an optionally substituted alkylene group. Numerical ranges may be indicated. For example, C3-C4 alkylene means 3 or 4 alkylenes. Unless otherwise stated in this specification, an alkylene group has a chain length of 1,000,000 atoms. The carbon atoms in the group are independently selected from oxo, fluoro, C1-C3 alkyl, C1-C3 fluoro, and optionally substituted with one or more substituents selected from the group consisting of alkyl, amino, and hydroxy. or two geminal, vicinal or hominal substitutions have the substitution They may also form a C3-C6 cycloalkyl together with the adjacent carbon atoms.
[0092] "Alkoxy" and "alkyl-O-" are used interchangeably and refer to alkyl groups linked to oxygen. represents an alkyl group.
[0093] "Alkylphenyl" refers to a C1-C4 alkyl substituted with a phenyl group. The phenyl group may be located anywhere on the carbon chain, for example, at the end of the carbon chain.
[0094] A "bicyclic ring system" refers to two connected rings. The rings are fused, i.e., two adjacent rings are connected together. They can share atoms, or they can be "spirocyclic," meaning they share only one atom. Good too.
[0095] "Cyanoalkyl" refers to an alkyl group substituted with a cyano group.
[0096] "Cycloalkyl" means a cyclic saturated hydrocarbon group. The cycloalkyl group has 3 to 12 carbon atoms and is fused to one to three carbocyclic rings. It is being formed.
[0097] Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopropyl ... Examples include dihexyl, cycloheptyl, and adamantyl.
[0098] "Fluoroalkyl" refers to mono- and polyfluoro-substituted alkyls up to perfluoro-substituted alkyls. Fluoromethyl, 1,1-difluoroethyl, and 1,1-difluoroethyl are examples of substituted alkyl groups. , trifluoromethyl or 1,1,1,2,2-pentafluorobutyl.
[0099] "Geminal substitution" refers to the substitution moieties (e.g., functional groups) being attached to the same atom in a molecule. For example, 1,1-dichloroethane is substituted with two geminal chlorine atoms. The ethane molecule is
[0100] The term "heteroalkylene" refers to a heteroalkyl group that is heterocyclic or heterocyclic, and that is substituted with an atom other than carbon, such as oxygen, nitrogen, or sulfur. an optionally substituted alkylene radical having one or more atoms in the backbone chain selected from the group consisting of It may also indicate a range of values that indicate the total chain length. For example, C1 to C 7 Heteroalkylene has a chain length of 1 to 7 atoms. For example, -OCH2CH2CH2 The O-group is called a "C5 heteroalkylene" and contains two heteroatoms within the stated chain length. The remainder of the molecule (e.g., C y and C z The bond between the ring atoms is heteroalkylene. through a carbon, nitrogen, oxygen or sulfur atom at a terminal end of the chain. The group may be optionally substituted. Unless stated otherwise in the specification, heteroalkyl The fluoro group is a group in which the carbon atoms in the group are independently oxo, fluoro, C1-C3 alkyl, C1 substituted with one or more substituents selected from C1 to C3 fluoroalkyl, amino, and hydroxy; or two geminal, vicinal or hominal substitutions The carbon atom bearing the substituent may together with the substituent form a C3-C6 cycloalkyl. In some embodiments, the heteroalkylene group may contain at least one nitrogen atom and at least one oxygen atom in the chain of atoms. In some embodiments, the heteroalkylene group has 1 to 2 heteroatoms selected from the group consisting of: has one heteroatom selected from a nitrogen atom and an oxygen atom in the atom chain.
[0101] "Heteroaryl" means an aryl group in which one or more atoms in the ring are an element other than carbon (one or more atoms in the ring are an element other than carbon). Aromatic monocyclic and bicyclic ring structures containing one or more heteroatoms. is typically an O, S or N atom. Examples of heteroaromatic groups include pyridinyl, ... rimidinyl, pyrrolyl, pyridazinyl, isoxazolyl, thiazolyl, oxazolyl, Includes indolyl, benzoxazolyl, benzothiazolyl and imidazolyl.
[0102] "Halogen" or "halo" refers to fluorine (fluoro), chlorine (chlorine), unless otherwise specified. In one embodiment, halo is a bromine (bromo) and iodine (iodo). is fluoro (-F) or chloro (-Cl).
[0103] "Hominally substituted" means that the substituents or groups are bonded in a 1,3-relationship within the molecule. For example, 1,3-dichloropropane ClCH2CH2CH2Cl is It is a propane molecule substituted with two chlorine atoms.
[0104] "Hydroxyalkyl" includes mono- and multiply hydroxy-substituted alkyl groups. There are.
[0105] Any variable part (e.g., R 3 , R y etc.) may be included within or within any component herein. or more than one time in formula (I) or other general formula, its meaning for each occurrence shall be The definition of any one of the substituents and / or substituents is independent of the definition of any other of the substituents and / or substituents in any ... Combinations of variables are permissible only if such combinations result in stable compounds. In selecting compounds of the present disclosure, one of skill in the art will appreciate the connectivity and stability of the chemical structure. Various substituents conforming to known principles, i.e., R 3 , R y etc. should be selected. Unless expressly stated otherwise, substitution by a specified substituent means Any within a ring (e.g., an aryl, heteroaryl ring, or saturated heterocycloalkyl ring) Although the ring atoms are permissible, such ring substitutions must be chemically feasible and must not result in stable compounds. A "stable" compound is one that can be prepared and isolated and whose structure and structure can be determined. and properties suitable for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject). remain essentially unchanged for a period of time sufficient to permit use of the compound for or a compound that can be made to remain essentially unchanged.
[0106] The term "substituted" is deemed to include multiple degrees of substitution with a specified substituent. When multiple substituent moieties are disclosed or claimed, The substituted compounds may contain one or more substituent moieties of the present disclosure or the claimed substituents. The group moieties may be independently substituted one or more times. It is intended that the (two or more) substituents may be the same or different.
[0107] "Vicinal substitution" means that the substituents or groups are attached to adjacent atoms in the molecule. For example, 1,2-dichloroethane is substituted with two vicinal chlorine atoms. This is an ethane molecule.
[0108] Unless expressly shown or described otherwise, the "flow" Variables with "optional" bonds, such as R in formula (I), 3 or R y is the variable region to which the A moiety is allowed at any available carbon atom in the ring. When "optionally substituted" is stated in any embodiment of the formula (I) or an embodiment thereof, containing the substituent(s) described in said moiety Similarly, compounds that do not contain the substituent(s) described in the moiety are also included. This means that
[0109] Wavy line [ka]
[0110] As used herein, indicates the point of attachment to the remainder of the compound.
[0111] The compounds of formula (I) may contain one or more asymmetric centers and may therefore be racemic. racemic mixtures, single enantiomers, diastereoisomeric mixtures and individual All asymmetric centers present in compounds of formula (I) may exist as diastereoisomers. The compounds of the present disclosure may have, independently of each other, an S or R configuration. All enantiomers and diastereomers and any combination of two or more stereoisomers Mixtures in any ratio, e.g. mixtures of enantiomers and / or diastereomers Therefore, both the levorotatory and dextrorotatory enantiomers are included. Enantiomerically pure forms, racemic forms and all forms of the two enantiomers Enantiomers in the form of mixtures of ratios are the subject of this disclosure. The present disclosure relates to both cis and trans forms and mixtures of these forms in any ratio. The present disclosure encompasses all such stereoisomeric forms of the compounds of formula (I). The structural formula or chemical name does not clearly indicate the specific configuration at the stereocenters. Where indicated, the enantiomer or enantiomers of the compound resulting from the specified stereocenter are also included. Stereoisomers are contemplated. The structural formula of the compound of formula (I) shows a straight line at the chiral center. When a chiral center is present, the structural formula represents both the S and R stereoisomers associated with that chiral center. This includes both the above-mentioned methods and mixtures thereof.
[0112] The compound of formula (I) can be reacted, for example, in a suitable solvent such as methanol or ethyl acetate or The chiral chromatograms can be obtained by fractional crystallization of the mixture or by using optically active stationary phases. The absolute stereochemistry is Crystalline products derivatized, if necessary, with reagents containing asymmetric centers of known absolute configuration or by X-ray crystallography of a crystalline intermediate. Alternatively, the absolute stereochemistry of any compound of formula (I) may be determined using the methods described in (CD). stereoisomers or isomers of known absolute configurations can be obtained using optically pure starting materials or reagents. It can be obtained by stereospecific synthesis.
[0113] If desired, racemic mixtures of the compounds can be fractionated so that the individual enantiomers are isolated. Separation can be achieved by methods well known in the art, for example, by separating compounds. Diastereoisomeric coupling of the mixture with enantiomerically pure compounds After formation of the dimer mixture, the dimer can be purified by standard methods, e.g., fractional crystallization or chromatography. Coupling reactions can be carried out by separating the individual diastereoisomers. In this case, the formation of a salt with an enantiomerically pure acid or base is Diasteromeric derivatives are obtained by cleavage of the added chiral residue. The racemic mixture of the compound can be converted into a pure enantiomer by chiral solidification. They may also be separated directly by chromatographic methods using a fixed phase, which are well known in the art. It is well known in the field.
[0114] In compounds of formula (I) described herein containing olefinic double bonds, unless otherwise specified Unless otherwise specified, both E and Z geometric isomers are intended to be included.
[0115] Some of the compounds described herein may have different points of attachment of hydrogen and one or more double bonds. For example, a ketone and its enol form can be keto- The individual tautomers as well as mixtures thereof are included in the compounds of formula I of the present disclosure. To be contained in something.
[0116] Some of the compounds described herein have a rotational energy hindrance around a single bond at a given temperature. If the walls are high enough to prevent free rotation, they can exist as conformers, thus This allows for the isolation of individual conformers with different properties. An example is the intermediates Int-4d-1 and Int-4d-2 (described later), which are The individual conformers as well as mixtures thereof can be resolved by fluid chromatography separation. The compounds are encompassed by the compounds of formula I of the present disclosure. Once resolved, the individual conformers can be established. rules, such as those set out in the International Union of Pure and Applied Chemistry (IUPAC) 2013 Recommendation Thus, it can be written as:
[0117] In the compounds of formula (I), atoms may be present in their natural isotopic abundance, and one Or multiple atoms with the same atomic number but atomic weight or mass number are overwhelmingly the most common in nature. Certain isotopes different from the atomic mass or mass number found in may be artificially enriched. The present disclosure as described and claimed herein provides compounds of formula (I) and All suitable isotopic variations of the embodiments are intended to be encompassed. For example, hydrogen (H ) are different isotopic forms of protium (1 H) and deuterium ( 2 H, and this specification Protium is the overwhelming majority of elements found in nature. Deuterium is a hydrogen isotope. Enrichment with deuterium can provide certain therapeutic benefits, e.g. This may result in increased half-life or reduced dosage requirements, or may improve the properties of biological samples. The isotopically enriched compounds of formula (I) can be used as standards for evaluating the activity of the compounds. The compounds can be synthesized without undue experimentation by conventional techniques well known to those skilled in the art. or by methods similar to those described in the schemes and examples herein, They can be prepared using enriched reagents and / or intermediates.
[0118] The term "pharmaceutically acceptable salt" refers to a compound prepared from a pharmaceutically acceptable non-toxic base or acid. When a compound of the present disclosure is acidic, its corresponding salt is pharmaceutically acceptable. These can be conveniently prepared from acceptable non-toxic bases, such as inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper ( Ferrous, ferrous, lithium, magnesium, manganese (both ferrous and ferrous), ferric, ferrous, lithium, magnesium, manganese (both ferrous and ferrous), 1) Potassium, sodium, zinc salts are preferred. Calcium, magnesium, potassium and sodium salts. Salts prepared from non-toxic organic bases include those from naturally occurring and synthetic sources. Examples of salts include primary, secondary, and tertiary amine salts derived from both Examples of pharmaceutically acceptable organic non-toxic bases that can be used include arginine, benzyl alcohol, and methyl alcohol. Tine, Caffeine, Choline, N,N ’-Dibenzylethylenediamine, diethylamine , 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, Ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glutamine Cosamine, histidine, hydrabamine, isopropylamine, cyclohexylamine, Synthin, methylglucamine, morpholine, piperazine, piperidine, polyamine resin, pro Caine, purine, theobromine, triethylamine, trimethylamine, tripropylamine amine, tromethamine, etc.
[0119] When a compound of the present disclosure is basic, its corresponding salt is pharmaceutically acceptable and non-toxic. The acid can be conveniently prepared from inorganic and organic acids such as acetic acid, benzene, Sulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid Acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, Malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, Examples of suitable carboxylic acids include carboxylic acid, succinic acid, sulfuric acid, tartaric acid, and p-toluenesulfonic acid. are citric acid, hydrobromic acid, hydrochloric acid, maleic acid, phosphoric acid, sulfuric acid and tartaric acid. When the compound of formula (I) contains both an acidic and a basic group in the molecule, the present disclosure also provides the salt form described. In addition to the above, the salts also include internal salts or betaines (zwitterions). By conventional methods known to those skilled in the art, for example by dissolving with an organic or inorganic acid or base. by combining in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present disclosure also provides a method for the preparation of thionyltransferases that are not directly suitable for pharmaceutical use due to their low physiological compatibility. are not suitable for use in products but for example for chemical reactions or for the preparation of pharmaceutically acceptable salts The present invention also includes any salts of the compounds of formula (I) which can be used as intermediates in the process of the present invention.
[0120] Additionally, the compounds of the present disclosure may be present in amorphous form and / or in one or more crystalline forms. Any amorphous form of the compound of formula (I) may exist, including this embodiment. and crystalline forms, as well as mixtures thereof, are intended to be encompassed within the scope of this disclosure. Additionally, some compounds of the present disclosure may be dissolved in water (i.e., hydrates) or common organic solvents, such as The compounds of the present invention may form solvates with, but not limited to, ethyl acetate. and hydrates, particularly pharmaceutically acceptable solvates and hydrates, as well as unsolvated and Anhydrous forms are also included within the scope of this disclosure.
[0121] Also, any compound of the present disclosure that undergoes conversion in vivo to a compound within the scope of the present disclosure may be used. Any pharmaceutically acceptable prodrug modifications are within the scope of this disclosure.
[0122] The present disclosure also provides compounds of formula (I) described below, from which the compounds of the present disclosure can be obtained. The present invention relates to a method for the preparation of an object.
[0123] The term "therapeutically effective (or efficacious) amount" and similar descriptions, e.g., "amount effective for treatment" means , tissues, systems, animal or human biology sought by researchers, veterinarians, physicians or other clinicians "I" is intended to mean the amount of a compound of formula (I) that elicits a therapeutic or medical response. In a preferred embodiment, the term "therapeutically effective amount" refers to a therapeutically effective amount that satisfies at least one clinically significant clinical endpoint in a human patient. The term "prophylactically effective (or effective) amount" refers to an amount of a compound of formula (I) that alleviates symptoms. and similar statements, such as "a prophylactically effective amount," are intended to be used by researchers, veterinarians, physicians, or other clinicians. biological or medical treatment that seeks to prevent or control in tissues, systems, animals or humans It is intended to mean an amount of a compound of formula (I) that prevents or reduces the risk of an event occurring. Figure.
[0124] Dosage of Compounds of Formula (I) Dosage regimens using the compounds of the present disclosure will depend on a variety of factors, including patient type, species, age, weight, sex and disease state; the severity of the condition being treated; the efficacy of the compound selected for administration; The dosage is selected according to the efficacy, route of administration, and the patient's renal and hepatic function. the therapeutically effective dose required to prevent, inhibit, or halt the progression of It is well within the skill of the art to consider such factors in determining a prophylactically effective dose. The specific daily dosage may be adjusted at the same time, for example, depending on the oncological condition. and a prophylactically effective amount for the prevention of, for example, an oncological condition. I want you to understand that this is possible.
[0125] While individual needs vary, determining optimal effective amount ranges for the compounds of the present disclosure may be difficult. It is within the skill of the art to provide such treatments for the conditions and disorders identified herein. For administration to humans in curative or prophylactic treatment, typical dosages of the compounds of the present disclosure are: The amount is from about 0.05 mg / kg / day to about 50 mg / kg / day, for example at least 0.05 mg g / kg, at least 0.08mg / kg, at least 0.1mg / kg, at least 0 0.2mg / kg, at least 0.3mg / kg, at least 0.4mg / kg or less At most 0.5 mg / kg, preferably 50 mg / kg or less, 40 mg / kg or less, 30 mg g / kg or less, 20 mg / kg or less, or 10 mg / kg or less, which may be, for example, about 2.5mg / day (0.5mg / kg×5kg) ~ Approx. 5000mg / day (50mg / kg× For example, the dosage of the compound can be from about 0.1 mg / kg / day to about 5 mg / kg / day. 0mg / kg / day, approx. 0.05mg / kg / day ~ approx. 10mg / kg / day, approx. 0.05mg / kg / day ~ approx. 5mg / kg / day, approx. 0.05mg / kg / day ~ approx. 3mg / kg / day, approx. 0.07mg / kg / day ~ approx. 3mg / kg / day, approx. 0.09mg / kg / day ~ approx. 3mg / kg / day, about 0.05mg / kg / day to about 0.1mg / kg / day, about 0.1mg / kg / ~1mg / kg / day, approx. 1mg / kg / day ~10mg / kg / day, approx. 1mg / kg / day ~ approx. 5mg / kg / day, approx. 1mg / kg / day ~ approx. 3mg / kg / day, approx. 3mg / day ~ Approx. 500mg / day, approx. 5mg / day ~ approx. 250mg / day, approx. 10mg / day ~ approx. 100mg / day The daily dose may be about 3 mg / day to about 10 mg / day, or about 100 mg / day to about 250 mg / day. Such doses may be administered in a single dose or divided into multiple doses.
[0126] Pharmaceutical Composition The compounds of formula (I) and their pharmaceutically acceptable salts are administered to animals, preferably mammals, Administered especially to humans as pharmaceuticals, either alone, in admixture with one another, or in the form of a pharmaceutical composition The term "subject" or "patient" refers to a subject receiving the therapeutic agent of the present invention for the prevention or treatment of a disease state. The present invention also includes animals, preferably mammals, and especially humans, that use the active agent.
[0127] Administering the drug to a subject includes both self-administration and administration to the patient by another person. The subject may be in need of treatment for an existing disease or disease state, or The subject may be a person desiring such treatment, or may be a person desiring to prevent the occurrence of said disease or disease state. or requires preventive measures to reduce the risk of its occurrence, or As used herein, the term "subject" refers to a subject who is already in a condition where the subject desires preventative treatment. "Needing" treatment or prophylactic treatment for an existing medical condition means that a medical professional has provided a medical professional with the necessary This includes both a determination of the need for, and the patient's desire for, such treatment.
[0128] Thus, the present disclosure provides compounds of formula (I) and their derivatives for use as pharmaceuticals. Pharmaceutically acceptable salts, mutant KRAS, HRAS and / or NRAS proteins and their use for modulating the activity of, in particular, the treatment of diseases or disorders described below and Its use in prophylaxis and for preparing a medicament for such a purpose is also Also provided are compounds of formula (I) and pharmaceutically acceptable salts thereof. The salts inhibit the KRAS G12C protein.
[0129] Further, the present disclosure provides a method for treating a patient suffering from atopic dermatitis, comprising administering to the patient an effective amount of at least one compound of formula (I) as an active ingredient. and / or a pharmaceutically acceptable salt thereof, and a conventional pharmaceutically acceptable carrier; one or more pharmaceutically acceptable carrier substances and / or excipients. A pharmaceutical composition comprising:
[0130] Thus, the present disclosure provides, for example, a compound of formula (I) and a medicament for use in a pharmaceutical composition comprising the compound of formula (I) as an active ingredient in an effective dose. and / or a pharmaceutically acceptable salt thereof and a conventional pharmaceutically acceptable carrier. said compounds and pharmaceutically acceptable salts thereof for use as pharmaceutical compositions; and The use of said compounds and / or their derivatives in the treatment or prevention of diseases or disorders described below, e.g., cancer The present invention relates to the use of pharmaceutically acceptable salts thereof, as well as to the preparation of medicaments for such purposes. provides for its use.
[0131] Pharmaceutical compositions according to the present disclosure may be in the form of, for example, pills, tablets, lacquered ) tablets, sugar-coated tablets, granules, hard gelatin capsules and soft gelatin capsules, aqueous, It can be administered orally in the form of a cholestane or oily solution, syrup, emulsion or suspension. or rectally, for example in the form of a suppository. Administration can also be parenterally, for example by injection. Alternatively, it may be administered subcutaneously, intramuscularly or intravenously in the form of a liquid for infusion.
[0132] Other suitable dosage forms include, for example, ointments, tinctures, sprays or transdermal therapeutic systems. stem or transdermally, for example in the form of microcapsules, implants or rods. The preferred mode of administration is determined, for example, by the type of disease to be treated and its severity. Depends on.
[0133] Amount of active compound of formula (I) and / or its pharmaceutically acceptable salt in the pharmaceutical composition is usually 0.01 to 200 mg per dose, for example 0.1 to 200 mg, preferably 1 to 200 mg, but may be more depending on the type of pharmaceutical composition. The amount of the active compound of formula (I) and / or its pharmaceutically acceptable salt in the pharmaceutical composition may vary. The amount of the pharmaceutical composition is usually 0.5 to 90 weight percent. Preparation of a pharmaceutical composition comprising a compound of formula (I) and / or a pharmaceutically acceptable salt thereof This can be carried out in a manner known per se. For this purpose, one or more compounds of formula (I) Several compounds and / or pharmaceutically acceptable salts thereof may be used in one or more solid or or together with a liquid pharmaceutical carrier substance and / or additive (or auxiliary substance), if desired. Therefore, it is possible to provide an appropriate dosage form in combination with other pharmaceutically active compounds having a therapeutic or prophylactic effect. or dosage form, which can then be used as a pharmaceutical in human or veterinary medicine. It can be done.
[0134] For the preparation of pills, tablets, dragees and hard gelatin capsules, lactose, denat. starch, e.g. corn starch or starch derivatives, talc, stearic acid or The carriers for gelatin soft capsules and suppositories are: For example, fats, waxes, semi-solid and liquid polyols, natural or hydrogenated oils, etc. Suitable carriers for the preparation of liquids, for example injectable solutions or emulsions or syrups, are: For example, water, a physiologically acceptable sodium chloride solution, an alcohol, for example ethanol , glycerol, polyols, sucrose, invert sugar, glucose, mannitol, vegetable oil The compound of formula (I) and its pharmaceutically acceptable salts can also be freeze-dried. and the resulting lyophilisate can be used, for example, to prepare a preparation for injection or infusion. It can also be used for the preparation of microcapsules, implants or rods. A suitable carrier is, for example, a copolymer of glycolic acid and lactic acid.
[0135] In addition to the active compound and carrier, the pharmaceutical composition may contain conventional additives, such as fillers, disintegrants, , binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings additives, flavoring agents, thickeners, diluents, buffer substances, solvents, solubilizers, for obtaining depot effect Also included are agents for the treatment of urinary tract infections, salts to modify osmotic pressure, coating agents or antioxidants. obtain.
[0136] Methods of Use of Compounds of Formula (I) According to the present application, a method for treating a cell comprising contacting a cell with a compound of formula (I) or a pharmaceutically acceptable salt thereof The present invention provides a method for inhibiting RAS-mediated cell signaling, comprising: Inhibition of signal transduction can be assessed by a variety of methods known in the art. Non-limiting examples include: (a) a decrease in the GTPase activity of RAS; b) a decrease in GTP binding affinity or an increase in GDP binding affinity; (c) the K off Increase in GDP or K off (d) reduction of downstream signaling molecules in the RAS pathway a decrease in the level of, for example, a decrease in pMEK, pERK, or pAKT levels; and / or (e) binding of the RAS complex to downstream signaling molecules, including but not limited to Raf; Measurement of one or more of the above can be achieved using kits and commercially available assays. Sei can be used.
[0137] The present application also provides a compound of formula (I) (or a pharmaceutically acceptable salt thereof) or and administering pharmaceutical compositions containing such compounds to patients with disease states, including, but not limited to, mutant KRAS , pathologies in which HRAS and / or NRAS proteins are involved (e.g., cancer), etc. and in some embodiments, for treating a condition involving a KRAS G12C mutation. Provides a method for using
[0138] In some embodiments, a method for treating cancer is provided, the method comprising administering a therapeutically effective amount of a compound of formula (I) (or a pharmaceutically acceptable salt thereof) or the above-mentioned compound containing such a compound The method includes administering any of the pharmaceutical compositions to a subject in need of such treatment. In embodiments, the cancer is characterized by a mutation in KRAS, HRAS, or NRAS, e.g., KRAS G1 In various embodiments, the cancer is mediated by a 2C mutation. In some embodiments, the cancer is gallbladder cancer, thyroid cancer, or It is bile duct cancer.
[0139] In some embodiments, the present disclosure provides for the treatment of a disorder in a subject in need thereof. The present invention provides a method for performing a KRAS, HRAS, or NRAS gene expression assay in a subject. determining whether the subject has a mutation (e.g., a KRAS G12C mutation); If the subject is determined to have the KRAS, HRAS, or NRAS mutation, the subject is The method includes administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0140] The compounds of the present disclosure have the potential to inhibit anchorage-independent cell growth and therefore abrogate tumor metastasis. Therefore, according to another embodiment of the present disclosure, an effective amount of the compounds disclosed herein may be administered. The present invention provides a method for inhibiting tumor metastasis, comprising administering the compounds of the present invention.
[0141] Mutations in KRAS, HRAS, or NRAS are associated with hematopoietic malignancies (e.g., blood, bone marrow, and It has also been confirmed in some specific cancers affecting the lymph nodes. An embodiment provides for the administration of a compound of Formula (I) to a subject in need of treatment for a hematopoietic malignancy (e.g., Such malignancies include, but are not limited to, leukemia, For example, compounds of the present disclosure may be used to treat acute lymphoblastic leukemia ( ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia Chronic Lymphocytic Lymphoma (CLL), Small Lymphocytic Lymphoma (SLL), Chronic Myeloid Leukemia (CML), Acute Monoclonal Antibody (ABO) and / or other leukemias. In other embodiments, the compounds are useful in treating lymphomas, such as Hodgkin's lymphoma or non-Hodgkin's lymphoma. In various embodiments, the compounds are useful in the treatment of plasma cell malignancies. Tumors, such as multiple myeloma, mantle cell lymphoma, and Waldenstrom's macrophage It is useful in the treatment of globulinemia.
[0142] The tumor or cancer has a mutation in KRAS, HRAS, or NRAS (e.g., KRAS G 12C mutation) is a mutation that affects the KRAS, HRAS, or NRAS proteins. By assessing the nucleotide sequence encoding the protein, KRAS, HR by assessing the amino acid sequence of the AS or NRAS protein; or To assess the protein characteristics of putative KRAS, HRAS, or NRAS mutants The sequence of wild-type human KRAS, HRAS or NRAS can be determined by methods known in the art. known in the field.
[0143] and to detect mutations within the nucleotide sequences of KRAS, HRAS, or NRAS. Methods such as polymerisation and cleavage are also known to those skilled in the art. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay, polymerase chain reaction- Single strand conformation polymorphism (PCR-SSCP) assay, real-time PCR assay, PCR Sequencing, variant allele-specific PCR amplification (MASA) assay, direct sequencing Sequencing, primer extension reaction, electrophoresis, oligonucleotide ligation assay B. Hybridization assay, TaqMan assay, SNP genotyping These include chromatin assays, high-resolution melting curve assays, and microarray analysis. In embodiments, the sample contains a mutation in KRAS, HRAS, or NRAS (e.g., KRAS G1 2C mutations) are evaluated by real-time PCR. Fluorescent probes specific for KRAS, HRAS, or NRAS G12C mutations are used If the mutation is present, the probe binds and fluorescence is detected. RAS, HRAS, or NRAS mutations in the KRAS, HRAS, or NRAS genes Direct sequencing of specific regions (e.g., exon 2 and / or exon 3) of the This is confirmed using the scanning method.
[0144] Mutations in the KRAS, HRAS, or NRAS proteins (e.g., KRAS G12C Methods for detecting mutations are known to those skilled in the art. Such methods include, but are not limited to: However, binding agents (e.g., antibodies) specific for mutant forms of KRAS, HRAS, or NRAS may be used. ), protein electrophoresis and Western blotting These include direct peptide sequencing and direct peptide sequencing.
[0145] The tumor or cancer has a mutation in KRAS, HRAS, or NRAS (e.g., KRAS G Some tissue samples were assessed to determine whether they contained the 12C mutation. In some embodiments, the sample is taken from a subject with a tumor or cancer. In some embodiments, the sample is a freshly collected tumor / cancer sample. In some embodiments, the sample is a frozen tumor / cancer sample. In some embodiments, the sample is a paraffin-fixed, paraffin-embedded sample. In some embodiments, the sample is processed into a cell lysate. In this form, the sample is processed into DNA or RNA.
[0146] The present application also provides a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. and a method for treating a hyperproliferative disorder comprising administering to a subject in need thereof a salt of the compound of formula (I). In some embodiments, the methods involve treating cancer, such as acute myeloid ) leukemia, adolescent cancer, childhood adrenocortical carcinoma, AIDS-related cancers (e.g., lymphoma) and Kaposi's sarcoma), anal cancer, appendix cancer, astrocytoma, atypical teratoid, basal cell carcinoma, Bile duct cancer, bladder cancer, bone cancer, brainstem glioma, brain tumor, breast cancer, bronchial tumor, Burkitt's disease lymphoma, carcinoid tumor, atypical teratoid, embryonal tumor, germ cell tumor, primary lymphoma, fetal Cervical cancer, childhood cancer, chordoma, cardiac tumor, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia CML, chronic myeloproliferative disorder, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell Follicular lymphoma, extrahepatic ductal carcinoma in situ (DCIS), embryonal tumors, CNS cancer, endometrial cancer, Ependymoma, esophageal cancer, nasal neuroblastoma, Ewing's sarcoma, extracranial germ cell tumor, extragonadal Germ cell tumors, eye cancer, fibrous histiocytoma of bone, gallbladder cancer, stomach cancer, gastrointestinal carcinoid tumor gastrointestinal stromal tumor (GIST), germ cell tumor, gestational trophoblastic tumor, hairy cell leukemia , head and neck cancer, heart cancer, liver cancer, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma pancreatic islet cell tumors, pancreatic neuroendocrine tumors, kidney cancer, laryngeal cancer, lip and oral cavity cancer, Liver cancer, lobular carcinoma in situ (LCIS), lung cancer, lymphoma, metastatic squamous cervical cancer of unknown primary origin Epithelial carcinoma, midline tract carcinoma, oral cancer; multiple endocrine neoplasia tumor syndrome, multiple myeloma / plasma cell neoplasm, mycosis fungoides, myelodysplastic syndrome, myelodysplasia Myeloproliferative / myeloproliferative neoplasms, multiple myeloma, Merkel cell carcinoma, malignant mesothelioma, malignant fibrous tissue of bone Histiocytoma and osteosarcoma, cancer of the nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's Lymphoma, non-small cell lung cancer (NSCLC), oral cancer, lip and oral cavity cancer, oropharynx Cancer, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, cancer of the paranasal sinuses and nasal cavity, Thyroid cancer, penile cancer, pharyngeal cancer, pleuropulmonary blastoma, primary central nervous system (CNS) lymphoma, Prostate cancer, rectal cancer, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer , stomach (gastric) cancer, small cell lung cancer; small intestine cancer, soft tissue cancer tumors, T-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, renal pelvis and Transitional cell carcinoma of the ureter, trophoblastic tumor, rare cancers of childhood, urethral cancer, For the treatment of subjects suffering from uterine sarcoma, vaginal cancer, vulvar cancer or virally induced cancer In some embodiments, the method relates to treating a non-cancerous hyperproliferative disorder, such as a skin condition. hyperplasia (e.g., psoriasis), restenosis or prostate (e.g., benign prostatic hyperplasia (BPH)) Regarding the treatment of.
[0147] In some embodiments, the method for treatment relates to the treatment of lung cancer, and the method is therapeutically effective. A quantity of a compound of the present disclosure (or a pharmaceutical composition containing such a compound) is administered to a subject in need thereof. In certain embodiments, the lung cancer is non-small cell lung cancer (NSCLC). C), for example, adenocarcinoma, squamous cell lung carcinoma, or large cell lung carcinoma. Other lung cancers that may benefit from the treatment of the compounds of formula (I) include: These include, but are not limited to, glandular tumors, carcinoid tumors, and undifferentiated carcinomas.
[0148] The present disclosure also provides methods for detecting the activity of mutant KRAS, HRAS, or NRAS proteins (e.g., For example, the activity caused by the KRAS G12C mutation can be inhibited by administering the protein of formula (I) in an effective amount. The present invention provides a method for modulating the activity of a compound of formula (I) by contacting the compound with a compound of formula (I). In some embodiments, the present disclosure provides: Mutant KRAS, HRAS, or NRAS proteins (e.g., KRAS G12C mutant) by contacting the mutany in solution with an effective amount of a compound of formula (I) Thus, methods for inhibiting the activity of a protein are provided. , by contacting a cell, tissue, or organ expressing the protein of interest with a mutant K Methods for inhibiting the activity of RAS, HRAS, or NRAS proteins are provided. In embodiments, the present disclosure provides a method for administering a therapeutic agent to a subject, such as, but not limited to, a rodent or mammal (e.g., a mammalian animal, e.g., a mammalian ... The activity of the protein in a subject (e.g., a human) is determined by administering to the subject an effective amount of a compound of formula (I). The present invention provides a method for inhibiting the
[0149] Combination therapy One or more additional pharmacologically active agents may be administered in combination with a compound of formula (I) (or The compound may be administered in combination with one or more additional compounds (e.g., a pharmaceutically acceptable salt thereof). The active agent is a drug or drugs that are active in the body different from the compound of formula (I). Prodrug is intended to mean an active drug, which is converted to a pharmaceutically active form after administration. The additional active agent may be a free acid or a free salt of the additional active agent. Generally, any suitable one or more Multiple additional active agents, such as chemotherapeutic agents or therapeutic antibodies, can be combined with the compounds of formula (I). In any combination, in a single dosage formulation (e.g., a fixed dose combination), or in an active One or more drugs that allow for parallel or sequential administration (co-administration of separate active drugs) It may also be used in multiple separate dosage formulations. and an acceptable salt thereof) in combination with radiation therapy, hormone therapy, surgery, or immunotherapy. That's fine.
[0150] The present application also provides that the additional active agent is a steroid active agent that acts on other pathways, or other components of the same pathway, or further used in combination with a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations known to modulate overlapping sets of target enzymes In one embodiment, such treatments include, but are not limited to, However, one or more compounds of formula (I) may be used in combination with chemotherapeutic agents, immunotherapeutic agents, hormonal agents, and In combination with antihormonal agents, targeted therapies, and antiangiogenic agents, synergistic or additive effects are observed. In another embodiment, such treatments may provide a synergistic or or radiation treatment to produce an additive therapeutic effect.
[0151] Examples of additional active agents (i.e., additional anti-cancer agents) include chemotherapeutic agents (e.g., , cytotoxic agents), immunotherapeutic agents, hormonal and antihormonal agents, targeted therapies and anticoagulants Many anticancer drugs belong to one or more of these groups. Some specific anti-cancer agents are referred to herein as specific (one or more) categorization into a group or subgroup(s), Many of these drugs are also listed in one or more other groups or subgroups. This may be possible, as would be understood in the state of the art. The classification of specific drugs into specific groups in this document is not intended to be limiting. It should be understood that many anti-cancer drugs are currently known in the art and are not intended to be limiting of the scope of the present disclosure. may be used in combination with the compound of formula (I).
[0152] Furthermore, the agent may be an agonist, antagonist, allosteric modulator, toxin, or or more generally, it may act to inhibit or stimulate its target (e.g., receptor or enzyme activation or inhibition). For example, growth factor specific One or more agents (e.g., antibodies, antigen-binding regions, or or soluble receptors), e.g., hepatocyte growth factor (HGF, also known as scatter factor) and an antibody or antigen-binding region that specifically binds to its receptor "c-met" is.
[0153] In one embodiment, the additional anti-cancer agent is a chemotherapeutic agent, an immunotherapeutic agent, a hormonal agent, an anti-hormonal agent, or an anti-cancer agent. In one embodiment, the therapeutic agent is a monoclonal antibody, a targeted therapy agent, or an anti-angiogenic agent (or angiogenesis inhibitor). In the present invention, the additional anti-cancer agent is selected from the group consisting of a chemotherapeutic agent, a mitotic inhibitor, a plant alkaloid, an alkyl Antibodies, anti-metabolites, platinum analogues, enzymes, topoisomerase inhibitors, retinoids, azides Lysine, antibiotics, hormones, antihormones, antiestrogens, antiandrogens, Adrenocorticotropic agents, androgenic agents, targeted therapies, immunotherapies, biological response modifiers, cytotoxic agents, Tokine inhibitors, tumor vaccines, monoclonal antibodies, immune checkpoint inhibitors, PD-1 agents, anti-PD-L1 agents, colony-stimulating factors, immunomodulatory agents, immunomodulatory imides (I MiD), anti-CTLA4 agent, anti-LAGl agent, anti-OX40 agent, GITR agonist, CAR -T cells, BiTEs, signal transduction inhibitors, growth factor inhibitors, tyrosine kinase inhibitors, EGFR inhibitors, histone deacetylase (HDAC) inhibitors, proteasome inhibitors , cell cycle inhibitor, anti-angiogenic agent, matrix metalloproteinase (MMP) inhibitor Drugs, hepatocyte growth factor inhibitors, TOR inhibitors, KDR inhibitors, VEGF inhibitors, HIF-1 α inhibitors, HIF-2α inhibitors, fibroblast growth factor (FGF) inhibitors, RAF inhibitors, MEK inhibitors, ERK inhibitors, PI3K inhibitors, AKT inhibitors, MCL-1 inhibitors, BC L-2 inhibitors, SHP2 inhibitors, HER-2 inhibitors, BRAF inhibitors, gene expression modulation A group consisting of drugs, autophagy inhibitors, apoptosis inducers, antiproliferative agents, and glycolysis inhibitors is selected from.
[0154] In one embodiment, the additional anti-cancer agent(s) is a chemotherapeutic agent. Non-limiting examples of chemotherapeutic agents include antimitotic drugs and plant alkaloids, alkyl Antioxidants, antimetabolites, platinum analogues, enzymes, topoisomerase inhibitors, retinoids, aziridines These include antibiotics as well as anti-inflammatory drugs.
[0155] Non-limiting examples of antimitotic drugs and plant alkaloids include taxanes, e.g., kaolin, kaolin, kaolin-3, kaolin-5, kaolin-6, kaolin-7, kaolin-8, kaolin-9, kaolin-10, kaolin-11, kaolin-12, kaolin-13, kaolin-14, kaolin-15, kaolin-16, kaolin-17, Bazitaxel, docetaxel, larotaxel, ortataxel, paclitaxel and tetrataxel Cetaxel; Demecolcine; Epothilone; Eribulin; Etoposide (VP-16); Phosphorus Etoposide; Navelbine; Noscapine; Teniposide; Taliblastine; Vinblastine ; vincristine; vindesine; vinflunine; and vinorelbine.
[0156] Non-limiting examples of alkylating agents include nitrogen mustards, e.g., chlorambucil, Sil, chlornafazine, colofsphamide, Itofosphane (cytophosphane), estramustine, ifosfamide, Mannomustine, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, Novembichin, phenesterine, Prednimustine, tris(2-chloroethyl)amine, trofosfamide, and uracil mustards; alkylsulfonic acids, such as busulfan, improsulfan and Piposulfan; nitrosoureas, such as carmustine, chlorozotocin, and fotemustine , lomustine, nimustine, ranimustine, streptozotocin and TA-07; methylamelamines, such as Altre thiamin, thiotepa, triethylenemelamine, triethylenethiophosphatamide (tr iethylenethiophosphaoramide), triethylene phosphorus amide and trimethylolomelamine; Bendamustine; Dacarbazine; Etogluside; Irofulven; Mahosuf Amido; Mitobronitrol; Mitolactol; Pipobroman; Procarbazine; Temozolo treosulfan; and triazicon.
[0157] Non-limiting examples of antimetabolites include folic acid analogs, e.g., aminopterin, denopterin, thiazol-1, edatrexate, methotrexate, pteropterin, raltitrexed, and Rimetrexate; purine analogues, e.g., 6-mercaptopurine, 6-thioguanine, Fludarabine, forodesine, thiamiprine and thioguanine; pyrimidine analogues, For example, 5-fluorouracil (5-FU), 6-azauridine, ancitabine, and azacitidine. dextrin, capecitabine, carmofur, cytarabine, decitabine, dideoxyuridine, Doxifuridine, doxifluridine, enocitabine, Floxuridine, galocitabine, gemcitabine, and sapacitabine; 3-aminopyridinone Benzene-2-carboxaldehyde thiosemicarbazone; Broxuridine; Cladribine; Cyclophosphamide; Cytarabine; Emiteflu; Hydroxyurea; Mercaptopurine; Nephrotoxicity larabine; pemetrexed; pentostatin; tegafur; and troxacitabine Examples include:
[0158] Non-limiting examples of platinum analogs include carboplatin, cisplatin, cycloplatin, Heptaplatin, lobaplatin, nedaplatin, oxaliplatin, satraplatin and triplatin tetranitrate.
[0159] Non-limiting examples of enzymes include asparaginase and pegaspargase .
[0160] Non-limiting examples of topoisomerase inhibitors include acridine carboxamides, ammono Fido, amsacrine, belotecan, elliptinium acetate, exatecan, indolocal Bazot, irinotecan, lurtotecan, mitoxantrone, la These include zoxan, rubitecan, SN-38, sobuzoxan, and topotecan.
[0161] Non-limiting examples of retinoids include alitretinoin, bexarotene, fenretinoin, These include acetaminophen, isotretinoin, liarozole, R11 retinamide, and tretinoin. can be.
[0162] Non-limiting examples of aziridines include benzodopa, carboquone, These include meturedopa and uredopa.
[0163] Non-limiting examples of antibiotics include intercalating antibiotics; anthracenediones; Anthracycline antibiotics, such as aclarubicin, amrubicin, and daunomycin , daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, nogar 6-Diazo-5-oxo-L-norleucine Aclacinomycin; Actinomycin; Authramycin n); azaserine; bleomycin; cactinomycin; calicheamicin; calabicin ( carabicin); carminomycin; carzinophilin; chromomycin; dactylin nomycin; detorubicin; esorubicin; esperamicin ;geldanamycin;marcellomycin;mitomycin Mitomycin C; Mycophenolic acid; Olivomycin; Novantrone; Peplomycin Porfiromycin; Potfiromycin; Pyruvic acid romycin; chelamycin; rebeccamycin; rhodolubicin; streptonigrin; Treptozocin; Tanespimycin; Tubercidin; Ubenimex; Zinostatin; Zino The statins stimalamer; and zorubicin.
[0164] In one embodiment, the additional anti-cancer agent(s) is / are a hormonal agent and / or or antihormonal agents (i.e., hormone therapy drugs). Non-limiting examples of agents include antiandrogens, such as abiraterone, apalutamide, and bisphosphonates. Carutamide, darolutamide, enzalutamide, flutamide, goserelin, leuprolide, and and nilutamide; antiestrogens, such as 4-hydroxytamoxifen, aromatase Enzyme inhibitor 4(5)-imidazole, EM-800, fosfestrol, fulvestrant , Keoxifene, LY 117018, Onapristone, Raloxifene, Tamoxifen adrenal cortical suppressants, such as aminoglutethimide; Dexaminoglutethimide, Mitochondrial androgenic drugs, such as calusterone, dromestane propionate nolon, epitiostanol, mepitiostane and testolactone; abarelix; Nastrozole; Cetrorelix; Deslorelin; Exemestane; Fadrozole; Finasteride; Formestane; Histrelin (RL 0903); Human chorionic gonadotropin lanreotide; LDI 200 (Milkhaus); letrozole; leuprole Phosphate; Mifepristone; Nafarelin; Nafoxidine; Osaterone; Prednisone; thyrotropin alfa; and triptorelin.
[0165] In one embodiment, the additional anti-cancer agent(s) is / are an immunotherapeutic agent (i.e., Non-limiting examples of immunotherapeutic agents include biological response modifiers, serotonin receptor agonists, and steroid receptor antagonists. Cytokine inhibitors, tumor vaccines, monoclonal antibodies, immune checkpoint inhibitors, Colony-stimulating factors and immunomodulatory agents are included.
[0166] Biological response modifiers, e.g., cytokine inhibitors (cytokines), e.g., interferon Non-limiting examples of interferons and interleukins include interferon alpha / interleukin Interferon alpha, e.g. interferon alpha-2, interferon alfa Interferon-2a, interferon alfa-2b, interferon alfa-nl, interferon alfa-2b Interferon alfa-n3, interferon alfacon-1, peginterferon interferon alfa-2a, pegylated interferon alfa-2b, and leukocyte interferon alpha; interferon beta, e.g., interferon beta-1a and interferon beta-2a; -Interferon beta-1b; interferon gamma, e.g., natural interferon cancer Interferon gamma-1a and interferon gamma-1b; aldesleukin; interleukin- 1 beta; interleukin-2; oprelvekin; sonermin; tasonermin; and Examples include virulizin.
[0167] Non-limiting examples of tumor vaccines include APC 8015, AVICINE, and bladder cancer vaccines. Vaccine, Cancer vaccine (Biomira), Gastrin 17 immunogen, Maruyama vaccine, Me Melanoma Lysate Vaccine, Melanoma Tumor Lysate Vaccine (New York Medical College, melanoma vaccine (New York University) ersity), melanoma vaccine (Sloan Kettering Institute ute), TICE® BCG (Bacillus Calmette-Gué rin) and viral melanoma cell lysate vaccine (Royal Newca Non-limiting examples of monoclonal antibodies include: are abagovomab, adecatumumab, aflibercept, alemtuzumab, and blinatumomab. Brentuximab vedotin, CA 125 MAb (Biomira), cancer MAb (Japan Pharmaceutical Development), Daclizma daratumumab, denosumab, edrecolomab, gemtuzumab zogamicin, HER- 2 and Fc MAb (Medarex), ibritumomab tiuxetan, idiotamine 105AD7 MAb (CRC Technology), idiotype CEA M Ab(Trilex), ipilimumab, lintuzumab, LYM-1-Iodine-131 MA b(Techni clone), mitumomab, moxetumomab, ofatumumab, polymorph Antiepithelial mucin-yttrium 90 MAb (Antisoma), ranibizumab, Rituximab Examples include ciclovir and trastuzumab.
[0168] Non-limiting examples of immune checkpoint inhibitors include anti-PD-1 agents or anti-PD-1 antibodies, such as cemiplimab, nivolumab, and pembrolizumab; anti-PD-L1 agents or Anti-PD-L1 antibodies, such as atezolizumab, avelumab, and durvalumab; anti-CTL A-4 agents or anti-CTLA-4 antibodies, such as ipilimumab; anti-LAG1 agents; and anti-O Examples include X40 agents.
[0169] Non-limiting examples of colony stimulating factors include darbepoetin alfa, epoetin alfa, Fa, epoetin beta, filgrastim, granulocyte-macrophage colony-stimulating factor, Lenograstim, religistim, millimostim, molgramostim, nartograstim, These include pegfilgrastim and sargramostim.
[0170] Non-limiting examples of additional immunotherapeutic agents include BiTEs, CAR-T cells, GITR antibodies, and the like. agonist, imiquimod, immunomodulatory imide drugs (IMiDs), mismatched double-stranded RNA (A mpligen), resiquimod, SRL 172 and thymalfasin.
[0171] In one embodiment, the additional anti-cancer agent(s) is / are a targeted therapy agent (i.e., Targeted therapy agents include, for example, monoclonal antibodies and small molecule drugs. Non-limiting examples of targeted therapeutic agents include signal transduction inhibitors, growth factor inhibitors, , tyrosine kinase inhibitors, EGFR inhibitors, histone deacetylase (HDAC) inhibitors Anti-inflammatory drugs, proteasome inhibitors, cell cycle inhibitors, angiogenesis inhibitors, matrix metallo Proteinase (MMP) inhibitors, hepatocyte growth factor inhibitors, TOR inhibitors, KDR inhibitors , VEGF inhibitors, fibroblast growth factor (FGF) inhibitors, MEK inhibitors, ERK inhibitors , PI3K inhibitors, AKT inhibitors, MCL-1 inhibitors, BCL-2 inhibitors, SHP2 inhibitors Drugs, HER-2 inhibitors, BRAF inhibitors, gene expression regulators, autophagy inhibitors, These include apoptosis inducers, antiproliferative agents and glycolytic inhibitors.
[0172] Non-limiting examples of signal transduction inhibitors include tyrosine kinase inhibitors, multikinase inhibitors, enzyme inhibitors, anlotinib, avapritinib, axitinib, dasatinib, dovitinib, ibuprofen Matinib, lenvatinib, lonidamine, nilotinib, nintedanib, pazopanib, pegvi These include somant, ponatinib, vandetanib and EGFR inhibitors.
[0173] Non-limiting examples of EGFR inhibitors include small molecule antagonists of EGFR, such as afatinib. brigatinib, erlotinib, gefitinib, lapatinib, and osimertinib; and antibody-based EGFR inhibitors, e.g., those that target the activation of EGFR by its natural ligand. The present invention also includes any anti-EGFR antibody or antibody fragment that can partially or completely block the EGFR receptor. As a body-based EGFR inhibitor, for example, Modjtahedi, H., et al. .,1993,Br.J.Cancer 67:247-253;Teramoto,T. .,et al.,1996,Cancer 77:639-645;Goldstei n et al,1995,Clin.Cancer Res.1:1311-1318 ;Huang,SM,et al.,1999,Cancer Res.15:59 (8):1935-40; and Yang, X., et al., 1999, Cancer r Res.59:1236-1243; monoclonal antibody Mab E7 .6.3 (Yang, 1999 supra); Mab C225 (ATCC accession no. HB-8508) or an antibody or antibody fragment having the binding properties; specific antisense Nucleotides or siRNA; afatinib, cetuximab; matuzumab; necitum nimotuzumab; panitumumab; and zalutumumab.
[0174] Non-limiting examples of histone deacetylase (HDAC) inhibitors include belinstat These include panobinostat, romidepsin, and vorinostat.
[0175] Non-limiting examples of proteasome inhibitors include bortezomib, carfilzomib, ibuprofen, and rifametin. These include xazomib, marizomib (salinosporamide a) and oprozomib.
[0176] Non-limiting examples of cell cycle inhibitors, e.g., CDK inhibitors, include abemaciclib, alfa These include vocidib, palbociclib, and ribociclib.
[0177] In one embodiment, the additional anti-cancer agent(s) is / are an anti-angiogenic agent (or are angiogenesis inhibitors), including but not limited to matrix metalloproteinase (M MP inhibitors; VEGF inhibitors; EGFR inhibitors; TOR inhibitors, e.g., everolimus and and temsirolimus; PDGFR kinase inhibitors, e.g., crenolanib; HIF-1α inhibitors anti-inflammatory drugs, such as PX 478; HIF-2α inhibitors, such as velzutiphan and HIF-2α inhibitors described in Patent Publication No. 2015 / 035223; fibroblast growth factor (FGF ) or FGFR inhibitors, e.g., B-FGF and RG 13577; hepatocyte growth factor inhibitors anti-Ang1 and anti-Ang2 agents; anti-Tie2 kinase inhibitors; T ek antagonists (U.S. Patent Application Publication No. 2003 / 0162712; U.S. Patent No. 6,413, 932); anti-TWEAK agents (U.S. Patent No. 6,727,225); and their ADAM disintegrin domains (U.S. Pat. App. No. 6,233,369) that antagonize ligand binding Patent Publication No. 2002 / 0042368); anti-eph receptor and / or anti-ephrin antibodies or The antigen-binding region (U.S. Patent Nos. 5,981,245; 5,728,813; 5 ,969,110; 6,596,852; 6,232,447; and No. 6,057,124); and anti-PDGF-BB antagonists and PDGF-BB ligands It is an antibody or antigen-binding region that specifically binds to the target antigen.
[0178] Non-limiting examples of matrix metalloproteinase (MMP) inhibitors include MM P-2 (matrix metalloproteinase 2) inhibitor, MMP-9 (matrix Metalloproteinase 9 inhibitors, prinomastat, RO 32-3555, and RS Examples of useful matrix metalloproteinase inhibitors include 13-0830. are described, for example, in WO 96 / 33172, WO 96 / 27583, European Patent No. 1004578, International Publication No. 98 / 07697, International Publication No. 98 / 03516, International Publication No. 98 / 34918, International Publication No. 98 / 34915, International Publication No. 98 / 337 68, WO 98 / 30566, EP 0606046, EP 09 31788, International Publication No. 90 / 05719, International Publication No. 99 / 52910, International Publication WO 99 / 52889, WO 99 / 29667, WO 1999 / 007 675, European Patent No. 1786785, European Patent No. 1181017, U.S. Pat. 09 / 0012085, U.S. Patent No. 5,863,949, U.S. Patent No. 5,861,5 10 and European Patent No. 0780386. Preferred MMP-2 inhibitors and MMP-9 inhibitors have little or no activity inhibiting MMP-1. More preferably, other matrix metalloproteinases (i.e. MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MM MMP-8, MMP-10, MMP-11, MMP-12 and MMP-13) compared with MM It selectively inhibits P-2 and / or MMP-9.
[0179] Non-limiting examples of VEGF inhibitors and VEGFR inhibitors include bevacizumab, cediazine, and cediazine. Ranib, CEP 7055, CP 547632, KRN 633, Orantinib, Pazo Panib, pegaptanib, pegaptanib octasodium, semaxanib, sorafenib, Sunitinib, a VEGF antagonist (Borean, Denmark) and VEGF-TRA P (trademark).
[0180] The additional anti-cancer agent(s) may also be another anti-angiogenic agent, e.g., Not specified, but 2-methoxyestradiol, AE 941, alemtuzumab, alfa α-D148 Mab (Amgen, US), alphastatin, anecortave acetate, Angiosidin, angiogenesis inhibitor (SUGEN, US), angiostatin, anti-Vn M ab (Crucell, Netherlands), atiprimod, axitinib, AZD 9935, BAY RES 2690 (Bayer, Germany), BC 1 (Genoa Institute) of Cancer Research, Italy), beloranib, Benefin (Lane Labs, US), cabozantinib, CDP 791 (Celltech Group, UK), chondroitinase AC, cilengitide, combretastatin A4 Prodrugs, CP 564959 (OSI, US), CV247, CYC 381 (H (Bard College, US), E 7820, EHT 0101, endostatin, enzasta Urin hydrochloride, ER-68203-00 (IVAX, US), fibrinogen E fragment, Flk-1 (ImClone Systems, US), FLT 1 (VEGFR 1) Form, FR-111142, GCS-100, GW 2286 (GlaxoSmith Kline, UK), IL-8, Ilomastat, IM-862, Irsogladine, KM -2550 (Kyowa Hakko, Japan), lenalidomide, lenvatinib, MAb alpha 5 beta 3 Integrin, second generation (Applied Molecular Evolution USA and MedImmune, US), MAb VEGF (Xenova, UK) , marimastat, maspin (Sosei, Japan), metastatin, motuporamine C, M -PGA, Ombulbulin, OXI4503, PI 88, Platelet Factor 4, PPI 2 458, Ramucirumab, rBPI 21 and BPI-derived antiangiogenic (XOMA, US ), regorafenib, SC-236, SD-7784 (Pfizer, US), SDX 103 (University of California, San Diego, US), SG 292 (Telios, US) S), SU-0879 (Pfizer, US), TAN-1120, TBC-1635, Tesevatinib, tetrathiomolybdate, thalidomide, thrombospondin 1 inhibitors, Tie-2 ligand (Regeneron, US), tissue factor pathway inhibitor (EntreM ed,US), tumor necrosis factor-alpha inhibitors, tumstatin, TZ 93, urokinase type II plasminogen activator inhibitors, vadimezan, vandetanib, vasostatin, Talanib, VE-cadherin-2 antagonist, xanthorrhizol, XL 784 (Exeli xis, US), ziv-aflibercept and ZD 6126.
[0181] In certain embodiments, the additional anticancer agent(s) is a RAS-RAF -Disrupt or inhibit ERK or PI3K-AKT-TOR signaling pathways, or or a further active agent that is an antagonist of PD-1 and / or PD-L1. In embodiments, the additional anti-cancer agent(s) is / are a RAF inhibitor, an EGFR inhibitors, MEK inhibitors, ERK inhibitors, PI3K inhibitors, AKT inhibitors, TOR inhibitors, MCL-1 inhibitors, BCL-2 inhibitors, SHP2 inhibitors, proteasome inhibitors or immunotherapy Immunotherapeutic agents, such as monoclonal antibodies, immunomodulatory imid drugs (IMiDs), anti-PD-1, Anti-PDL-1, anti-CTLA4, anti-LAGl and anti-OX40 agents, GITR agonists, C AR-T cells and BiTEs.
[0182] Non-limiting examples of RAF inhibitors include dabrafenib, encorafenib, and regorafenib. Examples of anti-cancer drugs include cefotaxime, sorafenib, and vemurafenib.
[0183] Non-limiting examples of MEK inhibitors include binimetinib, CI-1040, and cobimetinib. , PD318088, PD325901, PD334581, PD98059, Refamme These include selumetinib, selumetinib, and trametinib.
[0184] Non-limiting examples of ERK inhibitors include LY3214996, LTT462, and MK-8. 353, SCH772984, lavoxertinib, ulixertinib and International Publication No. and ERKi such as those described in Patent Publication No. 017 / 068412.
[0185] Non-limiting examples of PI3K inhibitors include 17-hydroxywortmannin analogs (e.g., For example, WO 06 / 044453; AEZS-136; alpelisib; AS-2 52424; Buparlisib; CAL263; Copanlisib; CUDC-907; Ductoli sib (WO 06 / 122806); demethoxyviridin; duvelisib; GNE -477;GSK1059615;IC87114;idelalisib;INK1117;L Y294002; Palomid 529; Paxalisib; Perifosine; PI -103; PI-103 hydrochloride; pictilisib (e.g., WO 09 / 036,08 No. 2;WO 09 / 055,730);PIK 90;PWT33597;SF1 126;sonolisib;TGI 00-115;TGX-221; These include XL147; XL-765; wortmannin; and ZSTK474.
[0186] Non-limiting examples of AKT inhibitors include Akt-1-1 (which inhibits Aktl) (Ba rnett et al.(2005)Biochem.J.,385(Pt.2),3 99-408);Akt-1-1,2(Barnett et al.(2005)Bi ochem.J.385(Pt.2),399-408);API-59CJ-Ome( For example, Jin et al. (2004) Br.J.Cancer 91,1808- 12); lH-imidazo[4,5-c]pyridinyl compounds (e.g., WO 050 No. 11700); indole-3-carbinol and its derivatives (e.g., U.S. Pat. No. 6,270,317); No. 6,656,963;Sarkar and Li(2004)J Nutr.134 (12 Supplement), 3493S-3498S); Perifosine, Dasmahapatra et al.(2004)Clin.Cancer Res.10(15),5242- 52, 2004); phosphatidylinositol ether lipid analogs (e.g., Gill s and Dennis(2004)Expert.Opin.Investig.D rugs 13,787-97); triciribine (Yang et al. (2004) Cancer Res. 64, 4394-9); imidazoxazone compounds, e.g., thiazolomethane 1,2-phenyl-3-amino-1-methyl-3-[4-(3-phenyl-5H-imidazo[ c]pyrido[3,4-e][1,3]oxazin-2-yl)phenyl]-cyclobutano afuresertib; capivasertib hydrochloride (WO 2012 / 137870); afuresertib; capivasertib MK2206; and patasertib.
[0187] Non-limiting examples of TOR inhibitors include deforolimus; ATP-competitive TORC1 / T ORC2 inhibitors, such as PI-103, PP242, PP30 and Torin )1; TOR inhibitors, rapamycin and its derivatives at the FKBP12 enhancer , e.g., temsirolimus, everolimus, WO 9409010; e.g., WO Lapapolis as disclosed in WO 98 / 02441 and WO 01 / 14387 Log, e.g. AP23573, AP23464 or AP23841; 40-(2-Hydro (hydroxyethyl)rapamycin, 40-[3-hydroxy(hydroxymethyl)methylpropional panoate]-rapamycin; 40-epi-(tetrazolyl)-rapamycin (ABT5 78); 32-deoxorapamycin; 16-pentynyloxy-32(S )-dihydrorapanycin, and WO 05 / 00543 Other derivatives disclosed in U.S. Pat. No. 5,258,389, WO 94 / 026494, and U.S. Pat. No. 5,258,389. 090101, WO 92 / 05179, U.S. Pat. No. 5,118,677, U.S. Pat. US Patent No. 5,118,678, US Patent No. 5,100,883, US Patent No. 5,15 No. 1,413, U.S. Pat. No. 5,120,842, International Publication No. 93 / 111130, International Publication No. 94 / 02136, International Publication No. 94 / 02485, International Publication No. 95 / 140 23, International Publication No. 94 / 02136, International Publication No. 95 / 16691, International Publication No. No. 6 / 41807, WO 96 / 41807 and U.S. Pat. No. 5,256,790 and phosphorus-containing rapamycin derivatives (e.g., those disclosed in International Publication No. WO 2004 / 013994). No. 05 / 016252).
[0188] Non-limiting examples of MCL-1 inhibitors include AMG-176, MIK665, and S63 845. Non-limiting examples of SHP2 inhibitors include those described in WO 2019 / 1 67000 and WO 2020 / 022323. can be done.
[0189] Further non-limiting examples of anti-cancer agents suitable for use include 2-ethylhydrazide, 2, 2',2"-Trichlorotriethylamine, ABVD, Aceglatone, Acemannan, Ace Ludofosfamide glycoside, alpharazine, amifostine, aminolevulinic acid, ana Grelide, ANCER, Ancestim, Anti-CD22 Immunotoxin, Anti-tumorigenic Herbs, Apa Zicone, Arglabin, Diarsenic Trioxide, Azathioprine, BAM 002 (Novelo s), bcl-2 (Genta), bestrabucil, biliko Dar (biricodar), bisantrene, bromocriptine, brostallicin, Liostatin, buthionine sulfoximine, calyculin, cell cycle non-specific anti-neoplastic agent, Celmoleukin, clodronate, clotrimazole, cytarabine ocfosfate, D A 3030 (Dong-A), defofamine, denileukin Diftitox, dexrazoxane, diaziconazole, dichloroacetic acid, dilazep, discodermo Lido, docosanol, doxercalciferol, edelfosine, eflornithine, EL 532 (Elan), elfomithine, elsamitrucin, E Niluracil, etanidazole, exisulind, ferruginol, folic acid supplements, e.g. Florinic acid, gacytosine, gallium nitrate , gimeracil / oteracil / tegafur combination drug (S-1), glycopin (glycopin ne), histamine dihydrochloride, HIT diclofenac, HLA-B7 gene therapy drug (Vi cal), human fetal alpha-fetoprotein, ibandronate, ibandronic acid, ICE chemotherapy regimen, imexon, iobenguane, IT-101 (CRLX101 ), laniquidar, LC 9018 (Yakult), leflunomide, lentinan, levamina Zole + fluorouracil, lovastatin, lucanton, masoprocol, melarsoprolol ol, metoclopramide, miltefosine, miproxifene , mitoguazone, mitozolomide, mopidamol, motexafine Gadolinium, MX6 (Galderma), naloxone + pentazocine, nitracrine , Nolatrexed, NSC 631570 Octreotide (Ukrain), Olapari B, P-30 protein, PAC-1, palifermin, pamidronate, pamidronic acid , sodium pentosan polysulfate, phenamet, picibanil, Pixantrone, platinum, podophyllic acid, porfimer sodium, PSK (polysaccharide K) , rabbit anti-thymocyte polyclonal antibody, Rasburie embodyment mbodiment), retinoic acid, rhenium Re 186 etidronate, romurti , samarium (153 Sm) lexidronam, schizophyllan, sodium phenylacetate , sparfosic acid, spirogermanium, strontium chloride -89, suramin, swainsonine, talaporfin, tariquidar, tazarotene, tegaf uryl-uracil, temoporfin, tenuazonic acid, tetrachlorodecaoxide, thrombo Poetin, Ethyl Ethiopurinse, Tirapazamine, TLC ELL-12, Toshitsu Momab-iodine 131, trifluridine and tipiracil combination, troponin I (Harbor University of Illinois, US), urethane, valspodar, verteporfin, zoledronic acid and zoledronic acid. Skidar is one example.
[0190] The present disclosure further provides a compound or pharmaceutical composition of formula (I) provided herein. and methods for use in combination with radiation therapy to treat cancer. Techniques for enforcing the law are known in the art, and such techniques are described herein. The administration of the compounds of formula (I) in this combination therapy is described in the present specification. It can be determined as described in the literature.
[0191] Radiation therapy can be administered in one of several ways or in a combination of ways, including but not limited to: However, external beam radiation therapy, internal radiation therapy, interstitial radiation therapy, stereotactic radiosurgery, systemic radiation therapy, It can be delivered by radiation therapy and permanent or temporary interstitial brachytherapy. "Brachytherapy," as used herein, refers to the treatment of a diseased site of a tumor or other proliferative tissue within the body. Radiation therapy delivered by spatially confined radioactive material inserted in or near the This term refers to the method of radioisotopes, including but not limited to, At-211, I-1 31, I-125, Y-90, Re-186, Re-188, Sm-153, Bi-21 This is intended to encompass exposure to radioactive isotopes of 2, P-32, and Lu. Radiation sources suitable for use as the disclosed cell conditioners The radiation source includes both solid and liquid materials. As a non-limiting example, the radiation source may be a radioactive nuclide. species such as I-125, I-131, Yb-169, Ir-192 as a solid source, I-125 as a solid source, or as a source of photons, beta particles, gamma radiation, or other therapeutic The radioactive material may be any other radionuclide that emits therapeutic light. made from any solution of a radionuclide (such as I-125 or I-131) The radioactive fluid may be a fluid containing a solid radionuclide, such as Au-198, Y-90 It may also be made using a slurry of a suitable fluid containing small particles of the The radionuclide or radionuclides may be made into a gel or radioactive microspheres.
[0192] The present disclosure also provides methods for treating inflammatory bowel disease, including inflammatory bowel disease, in which the additional active agent acts on other pathways, or other components of the same pathway, or further used in combination with a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations known to modulate overlapping sets of target enzymes In one embodiment, such treatments include, but are not limited to, However, one or more compounds of formula (I) may be used in combination with chemotherapeutic agents, immunotherapeutic agents, or hormonal agents. Synergistic or additive therapy in combination with other therapeutic agents, therapeutic antibodies, targeted therapy agents, and radiation treatments. It is said that it brings about effects.
[0193] The compounds of the present disclosure may be administered in combination with the drugs disclosed herein or other suitable anti-inflammatory drugs, depending on the condition being treated. Thus, in some embodiments, one or more The compounds of the present disclosure are co-administered with other agents as described above. The compounds described herein may be administered simultaneously with the second agent or separately. The administration of the two drugs may be simultaneous administration in the same dosage form, simultaneous administration in separate dosage forms, or and separate administration, i.e., the compound of formula (I) and any of the above-mentioned drugs may be administered together. Alternatively, the compounds of formula (I) may be formulated together in the same dosage form and administered simultaneously. and any of the above agents may be administered simultaneously, provided that both agents are present in separate formulations. Alternatively, any of the above agents may be administered immediately after the compound of formula (I), or In some embodiments of the separate administration protocol, the compound of formula (I) and any of the above-mentioned The desired drugs may be administered minutes apart, hours apart, or days apart.
[0194] In one aspect of the disclosure, the treatment of a disease / condition with a combination of pharmaceutically active compounds that can be administered separately. Since various arrangements are envisioned, the present disclosure further provides for combining separate pharmaceutical compositions into kit form. The kit comprises two separate pharmaceutical compositions: a compound of formula (I) and a second pharmaceutical composition. The kit may include containers, such as divided bottles, for containing the separate compositions. Further examples of containers include syringes, boxes and In some embodiments, the kit includes a container and a bag for use of the separate components. The kit form may comprise separate components in different dosage forms (e.g., oral). and parenterally) and may be given at different dosage intervals or as prescribed. This is particularly advantageous when a medical practitioner desires titration of the individual components of the combination.
[0195] The present disclosure also provides compounds of formula (I) or pharmaceutical compositions thereof for use in therapy. or a pharmaceutically acceptable salt thereof, or a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy. The present disclosure also provides compounds of formula (I) for use in the treatment of cancer. or a pharmaceutically acceptable salt thereof, or a compound of formula (I) or a pharmaceutically acceptable salt thereof. A compound of formula (I) or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of cancer. or a compound of formula (I) or a drug thereof for the preparation of a medicament for the treatment of cancer. The present disclosure also provides for the use of physiologically acceptable salts of the compounds of formula (I) in the treatment of cancer. a compound of formula (I) or a pharmaceutically acceptable salt thereof and a further anticancer agent, or cancer, The present disclosure also provides a method for preparing a medicament for treating cancer. a compound of formula (I) or a pharmaceutically acceptable salt thereof and a further anticancer agent, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of cancer. The present disclosure also provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of a compound selected from the group consisting of a medicament for treating cancer, ... A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in or a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating cancer. The present disclosure also provides pharmaceutical compositions containing the salts for use in the treatment of cancer. and a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof for or a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating cancer. The present invention provides pharmaceutical compositions comprising the extractable salts thereof and the use of the additional anti-cancer agent.
[0196] Methods for Preparing the Compounds of the Disclosure Several methods for preparing the compounds of the present disclosure are described in the following examples. and intermediates were purchased, made by known procedures, or otherwise described. That's right.
[0197] Throughout the synthetic schemes and examples, abbreviations and acronyms are as follows unless otherwise indicated: It can be used to mean: anhydr.=anhydrous;aq.=aqueous;atm=atmosphere;Bodipy-GDP=((2R ,3S,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purine benzo-9-yl)-3-(((2-(3-(5,5-difluoro-7,9-dimethyl-5H -4l4,5l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaboron thiamin-3-ylpropanamido)ethyl)carbamoyl)oxy)-4-hydroxytetrahydrofuran tetrahydrofuran-2-yl)methyl hydrogen diphosphate and ((2R,3R, 4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purine-9- yl)-4-(((2-(3-(5,5-difluoro-7,9-dimethyl-5H-414 ,5l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine-3 -yl)propanamido)ethyl)carbamoyl)oxy)-3-hydroxytetrahydro A mixture of 2-(2-methyl-2-furan-2-yl)methyl hydrogen diphosphates (Invitrogen en TM , Catalog No. G22360); br s = broad singlet; Bu = butyl; t -Bu = tert-butyl; cataCxium® C = trans-di(μ-a) acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II), C = CDCl3 = deuterated chloroform; CDI = 1,1'-carbonyldiimidazole, CELITE = diatomaceous earth; CF3 = trifluoromethyl; cGMP = cyclic guanosine monophosphate Phosphoric acid; CH3NO2 = nitromethane; DCM = dichloromethane; DETA-NO = diene Diethylenetriamine / nitric oxide adduct; DIAD = diisopropyl azodicarboxylate; D IEA / DIPEA = N,N-diisopropylethylamine; DME = dimethoxyethane , DMEA = N,N-dimethylethanamine, DMF = N,N-dimethylformamide; DMP = Dess-Martin periodinane; DMS = dimethyl sulfide; DMSO = dimethyl Diphenyl sulfoxide; DPPF or dppf = 1,1'-bis(diphenylphosphino) Ferrocene; DTT = dithiothreitol; EDTA = ethylenediaminetetraacetic acid; e quiv,eq.=equivalent; Et=ethyl; Et3N=triethylamine; EtOAc=acetic acid Ethyl acetate; EtOH = ethanol; Grubbs catalyst = (1,3-bis(2,4,6-trimethylsilyl)methyl) (2-imidazolidinylidene)dichloro(phenylmethylene)(tricycle (trihexylphosphine)ruthenium; GTP = guanosine triphosphate; h = hour; HEPE S = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HMDS = hexafluoroisopropyl hexamethydisilazane; HPLC = high performance liquid chromatograph Chromatography; Int. = intermediate; iPr = isopropyl; IP = inflection point; i-Pr OH = isopropanol; KHMDS = potassium bis(trimethylsilyl)amide; LC MS, LC / MS = liquid chromatography-mass spectrometry; min, min. = minutes; LDA = lithium diisopropylamide; M = molar; Me = methyl; MeCN,ACN = acetone Acetonitrile; MeOH = methanol; mp, mp = melting point; mpk = milligrams per Kilograms; MsCl = methanesulfonyl chloride; MPLC = medium pressure liquid chromatograph N = normality; NaOMe = sodium methoxide; NMR = nuclear magnetic resonance; ND = not measurable; PDA = photodiode array; Pet.ether = petroleum ether; P dC = palladium on carbon; Pd2(dba)3 = tris(dibenzylideneacetone) Dipalladium(0); Ph = phenyl; Pr = propyl; psi = pounds per square inch POCl3 = phosphorus(V) oxychloride; PTLC, prep TLC = preparative thin layer chromatography Chromatography; rac = racemic; RT = retention time; RP-HPLC = reversed-phase HPLC ;rt = room temperature;sat. = saturated;SFC = supercritical fluid chromatography;SOS = single crystal Sphos Pd G3 = (2-dicyclohexylphosphino-2',6 '-dimethoxybiphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium Ammonium(II) methanesulfonate; TBAF = tetra-n-butylammonium fluoride ;TBSCl = tert-butyldimethylsilyl chloride;TFA = trifluoroacetic acid; TLC = thin layer chromatography; THF = tetrahydrofuran; TMS = trimethylsilyl TWEEN = polyoxyethylene (20) sorbitan monolaurate; VCD = vibration Dynamic circular dichroism; v, v / v = volume, volume to volume; w, w / w = weight, weight to weight, XPho s-Pd-G3 = (2-dicyclohexylphosphino-2',4',6'-triisopropyl) Pyr-1,1'-biphenyl) [2-(2'-amino-1,1'-biphenyl)]paradiphenyl Sodium(II) methanesulfonate; μm = micrometer. [Example] The compounds described herein may be prepared according to the procedures of the following schemes and examples, using appropriate materials. can be prepared according to the methods described below and are further illustrated by the specific examples below. Only the compounds described in the examples constitute the genus that is considered to be part of this disclosure. The Examples further describe details for the preparation of compounds of the present disclosure. Those skilled in the art will appreciate that known variations of the conditions and processes of the following preparative procedures may be used to prepare such compounds. It will be readily understood that the present invention can be used to prepare compounds of the present invention. The following is provided for illustrative purposes only and is not intended to be a limitation on the present disclosure. Any intermediates shown are designated herein by number preceded by "Int-". is possible.
[0198] Concentration was by evaporation under reduced pressure (e.g., by rotary evaporation) unless otherwise noted. All temperatures are in degrees Celsius unless otherwise noted. Unless otherwise specified, mass spectrometry (MS) is performed using electrospray ionization mass spectrometry (ESI). The measurement was performed in positive ion detection mode, and m / z was [M+H] + ions are shown. 1 H NMR spectra were recorded at ambient temperature between 400 and 500 MHz unless otherwise noted. The proton reported as 0.5H is due to the signal of the rotamer. RP-HPLC uses acetonitrile and water as eluents, unless trifluoromethylpropional is used. C18-C18 with gradient elution using acetic acid or ammonium hydroxide as modifier Reversed-phase HPLC on functionalized preparative or semi-preparative columns is shown, and fractions were either lyophilized or Concentration was performed by rotary evaporation. Column chromatography on silica gel Purification by flash chromatography systems (e.g., ISCO®) ) or Biotage®) and commercially available pre-packed silica gel columns. The compounds described herein were prepared according to the experimental procedures and the solvent systems described. Unless otherwise specified in the table of compounds, they were synthesized as racemates. Some specific products / intermediates may include the designation "Peak 1" and / or "Peak 2". , this is the same as the chromatography column used to isolate the compound (e.g., SFC). The order of elution of the indicated products / intermediates from the column under the specified conditions is shown. For example, peak 1 is the first eluting compound under the specified conditions, e.g., the first eluting stereoisomer. The conformer (e.g., the first eluting conformer) is shown. Starting material 2,5-dichloro-3-nitro Pyridine and (E)-tert-butyldimethyl ((4-(4,4,5,5-tetramethyl) ethyl-1,3,2-dioxaborolan-2-yl)but-3-en-1-yl)oxy Silanes were purchased from Sigma Aldrich.
[0199] The SFC columns used for chiral resolution of stereoisomers are summarized in the table below: [Table 1]
[0200] Example 1a: 18,21-difluoro-2-[(2S)-2-methyl-4-(prop-2 -enoyl)piperazin-1-yl]-6-(propan-2-yl)-12,13-dihydrochloride Doro-4H,11H-1,19-ethenopyrido[4,3-f]pyrimido[1,6-h][ 1,5,8,10]benzodioxadiazacyclotridecin-4-one [ka]
[0201] Step A: 4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-2- Chloro-3-nitropyridine (Int-1a) 3-((tert-butyldimethylsilyl)oxy)propan-1-ol (7.60 g, 39.9 mmol) was dissolved in tetrahydrofuran (121 mL) and cooled to 0°C. Then, sodium hydride (1.60 g, 39.9 mmol) was added and the mixture was stirred at that temperature for 30 minutes. The reaction mixture was stirred for 1 hour. 2,4-dichloro-3-nitropyridine (7.00 g, 36. 3 mmol) was added in portions and the temperature was slowly raised to room temperature over 2 hours. Quench with saturated aqueous ammonium chloride, dilute with EtOAc, separate, and Wash with ethanol, dry over sodium sulfate, filter, concentrate, and load onto silica gel at 0-25% Purify with EtOAC / hexane up to 4-(3-((tert-butyldimethylsilyl) To obtain (2-chloro-3-nitropyridine Int-1a), (2-chloro-3-nitropyridine Int-1a) was obtained. MS(ESI)[M+H] + m / z 347. Step B: 4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3- Nitro-2-(prop-1-en-2-yl)pyridine (Int-1b) 4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-2-chloro -3-nitropyridine (5.00 g, 14.4 mmol) and cesium carbonate (14.1 g, 43.2 mmol) was added to a 200 mL round-bottom flask equipped with a magnetic stir bar and heated under nitrogen. The mixture was evacuated under nitrogen and mixed with DME (38.4 mL) / water (9.6 mL) and isopropyl alcohol. Add 1.25 mL of pinacol boronic acid (3.25 mL, 17.3 mmol) and add nitrogen. Degassed three times under nitrogen and bis(triphenylphosphine)palladium(II) dichloride (1 The reaction mixture was degassed under nitrogen and a reflux condenser was attached. The reaction mixture was cooled to room temperature and added with 50 mL of saturated aqueous ammonium chloride. Quench with ammonium hydroxide, extract with 2 x 100 mL EtOAc, and wash with brine. The extract was dried over sodium sulfate, filtered, concentrated, and then washed with 10 to 50% silica gel. Purify with EtOAc / hexane to obtain 4-(3-((tert-butyldimethylsilyl)isopropyl)methylsilyl) oxy)propoxy)-3-nitro-2-(prop-1-en-2-yl)pyridine (In t-1b) was obtained. MS(ESI) m / z 353. Step C: 4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-2- Isopropylpyridin-3-amine (Int-1c) 4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-nitro 1-(prop-1-en-2-yl)pyridine (4.20 g, 11.9 mmol) The solution was dissolved in ethanol (100 mL), degassed under nitrogen, and then prepared as Pd-C (10% w / w, wet ) (840 mg), degassed under nitrogen, and evacuated under a hydrogen balloon. The mixture was stirred at room temperature for 24 hours under a hydrogen atmosphere, filtered through Celite, and concentrated in vacuo. Condensed with 4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-2-isopropyl Isopropylpyridin-3-amine (Int-1c) was obtained, which was used without further purification. MS(ESI)[M+H] + :m / z 325. Step D: N-((4-(3-((tert-butyldimethylsilyl)oxy)propoxy )-2-Isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-furan Iodonicotinamide (Int-1d) 2,6-Dichloro-5-fluoronicotinamide (1.15 g, To a stirred solution of 5.48 mmol) of oxalyl chloride in DCM (2.60 mL, 5 0.20 mmol) was added and the reaction was heated to 75°C under a reflux condenser for 1 hour. The reaction mixture was cooled to 0°C and diluted with 4-(3-((tert-butyldimethylamino)methyl)-2-(2-methyl-2-propanol) in THF (5 mL). (Thiylsilyl)oxy)propoxy)-2-isopropylpyridin-3-amine (1.87 g, 5.75 mmol) was added dropwise. The reaction was stirred for 1 hour. Quench with saturated sodium ammonium chloride and extract with 2 x 50 mL EtOAc. Extracted, washed with brine, dried over sodium sulfate, filtered, concentrated in vacuo, and purified by silica gel Purification was performed in 0 to 100% hexane / 3:1 EtOAc / EtOH on a 100% hexane / 3:1 EtOAc / EtOH column. (4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-2-isopropyl (3-(4 ... The amide (Int-1d) was obtained. MS (ESI) [M+H] + : m / z 559 / 561 . Step E: 1-(4-(3-((tert-butyldimethylsilyl)oxy)propoxy) -2-isopropylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3- d] Pyrimidine-2,4(1H,3H)-dione (Int-1e) N-((4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-2 -isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluoro Nicotinamide (1.72 g, 3.07 mmol) was dissolved in THF (20 mL), Cool to 0°C and add a 1M solution of KHMDS in THF (6.46 mL, 6.46 mmol). The reaction was then cooled to room temperature over 1 hour. The mixture was quenched with hexane, extracted with 2 x 50 mL of EtOAc, washed with brine, and diluted with sodium sulfate. Dry over sodium, filter, concentrate in vacuo, and 1-(4-(3-((tert-butyldichloroisothiazolinone) Methylsilyl)oxy)propoxy)-2-isopropylpyridin-3-yl)-7-chlor 1H,3H)-dione( Int-1e) was obtained and used without further purification. MS (ESI) [M+H] + :m / z 523. Step F: 1-(4-(3-((tert-butyldimethylsilyl)oxy)propoxy) -2-isopropylpyridin-3-yl)-4,7-dichloro-6-fluoropyridin[2 ,3-d]pyrimidin-2(1H)-one (Int-1f) 1-(4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-2- Isopropylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3-d]pyridin Imidine-2,4(1H,3H)-dione (1.57 g, 3.00 mmol) was dissolved in CH Dissolved in N (20 mL) and DIEA (1.05 mL, 6.00 mmol) and PO Cl3 (0.336 mL, 3.60 mmol) was added and the reaction mixture was heated to 80°C for 1 hour. The reaction solution was evaporated using a rotary evaporator and dried under high vacuum for 10 minutes to give 1-(4-(3-( (tert-Butyldimethylsilyl)oxy)propoxy)-2-isopropylpyridine -3-yl)-4,7-dichloro-6-fluoropyrido[2,3-d]pyrimidine-2( 1H)-one (Int-1f) was obtained and used without further purification. MS(ESI) [M+ H] + :m / z 540.8 / 542.9. Step G: (S)-4-(1-(4-(3-((tert-butyldimethylsilyl)oxy) )propoxy)-2-isopropylpyridin-3-yl)-7-chloro-6-fluoro- 2-Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl 1-piperazine carboxylate (Int-1g) 1-(4-(3-((tert-butyldimethylsilyl)oxy)propoxy)-2- Isopropylpyridin-3-yl)-4,7-dichloro-6-fluoropyrido[2,3- d] Pyrimidin-2(1H)-one (1.63 g, 3.00 mmol) was dissolved in acetonitrile. (20 mL), cooled to 0 °C, and added DIEA (2.01 mL, 12.0 mmol). 1), followed by (S)-tert-butyl 3-methylpiperazine-1-carboxylate (0.7 The reaction was then diluted with 1:1 saturated bicarbonate The mixture was quenched with sodium / water, stirred for 5 minutes, and the organic layer was separated. Extract with 1 mL of EtOAc, combine, wash with brine, dry over sodium sulfate, Filter, concentrate, and wash with silica gel using 0 to 100% 3:1 EtOAc / EtOH / Hexane. Purify with hexane and use (S)-4-(1-(4-(3-((tert-butyldimethylsilyl) -2-isopropylpyridin-3-yl)-7-chloro-6-(2-isopropyloxy)propoxy Fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl) tert-Butyl 3-methylpiperazine-1-carboxylate (Int-1g) was obtained. S(ESI)[M+H] + m / z:705. Step H: (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl) )-1-(4-(3-hydroxypropoxy)-2-isopropylpyridin-3-yl) -2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl ethylpiperazine-1-carboxylate (Int-1h) (S)-4-(1-(4-(3-((tert-butyldimethylsilyl)oxy)propionyl) 2-Isopropylpyridin-3-yl)-7-chloro-6-fluoro-2-oxo So-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperane tert-Butyl 3-(2-methyl-2-propanol)-1-carboxylate (0.500 g, 0.709 mmol), Fluoro-2-(trifluoro-λ 4 -boraneyl phenolic acid sodium (0.200 g, 0.922 mmol), potassium acetate (0.278 g, 2.84 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride was added to a 20 mL scintillation vial equipped with a magnetic stir bar, The mixture was degassed under nitrogen, and then a mixture of dioxane (3.0 mL) and water (0.50 mL) was added. The reaction mixture was degassed twice and heated to 90° C. for 1 hour. The reaction mixture was cooled to room temperature and diluted with 10 mL of 1:1 water. Quench with saturated sodium bicarbonate and extract with 2 x 25 mL EtOAc. The crude residue was dissolved in 10 mL of THF and treated with THF. A 1M solution of BAF (1.77 mL, 1.77 mmol) was added and stirred at room temperature for 1.5 hours. The reaction was quenched with saturated NH4Cl, extracted once with EtOAc, and washed with brine. Wash with 0-10% NaOH, dry over sodium sulfate, filter, concentrate in vacuo, and load on silica gel Purification with 3:1 EtOAc / EtOH / hexanes to 0% yield gave (3S)-4-(6- Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-(3-hydroxyphenyl)- Propoxy)-2-isopropylpyridin-3-yl)-2-oxo-1,2-dihydriodide lopirido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carvone tert-Butyl ester (Int-1h) was obtained. MS (ESI) [M+H] + m / z:6 67. Process I:(Int-1i) (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1- (4-(3-hydroxypropoxy)-2-isopropylpyridin-3-yl)-2-o xo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperidine tert-Butyl hydroxylamine-1-carboxylate (61 mg, 0.091 mmol) and trimethylsilyl Phenylphosphine (60.0 mg, 0.229 mmol) was added to THF (4.7 mL). The solution was degassed under nitrogen and diisopropyl azodicarboxylate (36.0 μL, 0.183 m The solvent was removed in vacuo and the residue was sonicated with silica gel. Purification with 0 to 100% hexane / 3:1 EtOAc / EtOH gave Int-1 i was obtained. MS(ESI)[M+H] + m / z:647. Process J:Int-1j Int-1i (137 mg, 0.211 mmol) was dissolved in DCM (4 mL), TFA (0.814 mL, 10.6 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The residue was evaporated in vacuo to give crude Int-1j+3TFA, which was used without further purification. MS(ESI)[M+H] + m / z:549. Step K: Example 1a: 18,21-difluoro-2-[(2S)-2-methyl-4-(propanol) [6-(propan-2-yl)-12,1-prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-12,1-prop-2-enoyl 3-Dihydro-4H,11H-1,19-ethenopyrido[4,3-f]pyrimido[1,6 -h][1,5,8,10]benzodioxadiazacyclotridecin-4-one Int-1j+3TFA (200mg, 0.225mmol) in DCM (2.25mL ), cooled to 0°C, and added DIEA (157 μL, 0.898 mmol), chloride Acryloyl (20 μL, 0.25 mmol) was added and stirred for 1 hour. Quench by addition of L saturated sodium bicarbonate and extract with 2 x 10 mL EtOAc. , washed with brine, dried over sodium sulfate, filtered, concentrated in vacuo, and purified with silica gel The racemic material was purified by elution with 0 to 100% 3:1 EtOAc / EtOH. FC column A, conditions: Decomposition with MeOH containing 0.1% NH4OH, 18,21 -Difluoro-2-[(2S)-2-methyl-4-(prop-2-enoyl)piperazine -1-yl]-6-(propan-2-yl)-12,13-dihydro-4H,11H-1 ,19-Ethenopyrido[4,3-f]pyrimido[1,6-h][1,5,8,10]ben Dioxadiazacyclotridecin-4-one (Example 1a, peak 1) was isolated as a single conformer. Obtained as a sexual body.
[0202] MS(ESI)[M+H] + m / z:603 1 H NMR (500 MHz, DMSO -d6)δ 8.38(d,J=5.7Hz,1H),8.17(m,1H),7.52 -7.45(m,1H),7.06(d,J=5.9Hz,1H),6.98-6.90 (m,2H),6.90-6.79(m,1H),6.26-6.16(m,1H),5 .77(d,J=10.4Hz,1H),4.73(m,1H),4.45(m,2H) ,4.32(m,1H),4.19-4.06(m,2H),3.99(m,2H),3 .67-3.47(m,2H),3.19(m,1H),2.87(m,1H),1.9 6(m,1H),1.90-1.76(m,1H),1.41(m,3H),1.13( d,J=6.7Hz,3H),0.90(d,J=6.7Hz,3H).
[0203] Example 2a was prepared as described in Example 1, and Int-1g was treated with (2-hydroxypyridine It was prepared using 1,4-dimethyl-3-ylboronic acid. [Table 2]
[0204] Example 3a / 3b: 22-fluoro-2-[(2S)-2-methyl-4-(prop-2- (enoyl)piperazin-1-yl]-6-(propan-2-yl)-12,13-dihydrido 4H,11H-1,20-ethenopyrido[4',3':2,3]pyrimido[1',6 ':4,5][1,4,6,10]oxatriazacyclotridecyno[8,9,10-h i]indazol-4-one [ka]
[0205] Step A: (S)-4-(6-fluoro-1-(4-(3-hydroxypropoxy)-2- Isopropylpyridin-3-yl)-7-(1H-indazol-7-yl)-2-oxo -1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine tert-Butyl benzoate-1-carboxylate (Int-3a) (S)-4-(1-(4-(3-((tert-butyldimethylsilyl)oxy)propionyl) 2-Isopropylpyridin-3-yl)-7-chloro-6-fluoro-2-oxo So-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperane tert-Butyl 2-inosin-1-carboxylate (Int-1g) (71.4 mg, 0.101 m mol), 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- (yl)-1H-indazole (0.037 g, 0.152 mmol), potassium acetate (0 0.040g, 0.405mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium(II) dichloride dichloromethane complex (8.3 mg, 10.1 μmol ) was added to a 20 mL scintillation vial equipped with a magnetic stir bar and cooled under nitrogen. Degass, add dioxane (0.87 mL) / water (0.15 mL), and degas under nitrogen three times. The reaction mixture was cooled to room temperature and diluted with 2 mL of 1:1 water / saturated Quench with ammonium chloride, extract with 1 x 25 mL EtOAc, and then with brine. The crude residue was dissolved in 5 mL of THF and treated with TBAF in THF. Add 1.0 M solution (0.506 mL, 0.506 mmol) and stir at room temperature for 1.5 hours. The reaction was quenched with saturated NH4Cl and extracted with 1 x 15 mL of EtOAc. , washed with brine, dried over sodium sulfate, filtered, concentrated in vacuo, and purified with silica gel Purification was carried out with 0 to 100% 3:1 EtOAc / EtOH / DCM to obtain (S)-4- (6-fluoro-1-(4-(3-hydroxypropoxy)-2-isopropylpyridine -3-yl)-7-(1H-indazol-7-yl)-2-oxo-1,2-dihydropyridin Lido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid ert-butyl was obtained. Int-3a MS(ESI)[M+H] + m / z 673. Process B: Int-3b (S)-4-(6-fluoro-1-(4-(3-hydroxypropoxy)-2-isopropyl) (1H-indazol-7-yl)-2-oxo-1,2-pyridine -dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1- tert-Butyl carboxylate (58 mg, 0.086 mmol) was dissolved in dioxane (4.3 m Cyanomethylenetributylphosphorane (45.2 μl, 0.172 m mol), degassed under nitrogen, and heated to 120° C. overnight. The reaction mixture was concentrated in vacuo. Purification on silica gel with 0 to 100% 3:1 (EtOAc / EtOH) / DCM This resinous material was triturated with hexane to give Int 3b containing impurities. The resulting mixture was filtered, sonicated, filtered, and washed with 1× hexane to give Int-3b. ESI) [M+H] + m / z 655. Process C: Int-3c Int-3b (68 mg, 0.104 mmol) was dissolved in DCM (2.0 mL). Then, TFA (800 μl, 10.4 mmol) was added and the reaction mixture was stirred at room temperature for 1 hour. Concentration in vacuo gave Int-3c+3TFA as a crude residue which was used without further purification. MS(ESI)[M+H] + m / z 555. Step D: Example 3a / 3b 22-fluoro-2-[(2S)-2-methyl-4-(pro
[0043] -6-(propan-2-yl)-12,13-propan-2-yl -Dihydro-4H,11H-1,20-ethenopyrido[4',3':2,3]pyrimido[ 1',6':4,5][1,4,6,10]oxatriazacyclotridecyno[8,9, 10-hi]indazol-4-one Int-3c (90 mg, 0.146 mmol) was dissolved in 4 mL of DCM and DI EA (153 μl, 0.876 mmol) was added, the mixture was cooled to 0°C, and acryloyl chloride was added. (14.0 μl, 0.175 mmol) was added and stirred at that temperature for 1 hour. Quench with 2 mL of 1:1 saturated sodium bicarbonate / water and transfer to a 4 mL phase separator. Filter through, extract once with 5 mL of DCM, concentrate in vacuo, and rinse with silica gel from 0 to 100% Purification with 3:1 EtOAc / EtOH / DCM gave the racemic product. The product was purified by SFC chromatography on column T, conditions: 0.25% DMEA Decomposition with MeOH, 50% CO2 gave 22-fluoro-2-[(2S)-2-methyl- [4-(prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl) 4',3':2 ,3]pyrimido[1',6':4,5][1,4,6,10]oxatriazacyclotri Decino[8,9,10-hi]indazol-4-one (Example 3a, peak 1) was isolated as a single Obtained as conformers.
[0206] MS(ESI)[M+H] + m / z 609. 1 H NMR (600 MHz, DMS O-d6)δ 8.52(d,J=8.4Hz,1H),8.31(d,J=5.7Hz ,1H),8.28(s,1H),7.92(d,J=8.0Hz,1H),7.31( d,J=6.7Hz,1H),7.21(t,J=7.5Hz,1H),6.96(d, J=5.7Hz,1H),6.88(dd,J=16.9,10.4Hz,1H),6. 22(dd,J=16.8,8.6Hz,1H),5.78(dd,J=10.4,2. 4Hz,1H),5.11(m,1H),4.45(d,J=13.6Hz,0.5H) ,4.34(d,J=13.4Hz,0.5H),4.18(m,2.5H),4.08 (d,J=13.9Hz,0.5.H),4.00-3.77(m,3H),3.72( d,J=13.5Hz,0.5H),3.53(dt,J=14.0,7.6Hz,1H ),3.37(m,ov.1H)3.00(t,J=11.8Hz,0.5H),2.9 1(m,1H),2.41-2.24(m,1H),2.16(s,1H),1.37- 1.23(m,3H),1.15(d,J=6.8Hz,3H),0.88(d,J=6 .8Hz,3H). Example 3b, Peak 2-22-fluoro-2-[(2S)-2-methyl-4-(propanol) -2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-12,13- Dihydro-4H,11H-1,20-ethenopyrido[4',3':2,3]pyrimido[1 ',6':4,5][1,4,6,10]oxatriazacyclotridecyno[8,9,1 0-hi]indazol-4-one (Example 3b) MS (ESI) [M+H] + m / z 609. 1 H NMR(600MHz,DMSO-d6)δ 8.35(d,J=8.6 Hz,1H),8.31(d,J=5.6Hz,1H),8.29(s,1H),7.9 2(d,J=8.0Hz,1H),7.31(d,J=7.0Hz,1H),7.22( t,J=7.5Hz,1H),6.95(d,J=5.7Hz,1H),6.88(td ,J=17.5,11.1Hz,1H),6.22(t,J=14.1Hz,1H),5 .78(d,J=10.7Hz,1H),4.80(m,0.5H),4.77(m,0 .5H),4.48(d,J=13.7Hz,1H),4.42(d,J=13.3Hz ,0.5H),4.27(d,J=13.4Hz,0.5H),4.17(m,1.5z H),4.03(d,J=13.8Hz,0.5H),3.93-3.75(m,2H) ,3.74-3.54(m,2H),3.50(dt,J=13.8,7.4Hz,1H ),3.29(m,ov.0.5H),3.23(d,J=13.3Hz,0.5H), 2.91(p,J=6.7Hz,1H),2.36-2.25(m,1H),2.14( m,1H),1.47-1.39(m,3H),1.15(d,J=6.7Hz,3H) ,0.89(d,J=6.7Hz,3H).
[0207] Example 4: 18,21-difluoro-2-[(2S)-2-methyl-4-(prop-2- enoyl)piperazin-1-yl]-6-(propan-2-yl)-10,11,12, 13-Tetrahydro-4H-1,19-ethenopyrido[4,3-f]pyrimido[1,6- h][1,8,10]benzoxadiazacyclotridecin-4-one [ka]
[0208] Step A: (E)-4-(4-((tert-butyldimethylsilyl)oxy)but-1- (In)-3-nitro-2-(prop-1-en-2-yl)pyridine. t-4a) 2,4-Dichloro-3-nitropyridine (Int-1a) (10.7 g, 55.5 mm ol), cesium carbonate (63.3 g, 194 mmol), bis(triphenylphosphi (triphenylphosphite)palladium(II) dichloride (3.9 0 g, 5.55 mmol) was added to a 250 mL round-bottom flask equipped with a magnetic stir bar, Degas under nitrogen, charge with DME (90 mL) / water (22.5 mL), and degas under nitrogen twice. isopropenylboronic acid pinacol ester (11.0 mL, 58.3 mmol) The flask was equipped with a reflux condenser and stirred at 85°C for 5 hours. Cool to room temperature under argon flow and distill off (E)-tert-butyldimethyl ((4-(4,4 ,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-ene- 1-yl)oxy)silane (22.7 mL, 63.8 mmol) and 1,1'-bis( Diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex The reaction mixture was degassed under nitrogen three times and heated to 110°C. The reaction mixture was heated at reflux for 16 hours at rt. The reaction mixture was diluted with 300 mL of EtOAc and 200 mL of saturated sodium chloride. The aqueous and organic layers were filtered through a Celite pad, and the organic layer was separated. The aqueous layer was extracted with 250 mL of EtOAc. The aqueous solution was washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified on silica gel using 0 to 40% EtOAc / hexanes, followed by a slow gradient of 0 to 40% EtOAc / hexanes. Purify with 15% EtOAc / hexane to obtain (E)-4-(4-((tert-butyl) (dimethylsilyl)oxy)but-1-en-1-yl)-3-nitro-2-(prop- (1-en-2-yl)pyridine (Int-4a) was obtained. MS (ESI) [M+H] + m / z:349. Step B: 4-(4-((tert-butyldimethylsilyl)oxy)butyl)-2-isopropyl Propylpyridin-3-amine (Int-4b) 4-(4-((tert-butyldimethylsilyl)oxy)butyl)-3-nitro-2 -(prop-1-en-2-yl)pyridine (1.67 g, 4.76 mmol) in EtO The mixture was dissolved in 24.0 mL of H2O, degassed under nitrogen, and then cooled to room temperature. 3 mmol), the mixture was degassed under nitrogen and stirred overnight under a hydrogen atmosphere. The residue was dissolved in 5 mL of DCM and 0.2 μL of HCl was added. The solution was filtered through an M filter to remove traces of residual palladium on carbon, and 4-(4-(( tert-Butyldimethylsilyl)oxy)butyl)-2-isopropylpyridine-3- The amine was obtained. (Int-4b) MS (ESI) [M+H] + m / z:323. 1 H NMR(500MHz,CDCl3)δ 8.00(d,J=4.8Hz,1H),6. 86(d,J=4.8Hz,1H),3.70(m,4H),3.07(hept,J= 6.7Hz,1H),2.55-2.50(m,2H),1.73(m,2H),1.6 8-1.62(m,2H),1.33(m,6H),0.92(s,9H),0.08( s,6H). Step C: N-((4-(4-((tert-butyldimethylsilyl)oxy)butyl)- 2-Isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluoro Ionicotinamide (Int-4c) 2,6-Dichloro-5-fluoronicotinamide (4.42 g, To a stirred solution of 21.2 mmol) of oxalyl chloride in DCM at 75 °C was added a 2 M solution of oxalyl chloride (12.5 mmol). mL, 25.0 mmol) was added, and the reaction mixture was heated to 75°C under a reflux condenser for 1 hour. The reaction mixture was evaporated in vacuo and dried under high vacuum for 30 minutes. Add 20 mL of THF, cool to 0 °C, and dissolve 4-(4-((te rt-Butyldimethylsilyl)oxy)butyl)-2-isopropylpyridin-3-amine A solution of ethanol (6.20 g, 19.2 mmol) was added dropwise to the reaction mixture. The reaction mixture was stirred at 0°C for 1 hour. It was then quenched with saturated ammonium chloride at 0°C and diluted with 100 mL of EtOAc. The reaction was washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification on silica gel with 0 to 50% 3:1 EtOAc-EtOH / DCM gave and N-((4-(4-((tert-butyldimethylsilyl)oxy)butyl)-2- Isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluorodiphenyl Cotinamide (Int-4c) was obtained. MS (ESI) [M+H] + m / z 557 / 559. Step D: 1-(4-(4-((tert-butyldimethylsilyl)oxy)butyl)-2 -isopropylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3-d] Pyrimidine-2,4(1H,3H)-dione (Peak 1 SFC) (Int-4d-1) N-((4-(4-((tert-butyldimethylsilyl)oxy)butyl)-2-isopropyl Isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluoronicotinamide cinamide (5.10 g, 9.15 mmol) was dissolved in THF (15.2 mL), The mixture was cooled to 0°C, KHMDS (19.2 mL, 19.2 mmol) was added, and the mixture was allowed to cool to room temperature for 1 minute. The reaction mixture was cooled to 0°C and 100 mL of saturated ammonium chloride was added. Quench and extract with 2 x 150 mL EtOAc, wash with brine and add sodium sulfate. The residue was purified by silica gel chromatography (0 to 100%) in a 3:1 ratio. Purify with EtOAc / EtOH / DCM to obtain 1-(4-(4-((tert-butyldichloroisothiazolinone). Methylsilyl)oxy)butyl)-2-isopropylpyridin-3-yl)-7-chloro -6-Fluoropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (conformation This product was purified by SFC, column Q, conditions: 100% CO2 in 100% CO2 Dissolved in MeOH, 15% modifier: Peak 1-Int-4d-1-1-(4-(4-((tert-butyldimethylsilyl )Oxy)butyl)-2-isopropylpyridin-3-yl)-7-chloro-6-fluoro Dopirido[2,3-d]pyrimidine-2,4(1H,3H)-dione. MS(ESI) [ M+H] + m / z 521; and Peak 2-Int-4d-2-1-(4-(4-((tert-butyldimethylsilyl )Oxy)butyl)-2-isopropylpyridin-3-yl)-7-chloro-6-fluoro Dopirido[2,3-d]pyrimidine-2,4(1H,3H)-dione. MS(ESI) [ M+H] + m / z 521 obtained.
[0209] Steps E and F: (S)-4-(1-(4-(4-((tert-butyldimethylsilyl )Oxy)butyl)-2-isopropylpyridin-3-yl)-7-chloro-6-fluoro (2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3- tert-Butyl methylpiperazine-1-carboxylate (Int-4f-1) 1-(4-(4-((tert-butyldimethylsilyl)oxy)butyl)-2-isopropyl Propylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3-d]pyrimidin Zin-2,4(1H,3H)-dione (Peak 1 SFC) (Int-4d-1) (1. 80 g, 3.45 mmol) was added to acetonitrile (17.3 mL) and DIE under nitrogen degassing. A(1.81mL,10.36mmol), POCl3(0.386mL,4.15mm ol) was added and heated to 80°C for 30 minutes. Dimethylsilyl)oxy)butyl)-2-isopropylpyridin-3-yl)-4,7- Dichloro-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one (Int- The reaction mixture containing 4e-1 was cooled to 0°C and DIEA (1.81 mL, 10.4 mm ol) and (S)-tert-butyl 3-methylpiperazine-1-carboxylate (0.8 The reaction mixture was stirred at the same temperature for 20 minutes. Quench with water, extract with 2 x 25 mL EtOAc, wash with brine and sulfuric acid. Dry over sodium, filter, concentrate, and wash with silica gel in a 3:1 ratio of 0 to 100%. Purify with EtOAc / EtOH / hexane to obtain (S)-4-(1-(4-(4-((te rt-Butyldimethylsilyl)oxy)butyl)-2-isopropylpyridin-3-yl )-7-chloro-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyridin tert-Butyl 3-methylpiperazine-1-carboxylate (In t-4f-1) was obtained. MS (ESI) [M+H] +m / z 703. Step G: (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl) )-1-(4-(4-hydroxybutyl)-2-isopropylpyridin-3-yl)-2 -oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl piperazine-1-carboxylate (Int-4g-1) (S)-4-(1-(4-(4-((tert-butyldimethylsilyl)oxy)butyl )-2-Isopropylpyridin-3-yl)-7-chloro-6-fluoro-2-oxo- 1,2-Dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine tert-Butyl-1-carboxylate (1.50 g, 2.13 mmol), 3-fluoro- 2-(trifluoro-λ 4 -Voranail) phenolate (602 mg, 2.77 mmol) ), potassium acetate (837 mg, 8.53 mmol), 1,1'-bis(diphenylphos phino)ferrocene-palladium(II) dichloride dichloromethane complex (174mg, 0.213 mmol) into a 20 mL scintillation vial equipped with a magnetic stir bar. The mixture was degassed under nitrogen, and then dioxane (9 mL) / water (1.5 mL) was added and the mixture was stirred under nitrogen. The reaction mixture was degassed three times at 400°C and heated to 90°C for 1 hour. The reaction mixture was cooled to room temperature and diluted with 10 mL of 1:1 Quench with water / saturated sodium bicarbonate and extract with 2 x 25 mL EtOAc. The crude residue was dissolved in 10 mL of THF and concentrated in vacuo. Add 1M solution of TBAF (6.40 mL, 6.40 mmol) and incubate at room temperature for 1.5 hours. The reaction was quenched with 50 mL of saturated NH4Cl / 100 mL of EtOAc. The organic layer was separated and washed with 1 x 25 mL of saturated ammonium chloride. ammonium, washed with 25 mL of brine, dried over sodium sulfate, filtered, and vacuum Concentrate and load on silica gel in 0 to 100% 3:1 EtOAC / EtOH / hexanes. (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl)- -1-(4-(4-hydroxybutyl)-2-isopropylpyridin-3-yl)- 2-Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl 1-isopropylpiperazine-1-carboxylate (Int-4g-1) was obtained. MS (E SI) [M+H] + m / z 665. Process H:(Int-4h-1). (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1- (4-(4-hydroxybutyl)-2-isopropylpyridin-3-yl)-2-oxo -1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine tert-Butyl benzoate (1.10 g, 1.66 mmol) and triphenyl THF (66 mL) was added to 1.09 g of methyl phosphine (4.14 mmol), and the mixture was heated under nitrogen. Degassed under vacuum, sonicated, and diluted with diisopropyl azodicarboxylate (652 μL, 3.31 m The reaction was sonicated for 30 minutes and the solvent was removed under vacuum. The residue was then purified on silica gel with 0 to 100% 3:1 EtOAc / EtOH / hexanes The resulting mixture was purified by MS (ESI) [M+H] to give Int-4h-1. + m / z 647. Process I:Int-4i-1 Int-4i-1 (370 mg, 0.572 mmol) was dissolved in DCM (3.8 mL). The mixture was dissolved, and TFA (1.1 mL, 14.3 mmol) was added, followed by stirring at room temperature for 20 minutes. The solvent was removed in vacuo and the residue was azeotroped with 1x toluene / 1x pentane to give Int-4i-1. Obtained as the lys-TFA salt. MS(ESI)[M+H] + m / z 547. Step J: 18,21-difluoro-2-[(2S)-2-methyl-4-(prop-2-enyl)methyl] 10,11,12,1-(2-(2-aminoyl)piperazin-1-yl)-6-(propan-2-yl)- 3-Tetrahydro-4H-1,19-ethenopyrido[4,3-f]pyrimido[1,6-h [1,8,10]Benzoxadiazacyclotridecin-4-one (Example 4a) Int-4i-1+3TFA (385mg, 0.433mmol) in DCM (5.8m The mixture was cooled to 0°C and added DIEA (378 μL, 2.17 mmol), followed by Then, acryloyl chloride (38.7 μl, 0.48 mmol) was added. The reaction mixture was stirred for 15 minutes. Stir, quench with 2 mL of saturated sodium bicarbonate, pour into a phase separator, and add 1× Wash with 6 mL of DCM, evaporate in vacuo, and eluate with silica gel from 0 to 100% Purify with hexane (3:1 EtOAc / ethanol) to obtain 18,21-difluoro-2 -[(2S)-2-Methyl-4-(prop-2-enoyl)piperazin-1-yl]-6 -(propan-2-yl)-10,11,12,13-tetrahydro-4H-1,19- Ethenopyrido[4,3-f]pyrimido[1,6-h][1,8,10]benzoxadia Zacyclotridecin-4-one (Example 4a) was obtained. MS (ESI) [M+H] + m / z 601. MS(ESI)[M+H] + m / z 601. 1 H NMR (500M Hz,DMSO-d6)δ 8.39(d,J=4.9Hz,1H),8.36-8.2 7(m,1H),7.46(q,J=8.3Hz,1H),7.16(d,J=4.9H z,1H),7.10(d,J=8.4Hz,1H),6.97(t,J=8.7Hz, 1H),6.94-6.78(m,1H),6.25-6.17(m,1H),5.81 -5.74(m,1H),4.90(br s,1H),4.46-4.36(m,2H) ),4.31-4.11(m,1H),4.06-3.98(m,2H),3.91-3 .83(m,1H),3.72-3.6(m,1H),3.61-3.52(m,1H) ,3.29-3.11(m,1H),2.73-2.56(m,2H),2.45-2. 35(m,1H), 1.36-1.29(overlap m,4H), 1.30-1. 11(m,1H),1.05(d,J=6.7Hz,3H),0.83(d,J=6.6 Hz,3H).
[0210] 18,21-Difluoro-2-[(2S)-2-methyl-4-(prop-2-enoyl) Piperazin-1-yl]-6-(propan-2-yl)-10,11,12,13-tet Hydro-4H-1,19-ethenopyrido[4,3-f]pyrimido[1,6-h][1, 8,10]Benzoxadiazacyclotridecin-4-one (Example 4b) Example 4b was analyzed by SFC using the procedure described above for Example 4a. It was prepared from isomer Int-4d-2.
[0211] Example 4b: MS(ESI)[M+H] + m / z 601. 1 H NMR (500 M z,DMSO-d6)δ 8.45-8.32(m,2H),7.46(q,J=8.3 Hz,1H),7.16(d,J=4.9Hz,1H),7.10(d,J=8.5Hz ,1H),6.96(t,J=8.7Hz,1H),6.94-6.79(m,1H), 6.25-6.17(m,1H),5.8-5.74(m,1H),5.02(brs, 1H),4.45-4.37(m,1H),4.35-4,25(m,1H),4.18 -4.12(m,1H),4.08-4.0(m,2H),3.9-3.83(m,1H) ),3.82-3.73(m,1H),3.7-3.64(m,1H),3.16-3. 06(m,1H),2.68-2.58(m,2H),2.46-2.35(m,1H) ,1.39-1.2(overlap m,5H),1.05(d,J=6.7Hz,3 H), 0.81 (d, J = 6.5 Hz, 3 H).
[0212] Examples 5 and 6 were prepared in a similar manner to Example 4a, except that in step G, Int-4f-1 was converted to (1H- pyrazol-5-yl)boronic acid or 7-(4,4,5,5-tetramethyl-1,3,2 -dioxaborolan-2-yl)-1H-indazole acid was used instead. [Table 3]
[0213] Example 7: 2-[(3R,5S)-3,5-dimethyl-4-(prop-2-enoyl)pyrimidinyl] Perazin-1-yl]-18,21-difluoro-6-(propan-2-yl)-10, 11,12,13-Tetrahydro-4H-1,19-ethenopyrido[4,3-f]pyrimidin Do[1,6-h][1,8,10]benzoxadiazacyclotridecin-4-one [ka]
[0214] Process A: Int-7a Int-4h-1 (330 mg, 0.510 mmol) in MeOH (2.55 mL) and KOH (1 M in methanol) (1.53 mL, 1.53 mmol) was added. The reaction mixture was heated to 40° C. for 2 hours and then allowed to cool to room temperature overnight. Dilute with c, pour into 50 mL of saturated ammonium chloride, stir, separate the organic layer, and The resulting residue was washed with water, dried over sodium sulfate, filtered, and concentrated in vacuo. Purify on silica gel with 0 to 100% 3:1 EtOAc / EtOH / hexanes. MS (ESI) [M+H] + m / z 465. Process B: Int-7b Int-7a (16.5 mg, 0.036 mmol) was dissolved in acetonitrile (710 μL). Dissolve DIEA (18.6 μL, 0.107 mmol), POCl3 (3.97 The reaction mixture was heated to 80°C for 30 minutes. Cool and add another portion of DIEA (18.61 μL, 0.107 mmol) and (2R ,6S)-2,6-dimethylpiperazine-1-carboxylate tert-butyl (9.5mg , 0.044 mmol) was added, and the temperature was raised to room temperature over 2 hours. Concentrate and load on silica gel in 0 to 100% 3:1 EtOAc / EtOH / hexanes The resulting product was purified to give Int-7b. MS(ESI)[M+H] + m / z 661. Steps C to D: Example 7 Int-7b (10 mg, 0.015 mmol) was dissolved in CH2Cl2 and TFA (58.3 μl, 0.757 mmol) was added, the mixture was stirred at room temperature for 20 minutes, and concentrated under vacuum. Dissolve in CH2Cl2, add DIEA (13.2 μl, 0.076 mmol), The mixture was cooled to 0°C, and acryloyl chloride (1.2 μl, 0.015 mmol) was added. The reaction was quenched with 1 mL of saturated sodium bicarbonate and stirred in a phase separator. The mixture was poured into a 1×3 mL column, washed with 1×3 mL of CH2Cl2, concentrated, and then washed with silica gel from 0 to 100% Purification with 3:1 EtOAc / EtOH / hexanes at 2-[(3R,5S)-3, 5-Dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-18,21-di Fluoro-6-(propan-2-yl)-10,11,12,13-tetrahydro-4H -1,19-Ethenopyrido[4,3-f]pyrimido[1,6-h][1,8,10]ben 2-oxadiazacyclotridecin-4-one (Example 7) was obtained. MS (ESI) [M+ H] + m / z 615.
[0215] Example 8 was prepared in a similar manner to Example 7, using Int-7a as the piperazine component of Step B ( 2R,5S)-2,5-dimethylpiperazine-1-carboxylate tert-butyl ester It was prepared by adding [Table 4]
[0216] Example 9: 19-chloro-16-fluoro-2-[(2S)-2-methyl-4-(propanol) -2-enoyl)piperazin-1-yl]-10,11-dihydro-4H-1,17-enoyl Tenodibenzo[b,h]pyrimido[6,1-f][1,5,7]oxadiazacyclone Decyn-4-one [ka]
[0217] Step A: 2-(2-((tert-butyldimethylsilyl)oxy)ethyl)aniline ( Int-9a) 2-(2-aminophenyl)ethanol (2.00 g, 14.6 mL) in DCM (30 mL) To a stirred solution of 100 mmol of dimethylformamide (DMSO) was added TBSCl (2.86 g, 19.0 mmol) and imidazoline. HCl (2.98 g, 43.7 mmol) was added, and the mixture was incubated at 20 °C for 16 h under a N2 atmosphere. The reaction mixture was concentrated in vacuo and the residue was washed with silica gel, 0 to 10% EtO Purified by Ac / petroleum ether and purified by 2-(2-((tert-butyldimethylsilyl) (oxy)ethyl)aniline (Int-9a) was obtained. 1 H NMR (400 MHz, CD Cl3)δ 6.96-7.09(m,2H),6.62-6.80(m,2H),3. 98(br s,2H),3.87(t,J=6.24Hz,2H),2.78(t,J =6.11Hz,2H),0.87(d,J=1.71Hz,9H),-0.01(s, 6H). Step B: 2,5,6-Trichloronicotinamide (Int-9b) 2,5,6-Trichloronicotinic acid (8.70 g, 38.4 mmHg) in THF (90 mL) To a stirred solution of 1000 mg of CDI (6.85 g, 42.3 mmol) was added CDI (6.85 g, 42.3 mmol), and the reaction mixture was stirred for 5 min. The mixture was stirred at 0°C for 1 hour under a N2 atmosphere. Then toluene (20 mL) and ammonium hydroxide were added. ammonium (concentrated, 10.7 mL, 77.0 mmol) was added at 0° C., and the resulting mixture was The reaction mixture was stirred for 10 minutes at 20° C. The reaction mixture was quenched with water (30 mL) and ethyl acetate was added. The combined organic layers were washed with brine (50 mL) and extracted with chilled water (2 x 150 mL). The residue was dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. Purified in 0 to 100% EtOAc / petroleum ether at 2,5,6-trichloro- Ionicotinamide (Int-9b) was obtained. MS (ESI): m / z (M + MeCN + H )+ 266.1,268.1. Step C: N-((2-(2-((tert-butyldimethylsilyl)oxy)ethyl)fluor (phenyl)carbamoyl)-2,5,6-trichloronicotinamide (Int-9c) 2,5,6-Trichloronicotinamide (Int-9b) in THF (50 mL) (2. A stirred solution of 50 g (11.1 mmol) of oxalyl chloride (0.932 mL, 10.6 m mol) was added at 20°C, and the mixture was stirred at 65°C for 30 minutes under a N2 atmosphere. This was cooled to 20°C and 2-(2-((tert-butyldimethylsilyl)oxy) Ethyl)aniline (Int-9a) (2.93 g, 11.6 mmol) was added. The resulting mixture was stirred at 20° C. for 16 hours. The reaction mixture was diluted with brine (40 mL) and The mixture was quenched and extracted with ethyl acetate (2 x 60 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. The residue was purified on silica gel with 0 to 30% EtOAc / petroleum ether to give N-( (2-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)carba 2,5,6-trichloronicotinamide (Int-9c) was obtained. MS (ES I):[M+H] +m / z 502.3 / 504.3 Step D: 1-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl (1H,3H)-dichloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-di On (Int-9d) N-((2-(2-((tert-butyldimethylsilyl)oxy)-2-methyl-2-propanol)) in THF (50 mL) (3)ethyl)phenyl)carbamoyl)-2,5,6-trichloronicotinamide (3. To a stirred solution of potassium bis(trimethylsilyl)acetate (0.00 g, 5.97 mmol) in THF A 1 M solution of methyl 2-isopropyl ether (11.9 mL, 11.9 mmol) was added at 0°C, and the mixture was heated to 20°C. The reaction mixture was stirred for 30 minutes under N2 atmosphere. The mixture was quenched with 2 mL of ethyl acetate and extracted with ethyl acetate (2 x 80 mL). Wash with brine (20 mL), dry over Na2SO4, filter, and remove the solvent under reduced pressure. Evaporated and 1-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl )phenyl)-6,7-dichloropyrido[2,3-d]pyrimidine-2,4(1H,3H )-dione (Int-9d). The crude product was used in the next step without further purification. MS(ESI):[M+H] + m / z 466.2 / 468.1 Step E: 1-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl nyl)-4,6,7-trichloropyrido[2,3-d]pyrimidin-2(1H)-one ( Int-9e) 1-(2-(2-((tert-butyldimethylsilyl) )Oxy)ethyl)phenyl)-6,7-dichloropyrido[2,3-d]pyrimidine-2 A stirred solution of 4(1H,3H)-dione (2.30 g, 4.93 mmol) was added to DIEA ( 2.15 mL, 12.3 mmol) and POCl3 (0.689 mL, 7.40 mmol) l) was added at 25°C and the mixture was stirred at 80°C for 1 hour under N2 atmosphere. Concentrate and add 1-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)fluoride. (phenyl)-4,6,7-trichloropyrido[2,3-d]pyrimidin-2(1H)-one (Int-9e) was obtained, which was used in the next step without further purification. MS (ESI) : m / z (M+H) + 484.0 / 486.0. Step F: (S)-4-(1-(2-(2-((tert-butyldimethylsilyl)oxy) )ethyl)phenyl)-6,7-dichloro-2-oxo-1,2-dihydropyrido[2, 3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid tert-butyl Chill (Int-9f) 1-(2-(2-((tert-butyldimethylsilyl)oxy)-2-methyl-2-propanol) in DMF (40 mL) )ethyl)phenyl)-4,6,7-trichloropyrido[2,3-d]pyrimidine-2( To a stirred solution of 1H)-one (2.39 g, 4.93 mmol) was added DIEA (2.15 mL, 12.3 mmol) and (S)-3-methylpiperazine-1-carboxylic acid tert-butyl C., and the mixture was stirred at 20.degree. C. for 16 hours. The reaction mixture was stirred under N2 atmosphere. The reaction mixture was concentrated and the residue was purified by silica gel with 0 to 40% Purification with EtOAc / petroleum ether gave (S)-4-(1-(2-(2-((tert- Butyldimethylsilyl)oxy)ethyl)phenyl)-6,7-dichloro-2-oxo- 1,2-Dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine tert-Butyl 1-carboxylate (Int-9f) was obtained. MS (ESI): [M+H ] + m / z 648.2 / 650.2. Step G: (3S)-4-(1-(2-(2-((tert-butyldimethylsilyl)oxy) (2-(2-fluoro-6-hydroxyphenyl)-6-chloro-7-(ethyl)phenyl) -2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl ethylpiperazine-1-carboxylate (Int-9g) (S)-4-(1-(2-(2-( (tert-butyldimethylsilyl)oxy)ethyl)phenyl)-6,7-dichloro- 2-Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl 1-piperazinecarboxylate (1.00 g, 1.54 mmol), vinegar Potassium phosphate (0.756 g, 7.71 mmol) and 1,1'-bis(diphenylphosphine phino)ferrocene-palladium(II) dichloride dichloromethane complex (0.063g To a stirred solution of 1,2-dimethyl-3-(2-(2-methyl-2-propanol, 0.077 mmol) of 3-fluoro-2-(2-methyl-2-propanol) in 1,4-dioxane (3 mL) was added -2-(trifluoro-λ 4 -VolaNail) Phenol, Potassium Salt (0.538g, 2 0.47 mmol) was added at 90°C under N2 atmosphere, and the mixture was stirred at 20°C for 2 hours under N2 atmosphere. The reaction mixture was quenched with brine (20 mL) and ethyl acetate was added. The combined organic layers were washed with brine (20 mL) and The mixture was dried over 2SO4, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography. Purification with 0 to 50% EtOAc / petroleum ether afforded (3S)-4-(1-(2- (2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)-6-chloro -7-(2-fluoro-6-hydroxyphenyl)-2-oxo-1,2-dihydropyri Do[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid TE rt-Butyl (Int-9g) was obtained. MS (ESI): [M+H] + m / z 724 .4. Step H: (3S)-4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl) -1-(2-(2-hydroxyethyl)phenyl)-2-oxo-1,2-dihydropyri Do[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid TE rt-Butyl (Int-9h) (3S)-4-(1-(2-(2-((tert-butyldimethyl (( ... (2-Oxo-1,2-dihydropyrido[2,3-d]pyrimidine-4- tert-Butyl)-3-methylpiperazine-1-carboxylate (1.00g, 1.3 To a stirred solution of 1.8 mmol of TBAF in THF (4.14 mL, 4.14 mmol) l) was added and the mixture was stirred at 20°C for 16 hours under N2 atmosphere. The reaction mixture was vacuum After concentration, the residue was purified on silica gel with 0 to 8% MeOH / DCM to give (3S)- 4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-(2- Hydroxyethyl)phenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyridin tert-Butyl 3-methylpiperazine-1-carboxylate (In t-9h) MS(ESI): [M+H] + m / z 610.4 Process I: Int-9i (3S)-4-(6-chloro-7-(2-fluoro-6-hydro)- (2-hydroxyphenyl)-1-(2-(2-hydroxyethyl)phenyl)-2-oxo-1,2 -dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1- To a stirred solution of tert-butyl carboxylate (300 mg, 0.492 mmol) was added triphenyl. methyl phosphine (871 mg, 1.23 mmol) (37% loading on resin) was added, Then DIAD (0.096 mL, 0.492 mmol) was added at 70° C. The mixture The mixture was stirred at 70° C. for 1 hour under N2 atmosphere. The mixture was filtered and the filter cake was extracted with dichloromethane. The filtrate was concentrated in vacuo, and the residue was purified by preparative HPLC using water (10 mM N Purification by HCl / MeCN gave Int-9i. MS (ESI): [M +H] + m / z 592.2 Process J:Int-9j To a stirred solution of Int-9i (20 mg, 0.034 mmol) in DCM (2 mL) was added TF A (0.5 mL) was added and the mixture was stirred at 20°C for 30 min under N2 atmosphere. The mixture was concentrated in vacuo and the residue was purified by preparative HPLC in water (10 mM NH4HCO3) / MeCN Purification by HPLC gave Int-9j. MS (ESI): [M+H] + m / z 492 .2 Step K: 19-chloro-16-fluoro-2-[(2S)-2-methyl-4-(prop- 2-Enoyl)piperazin-1-yl]-10,11-dihydro-4H-1,17-ethene Nodibenzo[b,h]pyrimido[6,1-f][1,5,7]oxadiazacyclounde Syn-4-one (Example 9) Int-9j+TFA (20.5 mg, 0.034 mmol) in DCM (1.0 mL) To a stirred solution of DIEA (0.024 mL, 0.135 mmol) and acryloyl chloride (3.67 mg, 0.041 mmol) was added, and the mixture was heated at 20°C for 30 min under a N2 atmosphere. The mixture was stirred under atmosphere. The mixture was concentrated, and the residue was purified by preparative HPLC, water (10 mM NH4HCO3) / MeCN, and purified by 19-chloro-16-fluoro-2-[(2S)-2-methyl [4-(prop-2-enoyl)piperazin-1-yl]-10,11-dihydro-4 H-1,17-ethenodibenzo[b,h]pyrimido[6,1-f][1,5,7]oxa Diazacycloundecin-4-one (Example 9) was obtained as a mixture of conformers. MS (ESI):[M+H] + m / z 546.2 (400 MHz, methanol-d4) δ 8.43-8.30(m,1H),7.47-7.38(m,1H),7.37-7. 27(m,3H),7.20(br d,J=8.07Hz,1H),6.97(d,J =8.31Hz,1H),6.91-6.75(m,2H),6.31(br d,J= 16.14Hz,1H),5.84(dd,J=1.83,10.64Hz,1H),5 .32(br s,1H),4.96(br d,J=9.54Hz,1H),4.81 (br s,1H),4.74-4.59(m,1H),4.57-4.35(m,1H ),4.27-3.96(m,2H),3.78-3.40(m,2H),2.95(b r dd,J=7.70,13.57Hz,1H),2.36(br dd,J=6.3 6,15.41Hz,1H),1.57-1.36(m,3H).
[0218] Examples 10 to 15 4-(3-((tert-butyldimethylsilyl)oxy)propyl)-2-isopropyl Preparation of pyridin-3-amine (Int-10c) [ka]
[0219] Step A: 4-chloro-3-nitro-2-(prop-1-en-2-yl)pyridine (In t-10a) 2,4-Dichloro-3-nitropyridine (1 mL) in DME (150 mL) / water (30 mL) A stirred solution of CsCO (1.0 g, 57.0 mmol) was ), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2 -Dioxaborolane (9.58 g, 57.0 mmol) and bis(triphenylphosphine) (vinyl)palladium(II) dichloride (4.00 g, 5.70 mmol) and the resulting The resulting mixture was stirred at 85°C for 16 hours. The reaction mixture was cooled to room temperature and The combined organic phase was dried over anhydrous Na2SO4, filtered, and The residue was concentrated in vacuo and purified on silica gel with petroleum ether / Et0Ac=10 / 1 to give 4 -chloro-3-nitro-2-(prop-1-en-2-yl)pyridine (Int-10a ) was obtained. MS (ESI): [M+H] + m / z 198.8. Step B: (E)-4-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-1-yl)-3-nitro-2-(prop-1-en-2-yl)pyridine (In t-10b) 4-Chloro-3-nitro-2-(propan-1-yl)-1,2-dichloro ... A stirred solution of (10.0 g, 50.4 mmol) 1-en-2-ylpyridine was added to CsCO 3 (49.2 g, 151 mmol), (E)-tert-butyldimethyl ((3-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)oxy )silane (16.52 g, 55.4 mmol) and bis(triphenylphosphine) paraffin Radium(II) dichloride (3.53 g, 5.04 mmol) was added to the resulting mixture. The mixture was stirred at 90° C. for 16 hours. The reaction mixture was cooled to room temperature and diluted with EtOAc (200 mL×3 The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated in vacuo The residue was purified on silica gel eluting with petroleum ether / Et0Ac=5 / 1 to give (E)- 4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl )-3-nitro-2-(prop-1-en-2-yl)pyridine was obtained. MS(ESI) :[M+H] + m / z 335.1. Step C: 4-(3-((tert-butyldimethylsilyl)oxy)propyl)-2-isopropyl Isopropylpyridin-3-amine (Int-10c) (E)-4-(3-((tert-butyldimethylsilyl)oxy)prop-1-ene- 1-yl)-3-nitro-2-(prop-1-en-2-yl)pyridine (9.2 g, 2 A mixture of dry Pd-C (2.93 g, 27 0.5 mmol, 10% w / w) was added under an argon atmosphere, the mixture was degassed, and H2 was added for 3 The reaction mixture was purged twice and stirred under H atmosphere (40 psi) at 25 °C for 15 h. Filtration and concentration in vacuo gave the crude product, which was purified by silica gel from 0 to 30%. Purification with EtOAc / petroleum ether at rt gave 4-(3-((tert-butyldimethylsilyl) (aryl)oxy)propyl)-2-isopropylpyridin-3-amine (Int-10c) MS(ESI): [M+H] + m / z 309.3. 1 H NMR (400M Hz, CDCl3)δ:7.87(d,J=4.9Hz,1H),6.74(d,J=4 .9Hz,1H),3.79(br s,2H),3.57(t,J=5.7Hz,2H ),2.97(spt,J=6.7Hz,1H),2.52(t,J=7.5Hz,2H ),1.79-1.68(m,2H),1.23(d,J=6.6Hz,6H),0.8 5-0.83(m,9H),0.00(s,6H).
[0220] 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-isopropyl Preparation of pyridin-3-amine (Int-10f) [ka]
[0221] Step A: 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-chloro Iodo-3-nitropyridine (Int-10d) 2-((tert-butyldimethylsilyl)oxy)ethan-1-ol (9.05g , 51.3 mmol) was dissolved in tetrahydrofuran (155 mL) and cooled to 0°C. Then sodium hydride (2.05 g, 51.3 mmol) was added and the mixture was stirred at that temperature for 30 minutes. The reaction mixture was stirred. 2,4-dichloro-3-nitropyridine (9.00 g, 46.6 The reaction was then added in portions and allowed to warm slowly to room temperature over 2 hours. Quench with ammonium chloride, dilute with EtOAc, separate, and wash with brine , dried over sodium sulfate, filtered, concentrated, and purified by silica gel with 0 to 25% Et Purified by elution with OAc / hexane, and purified with 4-(2-((tert-butyldimethylsilyl )oxy)ethoxy)-2-chloro-3-nitropyridine (Int-10d) was obtained. S(ESI)[M+H] + m / z 333. Step B: 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-3-dimethylsilyl 2-(prop-1-en-2-yl)pyridine (Int-10e) 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-chloro- 3-Nitropyridine (12.0 g, 36.1 mmol), cesium carbonate (35.2 g, 1 08 mmol), bis(triphenylphosphine)palladium(II) dichloride (2. 53 g, 3.61 mmol) was added to a 250 mL round-bottom flask equipped with a magnetic stir bar. The mixture was degassed under nitrogen, charged with DME (72 mL) and water (18 mL), and degassed twice under nitrogen. Isopropenylboronic acid pinacol ester (7.45 mL, 39.7 mmol) The reaction mixture was cooled to room temperature and added with 100 mL of EtOAc. Dilute with 50 mL of saturated ammonium chloride, wash with brine, and dry over sodium sulfate. The mixture was dried, filtered, and concentrated in vacuo. Silica gel was washed with 0 to 20% EtOAc / Hexanes. Purification of 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)- 3-Nitro-2-(prop-1-en-2-yl)pyridine (Int-10e) was obtained. MS(ESI)[M+H] + m / z 339. Step C: 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-yl Isopropylpyridin-3-amine (Int-10f) 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-3-nitro- 2-(prop-1-en-2-yl)pyridine (10.0 g, 29.5 mmol) was dissolved in Et The solution was dissolved in 148 mL of OH, degassed under nitrogen, and purified by filtration to give Pd-C (0.629 g, 5.91 mL). The mixture was degassed under nitrogen and stirred for 24 hours under a hydrogen atmosphere. The product mixture was thoroughly purged with nitrogen. The purged product mixture was then poured onto a Celite pad. The filtrate was concentrated to dryness and 4-(2-((tert-butyldimethylsilyl )oxy)ethoxy)-2-isopropylpyridin-3-amine (Int-10f) Ta. 1 H NMR(500MHz,DMSO-d6)δ 7.73(d,J=5.3Hz ,1H),6.73(d,J=5.3Hz,1H),4.45(s,2H),4.09( d,J=4.5Hz,2H),3.95(dd,J=5.4,4.1Hz,2H),3. 16(p,J=6.7Hz,1H),1.14(d,J=6.7Hz,6H),0.88 (s,9H),0.07(s,6H).
[0222] 4-(3-((tert-butyldimethylsilyl)oxy)-2,2-difluoropropionate Preparation of (Int-10i)-2-isopropylpyridin-3-amine [ka]
[0223] Step A: 4-(3-((tert-butyldimethylsilyl)oxy)-2,2-difluoro (Iodopropoxy)-2-chloro-3-nitropyridine (Int-10g) 3-((tert-butyldimethylsilyl)oxy)-2,2-difluoropropane- 1-ol (6.45 g, 28.5 mmol) was dissolved in tetrahydrofuran (86 mL). The mixture was cooled to 0°C and sodium hydride (1.14 g, 28.5 mmol) was added. The reaction mixture was stirred at that temperature for 30 minutes. 5.00 g, 25.9 mmol) was added in portions, and the temperature was slowly increased to room temperature over 2 hours. The reaction was quenched with ammonium chloride, diluted with EtOAc and separated. Wash with brine, dry over sodium sulfate, filter, concentrate, and load onto silica gel. Purification was performed by eluting with 25% to 25% EtOAc / hexane to give 4-(3-((tert- Butyldimethylsilyl)oxy)-2,2-difluoropropoxy)-2-chloro-3- Nitropyridine (Int-10g) was obtained. MS (ESI) [M+H] + m / z 38 3. Step B: 4-(3-((tert-butyldimethylsilyl)oxy)-2,2-difluoro (Int-)-3-nitro-2-(prop-1-en-2-yl)pyridine 10h) 4-(3-((tert-butyldimethylsilyl)oxy)-2,2-difluoropropane (epoxy)-2-chloro-3-nitropyridine (7.00 g, 18.3 mmol), carbonate Sium (17.9 g, 54.8 mmol), bis(triphenylphosphine)palladium (II) dichloride (1.28 g, 1.83 mmol) was added to a 250 ml A 100 mL round-bottom flask was degassed under nitrogen and charged with DME (36 mL) and water (9.1 mL). ) and degassed twice under nitrogen. 8 mL, 20.1 mmol) was added and stirred at 85°C for 3 hours. The reaction mixture was cooled to room temperature. Dilute with 100 mL of EtOAc and wash with 50 mL of saturated ammonium chloride and brine. The mixture was washed, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification at 27°C with EtOAc / hexanes gave 4-(3-((tert-butyldimethylsilyl)methyl)methyl (2,2-difluoropropoxy)-3-nitro-2-(prop-1-enyl)oxy MS (ESI) [M+H] + m / z 38 9. Step C: 4-(3-((tert-butyldimethylsilyl)oxy)-2,2-difluoro (Isopropyloxy)-2-isopropylpyridin-3-amine (Int-10i) 4-(3-((tert-butyldimethylsilyl)oxy)-2,2-difluoropropane (2-(2-(2-hydroxypropyl)-3-nitro-2-(prop-1-en-2-yl)pyridine) (6.60 g, 1 7.0 mmol) was dissolved in EtOH (85 mL), degassed under nitrogen, and Pd—C (0 The mixture was degassed under nitrogen and then placed in a hydrogen atmosphere. The product mixture was thoroughly purged with nitrogen. The purged product mixture was stirred under vacuum for 24 hours. The mixture was filtered through a pad of Celite. The filtrate was concentrated to give 4-(3-((tert-butyl) (2,2-difluoropropoxy)-2-isopropylpyridine Int-10i was obtained as azine-3-amine. MS (ESI) [M+H] + m / z 3 61. In Examples 10 to 15, Int-10c and Int-10d were prepared in the same manner as in Example 1. Int-10f and Int-10i were used to prepare the compound, replacing the substituted protected piperazine in step G. In Example 11, (S)-2-(cyclohexyl)-2-(trimethylsil ... In step J, benzyl (aminomethyl)piperazine-1-carboxylate was reacted with substituted hydroxyl groups in MeOH. Radium / H2 was used. Examples marked with "###a" are the first elution peaks on the SFC. The examples marked with "Number ##b" correspond to the second eluting peak on SFC. In Example 15, in Step G, (S)-2-(piperazin-2-yl)acetonitrile Rubis (hydrochloride) was used. [Table 5] TIFF0007595127000056.tif223170
[0224] Example 16a / b: 19,22-difluoro-2-[(2S)-2-methyl-4-(propanol) [2-enoyl]piperazin-1-yl]-7-(propan-2-yl)-11,12 ,13,14-tetrahydro-4H-1,20-(ethanediylidene)-6,10-(methyl Theno)pyrimido[1,6-k][1,8,11,13]benzoxatriazacyclohex Sadecin-4-one [ka]
[0225] Step A: 5-chloro-3-nitro-2-(prop-1-en-2-yl)pyridine (In t-16a) 2-Bromo-5-chloro-3-nitropyridine (Int-16) (5.00 g, 21. 1mmol), bis(triphenylphosphine)palladium(II) dichloride (1.4 8g, 2.11mmol) and cesium carbonate (13.7g, 42.1mmol) in 25 The reaction vessel was evacuated and filled with nitrogen using a nitrogen balloon. DME (56 mL) and water (14 mL) were added to the reactor, and the resulting The resulting mixture was evacuated and refilled three times with a nitrogen balloon. 5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxabo Lorane (4.16 mL, 22.1 mmol) was added to the reaction vessel, and the resulting mixture was heated to 85 The mixture was heated to 100° C. for 4 hours. The product mixture was diluted with ethyl acetate (100 mL). The resulting product mixture was washed three times with saturated aqueous sodium bicarbonate (3 x 10 mL). The dried solution was filtered and the filtrate was concentrated to dryness. The resulting residue was purified by flash column chromatography on silica gel, first with hexane, Purification was performed by elution with a linear gradient of ethyl acetate-hexane to 20%. 1-(3-nitro-2-(prop-1-en-2-yl)pyridine (Int-16a) Ta. 1 H NMR(500MHz,CDCl3)δ 8.74(d,J=2.2Hz,1 H),8.09(d,J=2.2Hz,1H),5.38(dd,J=1.7,0.7H z,1H),5.17(t,J=1.0Hz,1H),2.22(t,J=1.2Hz, 3H). Step B: (E)-5-(4-((tert-butyldimethylsilyl)oxy)but-1- (Int-en-1-yl)-3-nitro-2-(prop-1-en-2-yl)pyridine -16b) 5-chloro-3-nitro-2-(prop-1-en-2-yl)pyridine (3.80g , 19.1 mmol), cesium carbonate (12.tg, 38.3 mmol) and XPho s-Pd-G3 (0.810 g, 0.957 mmol) was placed in a 250 mL round-bottom flask. The reactor was evacuated and refilled with nitrogen using a nitrogen balloon. Aqueous (51 mL) and water (13 mL) were added to the reaction vessel, and the resulting mixture was heated under nitrogen. The mixture was degassed for 30 seconds by bubbling. (E)-tert-butyldimethyl ((4-( 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3- (1-enyl)oxy)silane (7.17 g, 23.0 mmol) was added to the reaction vessel. The resulting mixture was heated at 90°C for 2 hours. The product mixture was cooled to room temperature. The resulting product mixture was transferred to a separatory funnel. The organic layer was isolated and washed with sodium sulfate. The dried solution was filtered and the filtrate was concentrated to dryness. Flash column chromatography on silica gel was performed, initially with hexane, followed by a linear gradient of 2 Purification was performed by elution with a gradient of ethyl acetate-hexanes up to 0% to obtain (E)-5-(4-( (tert-Butyldimethylsilyl)oxy)but-1-en-1-yl)-3-nitro To give 1-(2-prop-1-en-2-yl)pyridine (Int-16b), 1 HNM R(500MHz,CDCl3)δ 8.67(d,J=2.0Hz,1H),8.00 (d,J=2.0Hz,1H),6.46(t,J=1.8Hz,2H),5.34(d ,J=1.2Hz,1H),5.19-5.04(m,1H),3.76(t,J=6. 4Hz,2H),2.49(q,J=6.2Hz,2H),2.20(s,3H),0. 90(s,9H),0.07(s,6H). Step C: 5-(4-((tert-butyldimethylsilyl)oxy)butyl)-2-isopropyl Propylpyridin-3-amine (Int-16c) (E)-5-(4-((tert-butyldimethylsilyl)oxy)but-1-ene-1 -yl)-3-nitro-2-(prop-1-en-2-yl)pyridine (6.42 g, 1 8.4 mmol) was dissolved in EtOH (92 mL), degassed under nitrogen, and Pd—C (0 The mixture was degassed under nitrogen and then placed in a hydrogen atmosphere. The product mixture was thoroughly purged with nitrogen. The purged product mixture was stirred under vacuum for 24 hours. The mixture was filtered through a pad of Celite. The filtrate was concentrated to give 5-(4-((tert-butyl) (Isopropyldimethylsilyl)oxy)butyl)-2-isopropylpyridin-3-amine (Int -16c) was obtained. MS (ESI): [M+H] + m / z 323. Step D: N-((5-(4-((tert-butyldimethylsilyl)oxy)butyl)- 2-Isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluoro Ionicotinamide (Int-16d) 2,6-Dichloro-5-fluoronicotinamide (2.00 g, 9.57 mmol) The reaction vessel was evacuated and a nitrogen balloon was used to evacuate the reaction vessel. THF (9.57 mL) was added to the reaction vessel to dissolve the starting material. A 2M solution of oxalyl dichloride (5.74 mL, 11.5 mmol) was added dropwise to the reaction vessel. The resulting mixture was heated at 75°C for 1 hour. The intermediate solution was allowed to cool to room temperature. The resulting intermediate solution was concentrated to half its volume. THF (5 mL) was added to the reaction vessel. and the resulting mixture was cooled to 0° C. In a separate 4 mL vial, 5-(4- ((tert-butyldimethylsilyl)oxy)butyl)-2-isopropylpyridine- 3-amine (Int-16c, 3.09 g, 9.57 mmol) in THF (5 mL) This amine solution was added dropwise to the reaction vessel, and the resulting mixture was stirred at 0°C for 1 hour. The product mixture was allowed to warm to room temperature. The warmed product mixture was added to saturated sodium chloride solution. The reaction mixture was quenched with 2 mL of a 1:1 mixture of aqueous ammonium chloride and aqueous ammonium chloride. The thawed product mixture was extracted three times with ethyl acetate (3 x 20 mL). The combined organic layers The resulting residue was dried over sodium sulfate and concentrated to dryness. Column chromatography was performed using 5% (ethyl acetate:ethanol = 3:1 v / v )-dichloromethane, a linear gradient up to 100% (ethyl acetate:ethanol = 3: 1 v / v) and purified by elution with N-((5-(4-((tert-butyldimethyl (silyl)oxy)butyl)-2-isopropylpyridin-3-yl)carbamoyl)- 2,6-Dichloro-5-fluoronicotinamide (Int-16d) was obtained. MS (ES I) [M+H] + m / z:557 / 559. Step E: 1-(5-(4-((tert-butyldimethylsilyl)oxy)butyl)-2 -isopropylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3-d] Pyrimidine-2,4(1H,3H)-dione (Int-16e) N-((5-(4-((tert-butyldimethylsilyl)oxy)butyl)-2-isopropyl Isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluoronicotinamide Chlorhexidine amide (2.90 g, 5.20 mmol) was added to a 30 mL vial. The vessel was evacuated and refilled three times with a nitrogen balloon. THF (10.4 m L) was added to the reaction vessel, and the resulting mixture was cooled to 0°C. A 1M solution of (methylsilyl)amide (10.4 mL, 10.4 mmol) was added to the reaction vessel, The resulting mixture was stirred for 1 hour at 0° C. The product mixture was diluted with saturated aqueous ammonium chloride. (3 mL). The quenched product mixture was washed with ethyl acetate three times (3 The organic layers were combined and dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to dryness. The resulting residue was filtered through a silica gel flask. Purification was performed by column chromatography using 0 to 100 EtOAc / hexane. 1-(5-(4-((tert-butyldimethylsilyl)oxy)butyl)-2- Isopropylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3-d]pyridin Imidine-2,4(1H,3H)-dione (Int-16e) was obtained. MS (ESI) M+H] + m / z:521. Step F: (S)-4-(1-(5-(4-((tert-butyldimethylsilyl)oxy) )butyl)-2-isopropylpyridin-3-yl)-7-chloro-6-fluoro-2- Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpyridin tert-Butyl perazine-1-carboxylate (Int-16f) 1-(5-(4-((tert-butyldimethylsilyl)oxy)butyl)-2-isopropyl Propylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3-d]pyrimidin Add 20 mL of zinzine-2,4(1H,3H)-dione (500 mg, 0.959 mmol) to a 20 mL The reaction vessel was evacuated and refilled three times using a nitrogen balloon. Acetonitrile (1.9 mL), N,N-diisopropylethylamine (256 mL), 1.44 mmol) and phosphoryl trichloride (116 μL, 1.25 mmol). The resulting mixture was heated to 80° C. for 1 hour. The product mixture was concentrated to dryness. The residue was dissolved in acetonitrile (1.9 mL). Ethylamine (512 μl, 2.88 mmol) and (S)-3-methylpiperazine- 1-tert-butyl carboxylate (288 mg, 1.44 mmol) was added to the reaction vessel. The resulting mixture was stirred at 24°C for 1 hour. The product mixture was diluted with ethyl acetate (10 The diluted product mixture was diluted with saturated aqueous sodium bicarbonate three times (30 mL). The organic layer was washed with 10 mL of sodium sulfate. The dried solution was The resulting residue was purified by flash column chromatography on silica gel. Chromatography, initially hexane, followed by a linear gradient up to 66% (ethyl acetate-ethanol Purified by elution with (S)-4-(1-(5-(4 -((tert-butyldimethylsilyl)oxy)butyl)-2-isopropylpyridine -3-yl)-7-chloro-6-fluoro-2-oxo-1,2-dihydropyrido[2, 3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid tert-butyl The chiral compound (Int-16f) was obtained. MS (ESI) [M+H] +m / z:703. Step G: (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl) )-1-(5-(4-hydroxybutyl)-2-isopropylpyridin-3-yl)-2 -oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl piperazine-1-carboxylate (Int-16g) (S)-4-(1-(5-(4-((tert-butyldimethylsilyl)oxy)butyl )-2-Isopropylpyridin-3-yl)-7-chloro-6-fluoro-2-oxo- 1,2-Dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine tert-Butyl 1-carboxylate (535 mg, 0.761 mmol), 3-fluoro -2-(trifluoro-λ 4 -VolaNail) Potassium Phenolate (215mg, 0.9 89 mmol), potassium acetate (299 mg, 3.04 mmol), 1,1'-bis(di Phenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex ( (62.1 mg, 0.076 mmol) was placed in a 20 mL scintillator equipped with a magnetic stir bar. The solution was added to a reaction vial, degassed under nitrogen, and diluted with dioxane (3.3 mL) and water (543 mL). The reaction mixture was degassed under nitrogen three times and heated to 90°C for 1 hour. Cool, quench with 10 mL of 1:1 water / saturated sodium bicarbonate, and add 2 x 25 mL The crude residue was extracted with 10 mL of EtOAc, washed with brine and concentrated in vacuo. The mixture was dissolved in 1M TBAF solution (1.90 mL, 1.90 mmol) in THF. The reaction was quenched with saturated ammonium chloride and stirred at room temperature for 1.5 hours. Extract with 1x EtOAc, wash with brine, dry over sodium sulfate, filter, and Empty, concentrate, and then load on silica gel to elution with 0 to 100% EtOAc:EtOH, 3:1 / hexane. (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-2-methyl-2-propanol nyl)-1-(5-(4-hydroxybutyl)-2-isopropylpyridin-3-yl) -2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl ethylpiperazine-1-carboxylate (Int-16g) was obtained. MS (E SI) [M+H] + m / z:665. Process H:(Int-16h) (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1- (5-(4-hydroxybutyl)-2-isopropylpyridin-3-yl)-2-oxo -1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine tert-Butyl benzoate (100 mg, 0.150 mmol) and triflate Phenylphosphine (99 mg, 0.376 mmol) was placed in a 100 mL round-bottom flask. It was dissolved in HF (7.5 mL) under nitrogen. After sonication, the diazene-1,2-diamine was obtained. Diisopropyl carbonate (59.2 μl, 0.301 mmol) was added dropwise to the reaction mixture. The mixture was sonicated for 15 minutes. The product mixture was concentrated to dryness. The resulting residue was filtered through silica gel. Flash column chromatography in hexane, initially in hexane, with a linear gradient to 100% The mixture was purified by elution with a gradient of (ethyl acetate-ethanol = 3:1 v / v) and (In t-16h) was obtained. MS(ESI)[M+H] + m / z:647. Process I: Int-16i Int-16h (130 mg, 0.201 mmol) was added to a 20 mL vial. The reactor was evacuated and refilled three times with a nitrogen balloon. Trifluoroacetic acid (769 μL, 10.1 mmol) was added to the reaction vessel. was added dropwise to the reaction vessel, and the resulting mixture was stirred at 24° C. for 1 hour. The product mixture was concentrated. Int-16i was obtained. MS (ESI) [M+H] + m / z:547. Step J: 19,22-difluoro-2-[(2S)-2-methyl-4-(prop-2-enyl)methyl]
[0043] -7-(propan-2-yl)-11,12,13,1 4-Tetrahydro-4H-1,20-(ethanediylidene)-6,10-(metheno)pyridine Mido[1,6-k][1,8,11,13]benzoxatriazacyclohexadecin- 4-one (Example 16a) Int-16i+3-TFA (160 mg, 0.180 mmol) was placed in a 20 mL vial. The reactor was evacuated and refilled three times with a nitrogen balloon. DCM (1.8 mL) was added to the reaction vessel, and the resulting solution was cooled to 0°C. -Diisopropylethylamine (160 μL, 0.900 mmol) and acrylonitrile methyl methyl ether (21.4 μL, 0.270 mmol) was added to the reaction vessel, and the resulting mixture was heated to 0°C. The mixture was stirred at rt for 1 h. The product mixture was diluted with ethyl acetate (50 mL). The product mixture was washed three times with saturated aqueous sodium bicarbonate (3×10 mL). The dried solution was filtered and the filtrate was concentrated to dryness. The resulting residue was purified by flash column chromatography on silica gel, first with hexane, 100 The mixture was purified by elution with a gradient of ethyl acetate:ethanol (3:1) up to 100%. The body material was analyzed using SFC column U, with a 35% modifier. : Decomposed and separated in MeOH containing 0.25% N,N-dimethylethylamine Conformer: Peak 1 - Example 16a - MS (ESI) [M+H] + m / z:601. 1 HNM R(500MHz,DMSO-d6)δ 8.38(d,J=2.0Hz,1H),8. 22(dd,J=18.8,9.2Hz,1H),7.57-7.34(m,2H),7 .10(d,J=8.5Hz,1H),7.01-6.78(m,2H),6.21(d d,J=16.8,9.3Hz,1H),5.90-5.71(m,1H),4.80( s,1H),4.55-3.91(m,3H),3.82(td,J=9.7,4.7H z,1H),3.67-3.47(m,3H),3.19(d,J=21.4Hz,1H ),2.96(p,J=6.8Hz,1H),2.86-2.70(m,1H),2.5 7(d,J=4.2Hz,1H),1.85(td,J=10.8,10.2,5.7H z,1H),1.72(t,J=18.1Hz,1H),1.54-1.42(m,1H ),1.40(d,J=6.5Hz,3H),1.28(d,J=6.3Hz,1H), 1.17 (d, J = 6.7 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H); and Beauty Peak 2 - Example 16b-19,22-difluoro-2-[(2S)-2-methyl-4- (prop-2-enoyl)piperazin-1-yl]-7-(propan-2-yl)-11 ,12,13,14-Tetrahydro-4H-1,20-(ethanediylidene)-6,10 -(Metheno)pyrimido[1,6-k][1,8,11,13]benzoxatriazacycl Rohexadecin-4-one. MS(ESI) [M+H] + m / z:601 obtained.
[0226] Example 17: 18,21-difluoro-2-[(2S)-2-methyl-4-(prop-2 -enoyl)piperazin-1-yl]-6-(propan-2-yl)-10,11,13 ,14-Tetrahydro-4H-1,19-ethenopyrido[3,4-e]pyrimido[6,1 -c][9,2,4]benzoxadiazacyclotridecin-4-one [ka]
[0227] Step A: 2-(2-chloro-3-nitropyridin-4-yl)ethanol (Int-17 a) 2-Chloro-4-methyl-3-nitropyridine (50.0 g) in DMSO (150 mL) To a stirred solution of paraformaldehyde (6.96 g, 232 mmol) and benzyltrimethylammonium hydroxide (5.3 mL, approximately 0.02 equivalents, methanol At 20°C, HCl (40% in HCl) was added, and the mixture was stirred at 90°C for 4 hours under a N2 atmosphere. The reaction mixture was quenched with water (100 mL) and extracted with ethyl acetate (2 x 400 mL). The combined organic layers were washed with brine (4 x 60 mL) and dried over Na2SO4. The mixture was filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash silica gel chromatography. Purify by column chromatography with eluent 0 to 60% EtOAc / petroleum ether. 2-(2-chloro-3-nitropyridin-4-yl)ethanol (Int-17a) was obtained. MS(ESI):[M+H] + m / z:202. Step B: 2-(3-nitro-2-(prop-1-en-2-yl)pyridin-4-yl) Ethanol (Int-17b) 2-(2-chloro-3-nitropyridine-4-yl)pyridine in DME (100 mL) / water (20 mL) A stirred solution of Cs2CO3 (48.2 g, 148 mmol), 4,4,5,5-tetramethyl-2-(prop-1-ene-2- yl)-1,3,2-dioxaborolane (9.95 g, 59.2 mmol) and bis( Triphenylphosphine)palladium(II) dichloride (1.73g, 2.47mmol l) was added and the resulting mixture was stirred at 85° C. for 16 hours. The reaction was diluted with EtOAc (20 The combined organic phase was dried over anhydrous Na2SO4, filtered, and purified. The residue was purified by flash silica gel chromatography using petroleum ether / Et Purified with OAc=10 / 1 and 2-(3-nitro-2-(prop-1-en-2-yl)-2-methylpropanol) (I)pyridin-4-yl)ethanol (Int-17b) was obtained. MS (ESI): [M +H] + m / z:208. Step C: 4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-nitrile 2-(prop-1-en-2-yl)pyridine (Int-17c) 2-(3-nitro-2-(prop-1-en-2-yl)pyridinone) in DCM (120 mL) A stirred solution of (di-(4-yl)ethanol (9.1 g, 43.7 mmol) in TBSCl ( (8.56 g, 56.8 mmol) and imidazole (8.93 g, 131 mmol) The mixture was stirred at 20° C. for 16 hours under a N atmosphere. The reaction mixture was diluted with water (60 The mixture was quenched with 100 mL of dichloromethane and extracted with dichloromethane (100 mL × 2). The organic layer was washed with brine (80 mL), dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. The mixture was evaporated under reduced pressure and purified by flash silica gel chromatography to obtain a 0 to 8% Purification was carried out by eluting with a gradient of EtOAc / petroleum ether to give 4-(2-((ter t-Butyldimethylsilyl)oxy)ethyl)-3-nitro-2-(prop-1-ene- 2-yl)pyridine (Int-17c) was obtained. MS (ESI): [M+H] + m / z :323. Step D: 4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-isopropyl Propylpyridin-3-amine (Int-17d) 4-(2-((tert-butyldimethylsilyl)oxy)) in MeOH (100 mL) Ethyl)-3-nitro-2-(prop-1-en-2-yl)pyridine (13g, 40. PdC (2.15 g, 2.02 mmol, 10% w / w) was added to a stirred solution of 1.3 mmol of PdC with N The mixture was degassed and purged with hydrogen three times. The mixture was stirred at rt for 16 h under a hydrogen balloon (pressure: 15 psi). The coat was washed with methanol (100 mL). The filtrate was concentrated in vacuo to give 4-(2-((ter t-Butyldimethylsilyl)oxy)ethyl)-2-isopropylpyridin-3-amine (Int-17d) was obtained, which was used in the next step without further purification. MS (ESI ):[M+H] + m / z:295. Step E: N-((4-(2-((tert-butyldimethylsilyl)oxy)ethyl)- 2-Isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluoro Ionicotinamide (Int-17e) 2,6-Dichloro-5-fluoronicotinamide (3.00 g, To a stirred solution of 14.4 mmol of oxalyl dichloride (1.19 mL, 13.6 mmol) was added at 20°C, and the mixture was stirred at 65°C for 30 minutes under N2 atmosphere. Cool to 0°C and add 4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2 -Isopropylpyridin-3-amine (Int-17d, 4.65 g, 15.8 mmol) The resulting mixture was stirred at 0° C. for 10 min. The reaction mixture was quenched with aqueous sodium bicarbonate (saturated, 30 mL). The combined organic layers were extracted with brine (50 mL). The residue was washed with HCl, dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. was purified by flash silica gel chromatography using 0 to 40% EtOAc / petroleum Purification was carried out with ether eluent to give N-((4-(2-((tert-butyldimethylsilyl) aryl)oxy)ethyl)-2-isopropylpyridin-3-yl)carbamoyl)-2, 6-Dichloro-5-fluoronicotinamide (Int-17e) was obtained. MS (ESI) :[M+H] + m / z:529. Step F: 1-(4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2 -isopropylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3-d] Pyrimidine-2,4(1H,3H)-dione (Int-17f) N-((4-(2-((tert-butyldimethylsilyl)oxy)methyl)- ...methyl)-2-(((tert-butyldimethylsilyl)oxy)methyl) (Ethyl)-2-isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro A stirred solution of 4-5-fluoronicotinamide (4.00 g, 7.55 mmol) was added to potassium chloride. Mubis(trimethylsilyl)amide (15.1 mL, 15.1 mmol) was added at 0°C. The mixture was stirred at 20°C for 30 minutes under a N2 atmosphere. The mixture was quenched with sodium hydroxide (saturated, 20 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, and filtered. The solvent was evaporated under reduced pressure to give the crude product 1-(4-(2-((tert-butyldichloroisothiazolinone). Methylsilyl)oxy)ethyl)-2-isopropylpyridin-3-yl)-7-chloro -6-fluoropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (In t-17f) was obtained, which was used in the next step without further purification. MS (ESI): M+H] + m / z:493. Step G: 1-(4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2 -isopropylpyridin-3-yl)-4,7-dichloro-6-fluoropyridin[2,3 -d]pyrimidin-2(1H)-one (Int-17g) 1-(4-(2-((tert-butyldimethylsilyl) )Oxy)ethyl)-2-isopropylpyridin-3-yl)-7-chloro-6-fluoro Lopirido[2,3-d]pyrimidine-2,4(1H,3H)-dione (3.72 g, 7. To a stirred solution of 54 mmol) was added DIEA (3.29 mL, 18.9 mmol) and POC l3 (1.06 mL, 11.3 mmol) was added at 25 °C, and the mixture was heated at 80 °C for 1 h. The reaction mixture was stirred under N2 atmosphere. The reaction mixture was concentrated in vacuo to give the crude product 1-(4-(2-((t ert-butyldimethylsilyl)oxy)ethyl)-2-isopropylpyridin-3-yl 1H)-4,7-dichloro-6-fluoropyrido[2,3-d]pyrimidine-2(1H)- The one (Int-17g) was obtained, which was used in the next step without further purification. MS (E SI): [M-Cl+MeOH] + m / z:507. Step H: (S)-4-(1-(4-(2-((tert-butyldimethylsilyl)oxy) )ethyl)-2-isopropylpyridin-3-yl)-7-chloro-6-fluoro-2- Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpyridin tert-Butyl perazine-1-carboxylate (Int-17h) 1-(4-(2-((tert-butyldimethylsilyl)oxy)-2-methyl-2-propanol) in DMF (40 mL) )Ethyl)-2-isopropylpyridin-3-yl)-4,7-dichloro-6-fluoro Pyrido[2,3-d]pyrimidin-2(1H)-one (3.86g, 7.55mmol) To a stirred solution of DIPEA (3.30 mL, 18.9 mmol) and (S)-3-methyl tert-Butyl piperazine-1-carboxylate (1.89 g, 9.43 mmol) was added to 25 The mixture was stirred at 20°C for 30 minutes under N2 atmosphere. The reaction mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography using 0 to 40% EtOAc / silica gel Purification with an eluent of oil ether gave (S)-4-(1-(4-(2-((tert-butyl ether). ethyldimethylsilyl)oxy)ethyl)-2-isopropylpyridin-3-yl)-7- Chloro-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine tert-Butyl (Int-4-yl)-3-methylpiperazine-1-carboxylate (Int-17 h) was obtained. MS (ESI): [M+H] + m / z:675. Step I: (3S)-4-(1-(4-(2-((tert-butyldimethylsilyl)oxy) (2-chloro-6-fluoro)ethyl)-2-isopropylpyridin-3-yl)-7-(2-chloro-6-fluoro) (2,3-d)-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrid tert-Butyl (Int-4-yl)-3-methylpiperazine-1-carboxylate -17i) (S)-4-(1-(4-(2-( (tert-Butyldimethylsilyl)oxy)ethyl)-2-isopropylpyridine-3 -yl)-7-chloro-6-fluoro-2-oxo-1,2-dihydropyrido[2,3- d] tert-Butyl pyrimidin-4-yl-3-methylpiperazine-1-carboxylate (300 mg, 0.444 mmol), potassium acetate (218 mg, 2.22 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride To a stirred solution of 2-chloro- 6-fluorophenyl)boronic acid (116 mg, 0.666 mmol) was added, and the resulting The resulting mixture was stirred at 90°C for 2 hours under a N2 atmosphere. The reaction mixture was diluted with brine (10 ml The mixture was quenched with ethyl acetate (2×10 mL) and extracted with ethyl acetate (2×10 mL). Wash with 10 mL of ethyl acetate, dry over Na2SO4, filter, and evaporate the solvent under reduced pressure. The residue was purified by flash silica gel chromatography from 0 to 50% Purification was carried out with a gradient of EtOAc / petroleum ether eluent to give (3S)-4-(1-(4 -(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-isopropyl Lysin-3-yl)-7-(2-chloro-6-fluorophenyl)-6-fluoro-2- Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpyridin tert-Butyl perazine-1-carboxylate (Int-17i) was obtained. MS (ESI) :[M+H] + m / z:769. Step J: (3S)-4-(7-(2-chloro-6-fluorophenyl)-6-fluoro- 1-(4-(2-hydroxyethyl)-2-isopropylpyridin-3-yl)-2-o xo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperidine tert-Butyl radine-1-carboxylate (Int-17j) (3S)-4-(1-(4-(2-((tert-butyldimethyl Silyl)oxy)ethyl)-2-isopropylpyridin-3-yl)-7-(2-chloro -6-fluorophenyl)-6-fluoro-2-oxo-1,2-dihydropyrido[2, 3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid tert-butyl A stirred solution of TBAF (240 mg, 0.312 mmol) was added to a 1 M solution of TBAF in THF (0 0.936 mL, 0.936 mmol) was added, and the mixture was stirred at 20 °C for 1 h under N2 atmosphere. The reaction mixture was concentrated in vacuo and the residue was purified by flash silica gel chromatography. Purification was carried out with an eluent of 0 to 8% MeOH / DCM by (3S)-4-(7 -(2-chloro-6-fluorophenyl)-6-fluoro-1-(4-(2-hydroxy Ethyl)-2-isopropylpyridin-3-yl)-2-oxo-1,2-dihydropyridin Do[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid TE rt-Butyl (Int-17j) was obtained. MS (ESI): [M+H] + m / z:65 5. Step K: (3S)-4-(7-(2-chloro-6-fluorophenyl)-6-fluoro- 1-(2-isopropyl-4-(2-(vinyloxy)ethyl)pyridin-3-yl)- 2-Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl 1-piperazine carboxylate (Int-17k) (3S)-4-(7-(2-chloro-6-fluorophenyl)) in toluene (10 mL) -6-fluoro-1-(4-(2-hydroxyethyl)-2-isopropylpyridine-3 -yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl) tert-Butyl 3-methylpiperazine-1-carboxylate (500 mg, 0.763 m mol) to a stirred solution of chloro(1,5-cyclooctadiene)iridium(I) dimer (103mg,0.153mmol), Na2CO3(162mg,1.53mmol) and vinyl acetate (131 mg, 1.53 mmol) were added, and the mixture was heated at 100°C for 3 hours. The reaction mixture was concentrated in vacuo and the residue was purified by flash silica gel chromatography. chromatographically with 0 to 40% EtOAc / petroleum ether as eluent. Purify and obtain (3S)-4-(7-(2-chloro-6-fluorophenyl)-6-fluoro- 1-(2-isopropyl-4-(2-(vinyloxy)ethyl)pyridin-3-yl)- 2-Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl 1-isopropylpiperazine-1-carboxylate (Int-17k) was obtained. MS (ES I):[M+H] + m / z:681. Process L:Int-17l (3S)-4-(7-(2-chloro-6-fluorophenyl)- in DMF (15 mL) 6-Fluoro-1-(2-isopropyl-4-(2-(vinyloxy)ethyl)pyridine -3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl tert-Butyl 3-methylpiperazine-1-carboxylate (150 mg, 0.22 To a stirred solution of N,N-dicyclohexylmethylamine (688 mg, 3.5 mmol) 2mmol), tri-tert-butylphosphonium tetrafluoroborate (128mg , 0.440 mmol) and cataCxium® C (206 mg, 0.2 20 mmol) was added, and the mixture was stirred in a microwave at 160 °C for 1 h under a N2 atmosphere. The reaction mixture was concentrated in vacuo and the residue was purified by Al2O3 chromatography (0 to 10% Purification by MeOH / DCM eluent until Int-17l was obtained. I):[M+H] + m / z:645. Process M:Int-17m Int-17l (90 mg, 0.070 mmol) and MeOH (10 mL) were mixed and stirred. Pd-C (22 mg, 0.021 mmol, 10% w / w) was added to the mixture, and the mixture was degassed. The resulting mixture was purged with hydrogen (pressure: 15 ps) at 20 °C for 16 h. i) The mixture was filtered and the filter cake was washed with methanol (20 mL). The filtrate was concentrated in vacuo and the residue was purified by preparative HPLC chromatography, water (0.1% TFA)- Purification with MeCN gave Int-17m. MS (ESI): [M+H] + m / z:647. Step N: 18,21-difluoro-2-[(2S)-2-methyl-4-(prop-2-enyl)methyl] 10,11,13,1-(6-(propan-2-yl)-piperazin-1-yl)- 4-Tetrahydro-4H-1,19-ethenopyrido[3,4-e]pyrimido[6,1-c [9,2,4]benzoxadiazacyclotridecin-4-one (Example 17a and 17b) To a stirred solution of Int-17m (30 mg, 0.046 mmol) in DCM (2 mL) was added T FA (0.5 mL) was added and the mixture was stirred at 20° C. for 10 min. The reaction mixture was evaporated in vacuo The mixture was concentrated with 500 ml of HCl and the residue was dissolved in DCM (2 mL) and then DIEA (0.041 mL, 0.23 mmol) and acryloyl chloride (6.3 mg, 0.070 mmol) were added. The resulting mixture was stirred at 20° C. for 5 minutes. The reaction mixture was concentrated in vacuo, and the residue was Purified by preparative TLC plate eluting with 10% MeOH / DCM. The quality was analyzed by SFC column B, conditions: water (0.1% NH4OH)-35% MeOH. Solvent and separated conformers: Peak 1 - Example 17a - 18,21-difluoro-2-[(2S)-2-methyl-4 -(prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-1 0,11,13,14-Tetrahydro-4H-1,19-ethenopyrido[3,4-e]pi Rimid[6,1-c][9,2,4]benzoxadiazacyclotridecin-4-one. MS(ESI):[M+H] + m / z: 601; 1 H NMR (500 MHz, methano rule-d4)δ 8.42(d,J=5.0Hz,1H),8.33-8.21(m,1 H),7.37(dt,J=5.9,8.0Hz,1H),7.30(d,J=5.2H z,1H),7.08(d,J=7.6Hz,1H),7.01(t,J=8.9Hz, 1H),6.93-6.76(m,1H),6.32(br d,J=16.0Hz,1 H),5.84(dd,J=1.8,10.6Hz,1H),5.02(br s,1H ),4.67-4.50(m,2H),4.43-4.26(m,1H),4.02-3 .71(m,2H),3.61-3.53(m,1H),3.47(br s,1H), 3.42-3.32(m,3H),2.86(br d,J=7.9Hz,1H),2. 73-2.63(m,2H),2.49-2.33(m,2H),1.55(br t, J=6.7Hz,3H),1.20(d,J=6.9Hz,3H),0.99(br d ,J=6.1Hz,3H); and Peak 2 - Example 17b-18,21-difluoro-2-[(2S)-2-methyl-4- (prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-10 ,11,13,14-tetrahydro-4H-1,19-ethenopyrido[3,4-e]pyrid Mido[6,1-c][9,2,4]benzoxadiazacyclotridecin-4-one.M S(ESI) m / z(M+H) + :601; 1 H NMR (400 MHz, methanol- d4)δ 8.42(d,J=5.5Hz,1H),8.33(br t,J=8.2H z,1H),7.45-7.35(m,1H),7.31(d,J=5.1Hz,1H) ,7.08(d,J=7.4Hz,1H),7.02(t,J=8.6Hz,1H),6 .93-6.76(m,1H),6.33(br d,J=17.2Hz,1H),5. 84(dd,J=2.0,10.6Hz,1H),5.23(br s,1H),4.6 0(br s,2H),4.46(br d,J=13.7Hz,1H),4.26-4 .09(m,1H),3.97(br s,1H),3.78-3.40(m,3H), 3.37-3.15(m,2H),2.84(br d,J=6.7Hz,1H),2. 68(br dd,J=5.5,13.3Hz,2H),2.47(br s,1H), 2.35(td,J=6.8,12.9Hz,1H),1.46(d,J=7.0Hz, 3H),1.19(d,J=7.0Hz,3H),0.99(br d,J=6.3Hz ,3H) obtained.
[0228] Example 18a: 17,20-difluoro-2-[(2S)-2-methyl-4-(prop- 2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-10,11-di Hydro-1,18-ethenopyrido[3,4-e]pyrimido[6,1-c][9,2,4] Benzoxadiazacyclododecin-4(13H)-one [ka]
[0229] Step A: (S)-4-(7-chloro-6-fluoro-1-(4-(2-hydroxyethyl) )-2-Isopropylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2 ,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid tert- Butyl (Int-18a) 1-(4-(2-((tert-butyldimethylsilyl)oxy)-2-methyl-2-propanol) in DMF (50 mL) )Ethyl)-2-isopropylpyridin-3-yl)-4,7-dichloro-6-fluoro Pyrido[2,3-d]pyrimidin-2(1H)-one (Int-17g, 3.20g, 6 To a stirred solution of 0.26 mmol of DIEA (2.73 mL, 15.6 mmol) and (S )-3-methylpiperazine-1-carboxylate tert-butyl (1.57g, 7.82m mol) was added at 25°C, and the mixture was stirred at 20°C for 30 minutes under N2 atmosphere. The solution was concentrated in vacuo and the residue was dissolved in a gradient of 0 to 100% EtOAc / petroleum ether. The product was purified by flash silica gel chromatography using a solvent-free solvent to give (S)-4-( 7-chloro-6-fluoro-1-(4-(2-hydroxyethyl)-2-isopropyl)pyrrolidone Lysin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine- tert-Butyl 4-yl-3-methylpiperazine-1-carboxylate (Int-18a ) was obtained. MS (ESI): [M+H] + m / z:561. Process B: Int-18b (S)-4-(7-chloro-6-fluoro-2,4-dioxane) in 1,4-dioxane (4 mL) / water (1 mL) Oro-1-(4-(2-hydroxyethyl)-2-isopropylpyridin-3-yl)- 2-Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl tetrahydropiperazine-1-carboxylate (300 mg, 0.535 mmol), Potassium acetate (262 mg, 2.67 mmol) and 1,1'-bis(diphenylphosphine phino)ferrocene-palladium(II) dichloride dichloromethane complex (43.7mg To a stirred solution of (2-fluoro-6-formylphenyl)boronic acid (180 mg, 1.07 mmol) was added, and the mixture was heated at 90 °C for 30 min under N2 atmosphere. The reaction mixture was separated, the organic layer was dried over Na2SO4, filtered, and the solvent was removed. The residue was evaporated under reduced pressure and eluted with a gradient of 0 to 5% MeOH / DCM. Flash silica gel chromatography followed by reversed-phase MPLC 0% to 100% % MeCN (0.5% TFA) / HO to give Int-18b. S(ESI):[M+H] + m / z:649. Process C: Int-18c A stirred solution of Int-18b (60 mg, 0.092 mmol) in CH3NO2 (6 mL) The solution was diluted with triethylsilane (0.120 mL, 0.751 mmol) and TfOH (0.0 500 mL, 0.563 mmol) was added, and the mixture was stirred at 20 °C for 30 min under N2 atmosphere. The reaction mixture was concentrated in vacuo and the residue was diluted with water (0.04% NH3H2O + 10 mM Preparative HPLC was performed eluting with 10 to 100% B of NH4HCO3-MeCN. The resulting mixture was purified to give Int-18c. MS (ESI): [M+H] + m / z:533. Step D: 17,20-difluoro-2-[(2S)-2-methyl-4-(prop-2-enyl)methyl] Noyl)piperazin-1-yl]-6-(propan-2-yl)-10,11-dihydro -1,18-Ethenopyrido[3,4-e]pyrimido[6,1-c][9,2,4]benzo Oxadiazacyclododecin-4(13H)-one (Example 18a) Stirring Int-18c (99.0 mg, 0.186 mmol) in DCM (2.0 mL) The solution was treated with DIEA (0.0970 mL, 0.558 mmol) and acryloyl chloride (2 0.2 mg, 0.223 mmol) was added, and the mixture was incubated at 20 °C for 10 min under N2 atmosphere. The reaction mixture was concentrated in vacuo and the residue was purified by preparative HPLC, water (0.04% NH Purification was performed by elution with 20+10 mM NH4HCO3)-MeCN. The sample was decomposed by preparative SFC column L, conditions: 0.1% NH4OH, EtOH, 55% , isolated conformers: Peak 1 - Example 18a - 17,20-difluoro-2-[(2S)-2-methyl-4 -(prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-1 0,11-Dihydro-1,18-ethenopyrido[3,4-e]pyrimido[6,1-c][ 9,2,4]Benzoxadiazacyclododecin-4(13H)-one. MS(ESI) m / z(M+H) + :587; 1 H NMR (400MHz, methanol-d4) δ 8 .50(d,J=5.1Hz,1H),8.19(br t,J=10.8Hz,1H) ,7.56(d,J=5.1Hz,1H),7.46(dt,J=5.5,8.0Hz, 1H),7.24-7.15(m,2H),6.96-6.76(m,1H),6.32 (br d,J=17.2Hz,1H),5.84(br d,J=11.0Hz,1H ),4.97-4.91(m,1H),4.70(br t,J=15.1Hz,1H) ,4.59-4.37(m,2H),4.22-4.05(m,2H),4.00(d, J=9.4Hz,1H),3.86-3.63(m,3H),3.44-3.32(m, 1H),3.07(quin,J=6.7Hz,1H),2.59-2.47(m,1H ),2.44-2.29(m,1H),1.58(br t,J=7.2Hz,3H), 1.27(d,J=6.7Hz,3H),1.01(d,J=7.0Hz,3H) obtained.
[0230] Example 19: 18,21-difluoro-2-[(2S)-2-methyl-4-(prop-2 -enoyl)piperazin-1-yl]-6-(propan-2-yl)-10,11,12 ,13-Tetrahydro-1,19-ethenopyrido[3,4-e]pyrimido[6,1-c] [2,4,10]Benzotriazacyclotridecine-4,14-dione [ka]
[0231] Step A: N-((4-(3-((tert-butyldimethylsilyl)oxy)propyl) -2-isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluoro Oronicotinamide (Int-19a) Under a nitrogen atmosphere, a flask was charged with 2,6-dichloro-5-fluoronicotinamide (2.0 g, 9.6 mmol), THF (40 mL) and oxalyl chloride (2.0 M in DCM, 4.8 mL, 9.6 mmol) was added. The mixture was heated to 65°C for 30 minutes. After 1 minute, the mixture was cooled to room temperature and then added with 4-(3-((tert-butyldimethylsilyl) (Int-10c, 3)-2-isopropylpyridin-3-amine (Int-10c, 3)-(2-isopropyl) ... A mixture of 10.25 g (10.5 mmol) and THF (20 mL) was added. The mixture was stirred at room temperature for 1 hour. After 1 hour, the mixture was concentrated under reduced pressure. To the tube was added pyridine (50 mL), and the mixture was then cooled to 0°C. ert-butyldimethylchlorosilane (1.6 g, 10 mmol) was added. The mixture was allowed to warm to room temperature and stirred at room temperature for 1 hour. After 1 hour, the mixture was concentrated under reduced pressure and then added to silica gel. by column chromatography (0 to 60% ethyl acetate gradient in hexane). Purification gave an impure mixture. This mixture was repurified (from 0 to 70% in hexanes). methyl tert-butyl ether gradient), N-((4-(3-((tert-butyldi Methylsilyl)oxy)propyl)-2-isopropylpyridin-3-yl)carbamoyl (Int-19a)-2,6-dichloro-5-fluoronicotinamide was obtained. (ESI) m / z 543 [M+H] + Step B: 1-(4-(3-((tert-butyldimethylsilyl)oxy)propyl)- 2-Isopropylpyridin-3-yl)-7-chloro-6-fluoropyridin [2,3-d ]pyrimidine-2,4(1H,3H)-dione (Int-19b) N-((4-(3-((tert-butyldimethylsilyl)oxy)propyl)-2- Isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluorodiphenyl A mixture of cotinamide (Int-19a, 6.3 g, 12 mmol) and THF (60 mL) The mixture was treated with potassium bis(trimethylsilyl)amide (1.0 M in THF) at 0°C under a nitrogen atmosphere. 23 mL, 23 mmol) was added. The mixture was then allowed to warm to room temperature and then After 30 minutes, the mixture was added to saturated aqueous ammonium chloride (15 mL The mixture was quenched with ethyl acetate (2×200 mL) and then extracted with ethyl acetate (2×200 mL). The layers were washed with brine (100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. Then, crude 1-(4-(3-((tert-butyldimethylsilyl)oxy)propyl)- 2-Isopropylpyridin-3-yl)-7-chloro-6-fluoropyridin [2,3-d ] to give pyrimidine-2,4(1H,3H)-dione (Int-19b), which is further Used without purification or characterized. MS(ESI) m / z 507[ M+H] + Step C: 1-(4-(3-((tert-butyldimethylsilyl)oxy)propyl)- 2-Isopropylpyridin-3-yl)-4,7-dichloro-6-fluoropyridin [2, 3-d]pyrimidin-2(1H)-one (Int-19c) Crude 1-(4-(3-((tert-butyldimethylsilyl)oxy)propyl)-2 -isopropylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3-d] In a flask containing pyrimidine-2,4(1H,3H)-dione (Int-19b), Acetonitrile (100 mL) was added and DIEA (11 mL, 62 mmol) was added under a nitrogen atmosphere. l) and phosphorus oxychloride (1.7 mL, 18 mmol) were added at room temperature. The mixture was heated to 80° C. for 2 hours. After 2 hours, the mixture was allowed to cool to room temperature and then concentrated under reduced pressure. , 1-(4-(3-((tert-butyldimethylsilyl)oxy)propyl)-2-isopropyl 2,3-diisopropylpyridin-3-yl)-4,7-dichloro-6-fluoropyridin ]pyrimidin-2(1H)-one (Int-19c), which was used without further purification. MS(ESI) m / z 526 [M+H] + Step D: (S)-4-(7-chloro-6-fluoro-1-(4-(3-hydroxypropyl) (yl)-2-isopropylpyridin-3-yl)-2-oxo-1,2-dihydropyridin[ 2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid tert -Butyl (Int-19d) 1-(4-(3-((tert-butyldimethylsilyl) )oxy)propyl)-2-isopropylpyridin-3-yl)-4,7-dichloro-6 -Fluoropyrido[2,3-d]pyrimidin-2(1H)-one (Int-19c,6. A stirred solution of 22 g (11.8 mmol) of DIPEA (4.13 mL, 23.7 mmol) ) and (S)-tert-butyl 3-methylpiperazine-1-carboxylate (3.56 g , 17.8 mmol) was added at 30°C, and the mixture was stirred at 30°C for 1 hour under N2 atmosphere. The residue was purified by flash silica gel chromatography from 0 to 100% Et Purification was carried out with an eluent of OAc / Pet. to give (S)-4-(7-chloro-6-fluoro- 1-(4-(3-hydroxypropyl)-2-isopropylpyridin-3-yl)-2- Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpyridin tert-Butyl perazine-1-carboxylate (Int-19d) was obtained. MS (ESI) :[M+H] + m / z:575. Step E: (3S)-4-(7-(2-carbamoyl-6-fluorophenyl)-6-fluoro Oro-1-(4-(3-hydroxypropyl)-2-isopropylpyridin-3-yl) -2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl ethylpiperazine-1-carboxylate (Int-19E) 3-Fluoro-2-(4,4,5,5-trifluoromethyl-2-methylpropional) in 1,4-dioxane (7 mL) / water (2 mL) -Tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (387m g, 1.56 mmol), (S)-4-(7-chloro-6-fluoro-1-(4-(3- Hydroxypropyl)-2-isopropylpyridin-3-yl)-2-oxo-1,2- Dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate tert-Butyl carboxylate (Int-19d, 600 mg, 1.04 mmol) and acetic acid To a stirred solution of potassium carbonate (512 mg, 5.22 mmol) was added 1,1'-bis(diphenyl Phosphino)ferrocene-palladium(II) dichloride dichloromethane complex (85.0 mg, 0.104 mmol) was added at 20°C under a N2 atmosphere, and the mixture was heated at 90°C for 15 The reaction mixture was stirred under N2 atmosphere for 1 hour. The reaction mixture was quenched with brine (10 mL). The combined organic layers were washed with brine (10 mL). The residue was washed, dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. Flash silica gel chromatography was carried out using a 0 to 10% DCM / MeOH gradient. Purification with different eluents gave (3S)-4-(7-(2-carbamoyl-6-fluorophenyl)-2-methyl-2-propanol. (phenyl)-6-fluoro-1-(4-(3-hydroxypropyl)-2-isopropylphenyl) Lysin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine- tert-Butyl 4-yl-3-methylpiperazine-1-carboxylate (Int-19e ) was obtained. MS (ESI): [M+H] + m / z:678. Step F: (3S)-4-(7-(2-carbamoyl-6-fluorophenyl)-6-fluoro Oro-1-(2-isopropyl-4-(3-((methylsulfonyl)oxy)propyl) Pyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine tert-Butyl (Int-4-yl)-3-methylpiperazine-1-carboxylate (Int-19 f) (3S)-4-(7-(2-carbamoyl-6-fluorophenyl)-2-methyl-2-(2-methyl- ... 1-(4-(3-hydroxypropyl)-2-isopropylpyridinyl)-6-fluoro-1-(4-(3-hydroxypropyl)-2-isopropylpyridinyl) (3-phenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine-4- tert-Butyl)-3-methylpiperazine-1-carboxylate (Int-19e,6 A stirred solution of 100 mg, 0.885 mmol) of EtN (0.370 mL, 2.66 mmol) ol) and MsCl (0.207 mL, 2.66 mmol) were added at 0° C., and the mixture was The mixture was stirred at 30°C for 15 hours under N2 atmosphere. The reaction mixture was quenched with water (10 mL). The mixture was quenched and extracted with DCM (2 x 20 mL). The combined organic layers were washed with brine (10 mL). Washed with HCl, dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure to give the crude product. The product was purified by flash silica gel chromatography, and the resulting mixture was purified by elution from 0 to 100% petroleum Purification by ether / EtOAc gave (3S)-4-(7-(2-carbamoyl-6- fluorophenyl)-6-fluoro-1-(2-isopropyl-4-(3-((methylsulfonyl) (sulfonyl)oxy)propyl)pyridin-3-yl)-2-oxo-1,2-dihydropyridin-3-yl Lido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid To obtain ert-butyl (Int-19f), MS (ESI): [M+H] + m / z:7 56. Process G:Int-19g (3S)-4-(7-(2-carbamoyl-6-fluorophenyl)-2-methyl-2-propanol in DMF (5 mL) )-6-Fluoro-1-(2-isopropyl-4-(3-((methylsulfonyl)oxy) )propyl)pyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d ]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate tert-butyl ( A stirred solution of Int-19f (371 mg, 0.491 mmol) was added to NaH (39.3 mg , 0.982 mmol) (60% in mineral oil) was added at 0°C, and the mixture was heated at 30°C for 15 hours. The reaction mixture was stirred under a N2 atmosphere. The mixture was quenched with ethyl acetate (2 x 50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine ( 40 mL), dried over Na2SO4, filtered, and evaporated the solvent under reduced pressure. The residue was purified by prep-TLC (pure EtOAc) to give Int-19g. MS(ESI):[M+H] + m / z:660. Process H:Int-19h Stirring Int-19g (220 mg, 0.333 mmol) in CH2Cl2 (3 mL) To the solution was added TFA (1.5 mL) at 30° C., and the mixture was stirred at 30° C. for 1 hour. The mixture was concentrated in vacuo to give Int-19h. MS (ESI): [M+H] + m / z: 560. Step I: 18,21-difluoro-2-[(2S)-2-methyl-4-(prop-2-enyl)methyl] 10,11,12,1-(2-(2-aminoyl)piperazin-1-yl)-6-(propan-2-yl)- 3-Tetrahydro-1,19-ethenopyrido[3,4-e]pyrimido[6,1-c][2 ,4,10]benzotriazacyclotridecine-4,14-dione (Example 19a and 19b) Crude Int-19h + TFA (91.0 mg, 0.163 mmol) in DCM (2 mL) To a stirred solution of DIEA (0.0280 mL, 0.163 mmol) and acrylonitrile C., and the mixture was stirred at 0.degree. C. for 10 minutes. The residue was purified by prep-TLC (DCM:MeOH=10:1). The semiconducting substance was separated by SFC column H, conditions: 0.1% NH4OH, EtOH 35% And separate: Peak 1 - Example 19a - 18,21-difluoro-2-[(2S)-2-methyl-4 -(prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-1 0,11,12,13-Tetrahydro-1,19-ethenopyrido[3,4-e]pyrimide [6,1-c][2,4,10]benzotriazacyclotridecine-4,14-dione. MS(ESI):[M+H] + m / z: 614; (500HMz, methanol-d4) δ:8.48(d,J=5.0Hz,1H),8.33(br dd,J=9.1,14 .1Hz,1H),7.54(dt,J=5.3,8.0Hz,1H),7.42(d, J=5.2Hz,1H),7.32(t,J=8.7Hz,1H),7.26(d,J= 7.5Hz,1H),6.98-6.78(m,1H),6.34(br dd,J=4 .7,16.8Hz,1H),5.86(dd,J=1.8,10.5Hz,1H),5 .19-5.07(m,1H),4.55-4.46(m,2H),4.24-4.12 (m,1H),3.90(br d,J=9.9Hz,1H),3.83-3.60(m ,2H),3.40-3.30(br s,1H),3.19-3.06(m,1H), 2.78-2.65(m,1H),2.64-2.47(m,2H),2.21-2.0 8(m,1H),1.99-1.82(m,1H),1.52(br t,J=5.5H z,3H),1.16(d,J=6.9Hz,3H),0.82(br d,J=6.6 Hz,3H); and Peak 2 - Example 19b-18,21-difluoro-2-[(2S)-2-methyl-4 -(prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-1 0,11,12,13-Tetrahydro-1,19-ethenopyrido[3,4-e]pyrimide [6,1-c][2,4,10]benzotriazacyclotridecine-4,14-dione. MS(ESI):[M+H] + m / z: 614; 1 H NMR (500 MHz, methano rule-d4)δ:8.36(d,J=5.2Hz,1H),8.21(br t,J=9 .1Hz,1H),7.41(dt,J=5.3,8.0Hz,1H),7.30(d, J=5.2Hz,1H),7.19(t,J=8.7Hz,1H),7.13(d,J= 7.5Hz,1H),6.82-6.68(m,1H),6.22(br dd,J=4 .0,16.8Hz,1H),5.74(br d,J=10.7Hz,1H),5.0 9-4.97(m,1H),4.48-4.29(m,2H),4.13-4.00(m ,1H),3.79(br s,1H),3.70-3.46(m,2H),3.34- 3.13(m,1H),2.99(td,J=4.5,14.0Hz,1H),2.65 -2.51(m,1H),2.50-2.38(m,2H),2.08-1.96(m, 1H),1.88-1.75(m,1H),1.38(d,J=6.7Hz,3H),1 .03(d,J=6.7Hz,3H),0.68(br d,J=6.6Hz,3H) obtained.
[0232] Examples 20a and 20b: 17,20-difluoro-2-[(2S)-2-methyl-4 -(prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-1 2,13-Dihydro-1,18-ethenopyrido[3,4-e]pyrimido[6,1-c][ 7,2,4]benzoxadiazacyclododecin-4(11H)-one [ka]
[0233] Step A: 4-Methoxy-3-nitro-2-(prop-1-en-2-yl)pyridine (I nt-20a) 4-Chloro-3-nitro-2-(prop-1-en-2-yl) ) A stirred solution of pyridine (Int-10a, 8.00 g, 40.3 mmol) was added to sodium Methoxide (5.44 g, 101 mmol) was added, and the resulting mixture was heated at 75° C. for 16 h. The reaction mixture was concentrated in vacuo and the residue was diluted with water (40 mL) and EtOAc (100 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and partitioned between 100 ml of ethyl acetate and 100 ml of ethyl acetate. The residue was purified by flash silica gel chromatography using petroleum ether / Et0Ac. Purified by HPLC using 4-methoxy-3-nitro-2-(prop-1-en-2-yl)-2-methyl-2-propenyl-1-methylpropanol. (Int-20a)pyridine was obtained. MS (ESI): [M+H] + m / z:19 5. Step B: 2-Isopropyl-4-methoxypyridin-3-amine (Int-20b) 4-Methoxy-3-nitro-2-(prop-1-ene-2-) in MeOH (300 mL) A solution of Pd-C( 1.59 g, 0.67 mmol, 5% w / w) was added at 25°C under an argon atmosphere. The mixture was stirred at 25 °C under H atmosphere (15 psi) for 15 h. A batch of Pd-C (4.76 g, 2.01 mmol, 5% w / w) was added and the mixture The mixture was stirred at 25°C under H2 atmosphere (30 psi) for 15 hours. The mixture was filtered and the filtrate was Evaporation under reduced pressure gave the crude product, which was diluted with 0 to 30% ethyl acetate / petroleum ethanol. Purification was performed by flash silica gel chromatography using a gradient of ether as eluent. , to give 2-isopropyl-4-methoxypyridin-3-amine (Int-20b). S(ESI):[M+H] + m / z:167. Step C: 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-methoxyphenyl)- Lysin-3-yl)carbamoyl)nicotinamide (Int-20c) 2,6-Dichloro-5-fluoronicotinamide (8.70 g, To a solution of 2.5g of oxalyl chloride (3.52 mL, 41.6 mmol), add oxalyl chloride (3.52 mL, 41.6 mmol) for 25 minutes. C. under a N2 atmosphere, and the mixture was stirred at 65.degree. C. for 30 minutes. The reaction mixture was then stirred at room temperature. Cool to rt and add 2-isopropyl-4-methoxypyridine-3-amine in THF (65 mL). Int-20b (6.92 g, 41.6 mmol) was added and the mixture was heated at 25°C for 1 The mixture was evaporated under reduced pressure to give the crude product, which was purified by flash filtration. Silica gel chromatography using a gradient of 0 to 10% MeOH / DCM as eluent. Purified by 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-methanone) (pyridin-3-yl)carbamoyl)nicotinamide (Int-20c) was obtained. S(ESI):[M+H] + m / z:401. Step D: 7-chloro-6-fluoro-1-(2-isopropyl-4-methoxypyridine- 3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Int- 20d) 2,6-Dichloro-5-fluoro-N-((2-isopropyl) -4-methoxypyridin-3-yl)carbamoyl)nicotinamide (Int-20c, A solution of 11.5 g, 28.7 mmol) of KHMDS (71.7 mL, 71.7 mmol) ) (1.0 M in THF) was added at 0° C. under N2 atmosphere. The mixture was stirred at 25° C. for 30 min. The mixture was evaporated under reduced pressure to give the crude product, which was diluted to 0-10%. Flash silica gel chromatography using a gradient eluent of MeOH / DCM Purified by 7-chloro-6-fluoro-1-(2-isopropyl-4-methoxypyridine). 1H,3H)-pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione(I nt-20d) was obtained. MS (ESI): [M+H] + m / z:365. Step E: 4,7-dichloro-6-fluoro-1-(2-isopropyl-4-methoxypyridine) Int-20e ) 7-chloro-6-fluoro-1-(2-isopropyl-4-methyl)-2-(2-methyl-2-methylpropional) in MeCN (40 mL) (1H,3H)-2,4(1H,3H)-(2,3-doxypyridin-3-yl)pyrido[2,3-d]pyrimidine A stirred solution of dione (Int-20d, 3.64 g, 9.98 mmol) was added to DIEA (4. 36 mL, 25.0 mmol) and POCl3 (2.33 mL, 25.0 mmol) The mixture was stirred at 80° C. for 30 minutes. The reaction mixture was concentrated in vacuo to give 4, 7-Dichloro-6-fluoro-1-(2-isopropyl-4-methoxypyridine-3-yl) 1H)pyrido[2,3-d]pyrimidin-2(1H)-one was obtained, which was then subjected to HPLC without further purification. Used in the next step (Int-20e). MS (ESI): [M+H] + m / z:3 83. Step F: (S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methyl)- (2,3-d)pyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin tert-Butyl (Int-4-yl)-3-methylpiperazine-1-carboxylate 20f) 4,7-Dichloro-6-fluoro-1-(2-isopropyl)- in MeCN (40 mL) 4-Methoxypyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one A stirred solution of (Int-20e, 3.80 g, 9.92 mmol) was added to DIEA (5.20 m L, 29.7 mmol) and (S)-3-methylpiperazine-1-carboxylic acid tert -butyl (3.97 g, 19.8 mmol) was added at 25°C, and the mixture was heated at 80°C for 30 minutes. The reaction mixture was concentrated in vacuo and the residue was extracted with petroleum ether / Et0Ac=1 / 1. The (S)-4-(7 -chloro-6-fluoro-1-(2-isopropyl-4-methoxypyridin-3-yl) -2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl ethylpiperazine-1-carboxylate (Int-20f) was obtained. MS (E SI):[M+H] + m / z:548. Step G: (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl) )-1-(2-isopropyl-4-methoxypyridin-3-yl)-2-oxo-1,2 -dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1- tert-Butyl carboxylate (Int-20g) (S)-4-(7-chloro-6-phenylpropanol) in 1,4-dioxane (15 mL) / water (3 mL) Fluoro-1-(2-isopropyl-4-methoxypyridin-3-yl)-2-oxo-1 ,2-Dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine- 1-tert-butyl carboxylate (Int-20f, 1.14 g, 2.08 mmol), Potassium acetate (1.02 g, 10.4 mmol) and 1,1'-bis(diphenylphosphine phino)ferrocene-palladium(II) dichloride dichloromethane complex (0.170g To a stirred solution of 1,4-dioxane (0.5 mL) was added 1,4-dioxane (0.208 mmol). Potassium trifluoro(2-fluoro-6-hydroxyphenyl)borate (0.909 g, 4.17 mmol) was added at 90°C under a N2 atmosphere. The mixture was heated at 90°C for 0.5 The reaction mixture was stirred under N2 atmosphere for 1 hour. The reaction mixture was quenched with brine (10 mL). The combined organic layers were washed with brine (10 mL) and extracted with ethyl acetate (2 x 100 mL). The residue was washed with HCl, dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. was purified by flash silica gel chromatography using a gradient of 0 to 50% DCM / MeOH Purification by gradient elution afforded (3S)-4-(6-fluoro-7-(2-fluoro-6 -hydroxyphenyl)-1-(2-isopropyl-4-methoxypyridin-3-yl) -2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl ethylpiperazine-1-carboxylate (Int-20g) was obtained. MS (E SI):[M+H] + m / z:624. Step H: (3S)-4-(6-fluoro-7-(2-fluoro-6-(((trifluoro) Methyl)sulfonyl)oxy)phenyl)-1-(2-isopropyl-4-methoxypyridine Zin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine-4 -yl)-3-methylpiperazine-1-carboxylate tert-butyl ester (Int-20h) (3S)-4-(6-fluoro-7-(2-fluoro-6-hydro)- (2-isopropyl-4-methoxypyridin-3-yl)-2-phenyl xo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperidine tert-Butyl hydroxylamine-1-carboxylate (Int-20g, 500mg, 0.803m Pyridine (191 mg, 2.41 mmol) was added to a stirred solution of Tf2 0 (0.407 mL, 2.41 mmol) was added at 0 °C under a N atmosphere. The mixture The reaction mixture was stirred at 20°C for 2 hours under N2 atmosphere. The mixture was quenched with ethyl acetate (2 x 50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine (1 0 mL), dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash silica gel chromatography using 0 to 10% DCM Purification was performed using a gradient eluent of (3S)-4-(6-fluoro-7-(2- Fluoro-6-(((trifluoromethyl)sulfonyl)oxy)phenyl)-1-(2 -isopropyl-4-methoxypyridin-3-yl)-2-oxo-1,2-dihydropyridin Lido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid Int-butyl (Int-20h) was obtained. MS (ESI): [M+H] + m / z:7 55. Step I: (3S)-4-(7-(2-((E)-3-((tert-butyldimethylsilyl) (1-phenyl)oxy)prop-1-en-1-yl)-6-fluorophenyl)-6-fluoro- 1-(2-Isopropyl-4-methoxypyridin-3-yl)-2-oxo-1,2-di Hydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxamide tert-Butyl benzoate (Int-20i) (3S)-4-(6-fluoro-7-(2-fluoro-6-(( (Trifluoromethyl)sulfonyl)oxy)phenyl)-1-(2-isopropyl-4 -Methoxypyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d] tert-Butyl pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (I To a stirred solution of (E)-tert-butyl 2-hydroxybenzoate (nt-20h, 350 mg, 0.464 mmol), ethyldimethyl((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (2-yl)allyl)oxy)silane (208 mg, 0.696 mmol), potassium phosphate (1.39 mL, 1.39 mmol) (1 M in water) and chloro(2-dicyclohexyl) cyclophosphino-2',6'-dimethoxy-1,1'-biphenyl) [2-(2'-amino 33.4 mg, 0.046 mmol ) was added at 25°C under N2 atmosphere, and the mixture was stirred at 60°C for 12 hours under N2 atmosphere. The reaction was quenched with water (10 mL) and extracted with EtOAc (50 mL x 3). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue Flash silica gel chromatography, elution with petroleum ether / EtOAc = 1 / 2 Purified by (3S)-4-(7-(2-((E)-3-((tert-butyldimethyl (ethylsilyl)oxy)prop-1-en-1-yl)-6-fluorophenyl)-6-fluoro Fluoro-1-(2-isopropyl-4-methoxypyridin-3-yl)-2-oxo-1 ,2-Dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine- 1-tert-Butyl carboxylate Int-20i was obtained. MS (ESI): [M+H] + m / z:777. Step J: (3S)-4-(7-(2-(3-((tert-butyldimethylsilyl)oxy) (2-isopropyl)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4 -Methoxypyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d] tert-Butyl pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (I nt-20j) (3S)-4-(7-(2-((E)-3-((tert-butyl) (dimethylsilyl)oxy)prop-1-en-1-yl)-6-fluorophenyl)- 6-Fluoro-1-(2-isopropyl-4-methoxypyridin-3-yl)-2-oxo So-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperane tert-Butyl 2-(2-methyl-1-propanol)diol (Int-20i, 200 mg, 0.257 mmHg) Pd-C (27.4 mg, 0.257 mmol, 10% w / w) was added to a stirred solution of The mixture was degassed and purged with hydrogen three times and stirred at 25°C for 12 hours under a N2 atmosphere. The mixture was stirred under a H balloon (15 psi) for 1 hour. The mixture was filtered and the filtrate was concentrated in vacuo. (3S)-4-(7-(2-(3-((tert-butyldimethylsilyl)oxy)pro (2-isopropyl-4-methoxyphenyl)-6-fluorophenyl (Cipiridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin tert-Butyl 3-methylpiperazine-1-carboxylate (Int-2 0j) was obtained. MS(ESI): [M+H] + m / z:779. Step K: 6-fluoro-7-(2-fluoro-6-(3-hydroxypropyl)phenyl) )-1-(4-hydroxy-2-isopropylpyridin-3-yl)-4-((S)-2 -methylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one ( Int-20k) (3S)-4-(7-(2-(3-((tert-butyldibenzoyl) Methylsilyl)oxy)propyl)-6-fluorophenyl)-6-fluoro-1-(2 -isopropyl-4-methoxypyridin-3-yl)-2-oxo-1,2-dihydropyridin Lido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid To a stirred solution of ert-butyl ether (Int-20j, 110 mg, 0.141 mmol) was added KI (23.4 mg, 0.141 mmol) and chlorotrimethylsilane (15.3 mg, 0.141 mmol) was added and the resulting mixture was stirred at 80° C. for 16 hours. The material was used directly in the next step without further purification (Int-20k). MS (ESI) :[M+H] + m / z:551. Step L: (3S)-4-(6-fluoro-7-(2-fluoro-6-(3-hydroxypropyl) propyl)phenyl)-1-(4-hydroxy-2-isopropylpyridin-3-yl)- 2-Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl 1-piperazinecarboxylate (Int-20l) 6-Fluoro-7-(2-fluoro-6-(3-hydroxypropyl)amino)propanol in MeCN (1 mL) Phenyl)phenyl)-1-(4-hydroxy-2-isopropylpyridin-3-yl)-4 -((S)-2-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidine-2( 1H)-one (Int-20k, 110 mg, 0.100 mmol) in water ( Sodium bicarbonate in 0.2 mL of BocO (0.035 mL, 0.15 mmol) (8.4 mg, 0.10 mmol) was added at 0°C under a N2 atmosphere. The mixture was heated to 25°C. The mixture was stirred at rt for 1 h under N2 atmosphere. The mixture was extracted with EtOAc (10 mL × 3) and the combined The combined organic phase was dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated in vacuo. Purify by preparative TLC plate (SiO2, DCM / MeOH=10 / 1) and (3S) -4-(6-fluoro-7-(2-fluoro-6-(3-hydroxypropyl)phenyl) )-1-(4-hydroxy-2-isopropylpyridin-3-yl)-2-oxo-1, 2-Dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1 tert-Butyl carboxylate (Int-20l) was obtained. MS (ESI): [M+H] + m / z:651. Process M:Int-20m (3S)-4-(6-fluoro-7-(2-fluoro-6-( 3-hydroxypropyl)phenyl)-1-(4-hydroxy-2-isopropylpyridin (3-phenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine-4- tert-Butyl)-3-methylpiperazine-1-carboxylate (Int-20l,3 A stirred solution of 5.0 mg, 0.0550 mmol of triphenylphosphine (36.0 m g, 0.137 mmol) was added. The mixture was stirred at 65 °C under a N2 atmosphere, and then (E)-diazene-1,2-dicarboxylate di-tert-butyl (25.3 mg, 0. 110 mmol) was added. The reaction mixture was stirred at 65°C for 3 hours. The mixture was cooled to room temperature. and directly purified by preparative TLC plate (SiO2, DCM / MeOH=10 / 1). MS(ESI):[M+H] + m / z:633. Process N: Int-20n Int-20m (22mg,0.03 in DCM (0.5mL) / TFA (0.1mL) The solution of Int-20n (5 mmol) was stirred at 25° C. for 10 min. The mixture was concentrated in vacuo to give Int-20n which was further purified and used in the next step. MS(ESI): [M+H] + m / z:533. Step O: 17,20-difluoro-2-[(2S)-2-methyl-4-(prop-2-enyl)methyl] [6-(propan-2-yl)-12,13-dihydro-(6-(propan-2-yl)piperazin-1-yl)] -1,18-Ethenopyrido[3,4-e]pyrimido[6,1-c][7,2,4]benzo Oxadiazacyclododecin-4(11H)-one (Examples 20a and 20b) Stir Int-20n (18.5 mg, 0.0350 mmol) in DCM (0.5 mL). The stirred solution was added with DIEA (0.0180 mL, 0.104 mmol) and acryloyl chloride ( The resulting mixture was stirred at 0°C for 10 minutes. The mixture was directly purified by preparative TLC plate (SiO2, DCM / MeOH =10 / 1). The racemic material was separated using a preparative SFC column N; conditions: 0.1% NH4OH M Conformers separated and resolved by eOH, 55%: Peak 1 - Example 20a-17,20-difluoro-2-[(2S)-2-methyl-4 -(prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-1 2,13-Dihydro-1,18-ethenopyrido[3,4-e]pyrimido[6,1-c][ 7,2,4]Benzoxadiazacyclododecin-4(11H)-one. MS(ESI) :[M+H] + m / z: 587; 1 H NMR (400 MHz, methanol-d4) δ :8.40(d,J=5.9Hz,1H),8.17(br d,J=8.2Hz,1H ),7.49-7.32(m,1H),7.18-7.09(m,2H),7.05(t ,J=9.0Hz,1H),6.95-6.74(m,1H),6.31(br d,J =16.4Hz,1H),5.84(br d,J=10.2Hz,1H),4.77- 4.62(m,2H),4.59(br s,1H),4.51-4.15(m,1H) ,4.03-3.94(m,1H),3.70(br d,J=13.7Hz,2H), 3.43-3.31(m,1H),3.07-2.93(m,1H),2.85(br, 1H),2.18-2.06(m,1H),1.94(br,1H),1.81-1.6 5(m,2H),1.57(br t,J=7.4Hz,3H),1.28(d,J=6 .7Hz,3H), 0.99(d,J=6.7Hz,3H); and Peak 2 - Example 20b-17,20-difluoro-2-[(2S)-2-methyl-4 -(prop-2-enoyl)piperazin-1-yl]-6-(propan-2-yl)-1 2,13-Dihydro-1,18-ethenopyrido[3,4-e]pyrimido[6,1-c][ 7,2,4]Benzoxadiazacyclododecin-4(11H)-one. MS(ESI) :[M+H] + m / z: 587; 1 H NMR (400 MHz, methanol-d4) δ :8.40(d,J=5.9Hz,1H),8.32(br d,J=8.6Hz,1H ),7.46-7.37(m,1H),7.13(dd,J=12.5,7.0Hz,2 H),7.04(t,J=9.0Hz,1H),6.84(br dd,J=16.4, 9.8Hz,1H),6.32(br d,J=16.8Hz,1H),5.84(dd ,J=10.6,2.0Hz,1H),5.33(br s,1H),4.72(br d,J=11.7Hz,1H),4.59(br,1H),4.46-4.22(m,2 H),4.12-3.78(m,3H),3.46(br s,1H),3.00(br d,J=6.7Hz,1H),2.83(br s,1H),2.11(br t,J =10.6Hz,1H),1.93(br s,1H),1.79-1.64(m,1H ),1.37(br s,3H),1.28(d,J=7.0Hz,3H),0.99( d, J = 6.7 Hz, 3 H) obtained.
[0234] 2-chloro-5-fluoro-6-(2-fluoro-6-hydroxyphenyl)nicotinoid Preparation of tolyl (Int-21) [ka]
[0235] 2,6-Dichloro-5-fluoronicotinonitrile (2.86 g, 15 mmol), Potassium trifluoro(2-fluoro-6-hydroxyphenyl)borate (3.60g, 1 6.5mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropa Radium(II) (0.549 g, 0.750 mmol) and potassium acetate (2.94 g, 30.0 mmol) were combined in a 500 mL round-bottom flask. The mixture was purged three times. Dioxane (150 mL) and water (15 mL) (10:1) were added. The reaction mixture was stirred at 60°C for 16 hours. The mixture was diluted with water and washed with ethyl acetate for 3-4 hours. Extracted four times and dried over anhydrous Na2SO4, then the solvent was evaporated under vacuum. , and purified by silica gel column chromatography using a 10% to 30% EtOAc / hexanes solution. Purified using hexane and 2-chloro-5-fluoro-6-(2-fluoro-6-hydrogen (oxyphenyl)nicotinonitrile (Int-21) was obtained. 1 H NMR (400 MHz) ,CDCl3)δ:8.91(s,1H),7.90(d,J=8.0Hz,1H),7 .39(q,J=1.6Hz,1H),6.89(d,J=8.4Hz,1H),6.7 9-6.75(m,1H).
[0236] 2-(3-amino-2-isopropylpyridin-4-yl)ethanol (Int-22) Preparation of [ka]
[0237] 4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-methyl-2-propanol in THF (10 mL) (Int-7c, 1 g, 3.4 mmol)-2-isopropylpyridin-3-amine To the stirred solution of TBAF (8.49 mL, 8.49 mmol) (1 M in THF) was added at 20 °C. The mixture was stirred at 20°C for 4 hours under a nitrogen atmosphere. Rush silica gel chromatography was performed using 0 to 100% EtOAc / petroleum Purification was carried out using ether eluent to obtain 2-(3-amino-2-isopropylpyridine-4 -yl)ethanol (Int-22) was obtained. 1 H NMR (400 MHz, CDCl3 )δ:7.99(d,J=4.7Hz,1H),6.84(d,J=4.7Hz,1H) ,3.97(t,J=6.1Hz,4H),3.16-2.95(m,1H),2.80 (t,J=6.1Hz,2H),1.31(d,J=6.7Hz,6H).
[0238] Potassium (3,6-difluoro-2-hydroxyphenyl)trifluoroborate (Int Preparation of -23c) [ka]
[0239] Step A: (3,6-Difluoro-2-methoxyphenyl)boronic acid (Int-23a) 1,4-Difluoro-2-methoxybenzene (2.40 mL, 20.8 mmol) It was dissolved in HF (20.8 mL) under nitrogen. The resulting solution was cooled to 0°C. F- A 1 M solution of lithium diisopropylamide in hexane (25.0 mL, 25.0 mm ol) was added dropwise to the reaction mixture at 0° C. The resulting mixture was stirred at 0° C. for 15 minutes, and then Trimethyl borate (2.79 mL, 25.0 mmol) was added dropwise to the reaction vessel. The mixture was stirred at 0°C for 30 min. An ice-cold 2M aqueous sulfuric acid solution (52.0 mL, 10 4 mmol) was added dropwise to the reaction mixture, and the resulting mixture was stirred at 0°C for 2 hours. The mixture was extracted three times with chloroform (3 x 100 mL). The organic layer was dried over sodium sulfate. The dried solution was filtered and the filtrate was concentrated to dryness. (3,6-difluoro-2-methoxyphenyl)boronic acid (Int-23a) The resulting residue was used directly in the next step without purification.
[0240] Step B: (3,6-Difluoro-2-hydroxyphenyl)boronic Acid (Int-23b) (3,6-Difluoro-2-methoxyphenyl)boronic acid (2.8 g, 14.9 mmol) ) was dissolved in DCM (49.7 mL) under nitrogen. The resulting solution was cooled to 0°C. Carefully add neat tribromoborane (4.31 mL, 44.7 mmol) to the reaction vessel. The reaction mixture was stirred at 0° C. for 15 minutes, at which point TLC showed complete conversion of the starting material. The product mixture was carefully quenched by dropwise addition of ice-cold water (5 mL). The product mixture was extracted three times with chloroform (3 x 100 mL). The organic layer was washed with sodium sulfate. The dried solution was filtered and the filtrate was concentrated to dryness. The resulting residue containing (2-difluoro-2-hydroxyphenyl)boronic acid (Int-23b) The residue was used directly in the next step without purification.
[0241] Step C: Potassium (3,6-difluoro-2-hydroxyphenyl)trifluoroborate (Int-23c) (3,6-Difluoro-2-hydroxyphenyl)boronic acid (2.59g, 14.9mm ol) was added to a 250 mL round-bottom flask. The reaction vessel was evacuated and nitrogen Methanol (18.6 mL) was added to the reaction vessel to dissolve the starting material. In a separate 40 mL vial, potassium bifluoride (4.65 g, 59.6 mmol) was added. 1) and water (18.6 mL) were added. The resulting fluoride solution was stirred in the reaction vessel by flowing. The resulting mixture was stirred at 24°C for 16 hours. The product mixture was diluted with acetone ( The diluted product mixture was filtered and the filtrate was concentrated to dryness. The residue was diluted with acetone (100 mL). The diluted mixture was filtered and the filtrate was concentrated to dryness. The resulting residue was diluted with acetone (3 mL), and the solution was then diluted with hexane ( The product was collected by filtration and purified by trituration with 200 mL of HCl (3,6 -difluoro-2-hydroxyphenyl) potassium trifluoroborate (Int-23c ) was obtained. 1H NMR(500MHz,DMSO-d6)δ 8.14(q,J=14 .7Hz,1H),6.86(ddd,J=10.8,8.8,5.2Hz,1H),6 .32(td,J=8.3,3.2Hz,1H).
[0242] Potassium (3,6-difluoro-2-hydroxyphenyl)trifluoroborate (Int Preparation of -24) [ka]
[0243] (2,3-Difluoro-6-hydroxyphenyl)boronic acid (0.500 g, 2.88 m mol) was added to a 250 mL round-bottom flask. The reaction vessel was evacuated and nitrogen was added. The reaction vessel was refilled three times using a plain balloon. Methanol (3.59 mL) was added to the reaction vessel. The starting materials were dissolved. In a separate 40 mL vial, potassium bifluoride (0.898 g, 11.5 mmol) and water (3.59 mL) were added. The resulting mixture was stirred at 24°C for 16 hours. The mixture was diluted with acetone (20 mL). The diluted product mixture was filtered and the filtrate was concentrated. The resulting residue was diluted with acetone (40 mL) and the diluted mixture was filtered. The filtrate was concentrated to dryness. The resulting residue was diluted with acetone (3 mL). The solution was triturated with hexane (200 mL). The product was isolated by filtration. Collect and prepare potassium (3,6-difluoro-2-hydroxyphenyl)trifluoroborate (Int-24) was obtained. 1 H NMR (500 MHz, DMSO-d) δ 7.84 (q,J=13.3Hz,1H),6.91(q,J=8.3Hz,1H),6.32( dd, J = 10.0, 5.0 Hz, 1 H).
[0244] Potassium trifluoro(2-hydroxy-3-(trifluoromethyl)phenyl)borate Preparation of (Int-25) [ka]
[0245] 2-Hydroxy-3-(trifluoromethyl)propanol in methanol (3.04 mL) / water (3.04 mL) (fluoromethyl)phenylboronic acid (500 mg, 2.43 mmol) with potassium hydrogen fluoride To the reaction mixture was added ethanol (759 mg, 9.71 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with acetone (20 mL) and filtered. The filtrate was concentrated in vacuo and dissolved in acetone. Hexane was added (approximately 4 mL) and the mixture was filtered again. The solution was concentrated again to obtain trifluoro(2-hydroxy-3-(trifluoromethyl)phenyl) Potassium borate (Int-25) was obtained. MS(ESI) m / z 229 [MK] - .
[0246] Potassium trifluoro(2-hydroxy-5-(trifluoromethyl)phenyl)borate Preparation of (Int-26) [ka]
[0247] (2-hydroxy-5-(trifluoromethyl)phenyl)boronic acid (0.500g, 2 The reaction vessel was evacuated. The reaction vessel was emptied and refilled with nitrogen three times. Methanol (3.04 mL) was added to the reaction vessel to separate the starting material. In a separate 40 mL vial, potassium bifluoride (0.759 g, 9 0.71 mmol) and water (3.04 mL) were added. The resulting fluoride solution was added to the reaction vessel. The resulting mixture was stirred at 24°C for 16 hours. The product mixture was diluted with acetone (25 mL). The diluted product mixture was filtered and the filtrate was concentrated to dryness. The resulting residue was diluted with acetone (50 mL). The diluted mixture was filtered. The resulting residue was diluted with acetone (3 mL), and the solution was then Triturated with hexane (50 mL) and collected the product by filtration. Potassium trifluoro(2-hydroxy-5-(trifluoromethyl)phenyl)borate (Int-26) was obtained. 1 H NMR (500 MHz, DMSO-d) δ 7.91 (q,J=9.7Hz,1H),7.41(d,J=2.5Hz,1H),7.28(d d,J=8.4,2.5Hz,1H),6.69(d,J=8.4Hz,1H).
[0248] Potassium trifluoro(3-fluoro-2-hydroxyphenyl)borate (Int-27 Preparation of [ka]
[0249] (3-Fluoro-2-hydroxyphenyl)boronic acid (1.15 g, 7.38 mmol) The reaction vessel was evacuated and a nitrogen balloon was placed in the flask. Methanol (14.8 mL) was added to the reaction vessel to dissolve the starting material. In a separate 40 mL vial, potassium bifluoride (2.30 g, 29.5 The resulting fluoride solution was poured into the reaction vessel. The resulting mixture was stirred at 24°C for 16 hours. The diluted product mixture was filtered and the filtrate was concentrated to dryness. The resulting residue was diluted with acetone (100 mL). The diluted mixture was filtered and the filtrate was The resulting residue was diluted with acetone (3 mL), and the solution was then diluted with hexane. The product was collected by filtration and triturated with 200 mL of ethanol. Potassium trifluoro(3-fluoro-2-hydroxyphenyl)borate (Int-27) obtained. 1 H NMR(500MHz,DMSO-d6)δ 7.43(d,J=9.6 Hz,1H),6.92(dd,J=7.2,1.6Hz,1H),6.83(ddd, J=11.8,7.9,1.7Hz,1H),6.60(td,J=7.6,4.3Hz ,1H).
[0250] Potassium (4,5-difluoro-2-hydroxyphenyl)trifluoroborate (Int Preparation of -28) [ka]
[0251] (4,5-Difluoro-2-hydroxyphenyl)boronic acid (0.500 g, 2.88 m mol) was added to a 250 mL round-bottom flask. The reaction vessel was evacuated and nitrogen was added. The reaction vessel was refilled three times using a plain balloon. Methanol (3.59 mL) was added to the reaction vessel. The starting materials were dissolved. In a separate 40 mL vial, potassium bifluoride (0.898 g, 11.5 mmol) and water (3.59 mL) were added. The resulting mixture was stirred at 24°C for 16 hours. The mixture was diluted with acetone (25 mL). The diluted product mixture was filtered and the filtrate was concentrated. The resulting residue was diluted with acetone (40 mL) and the diluted mixture was filtered. The filtrate was concentrated to dryness. The resulting residue was diluted with acetone (3 mL). The solution was triturated with hexane (approximately 20 mL). The product was isolated by filtration. Collect and prepare potassium (4,5-difluoro-2-hydroxyphenyl)trifluoroborate (Int-28) was obtained. 1 H NMR (500 MHz, DMSO-d) δ 7.52 (qd,J=9.7,1.4Hz,1H),6.92(t,J=10.9Hz,1H), 6.51(dd,J=12.8,6.5Hz,1H).
[0252] Potassium (2-chloro-6-hydroxyphenyl)trifluoroborate (Int-29) Preparation of [ka]
[0253] (2-chloro-6-hydroxyphenyl)boronic acid (0.500 g, 2.90 mmol) The reaction vessel was evacuated and a nitrogen balloon was placed in the flask. Methanol (3.63 mL) was added to the reaction vessel to remove the starting material. In a separate 40 mL vial, potassium bifluoride (0.906 g, 11 0.6 mmol) and water (3.63 mL) were added. The resulting fluoride solution was The resulting mixture was stirred at 24° C. for 16 hours. The diluted product mixture was filtered and the filtrate was concentrated to dryness. The resulting residue was diluted with acetone (100 mL). The diluted mixture was filtered. The resulting residue was diluted with acetone (3 mL), and the solution was then Triturated with hexane (200 mL). The product was collected by filtration. , (2-chloro-6-hydroxyphenyl) potassium trifluoroborate (Int-29 ) was obtained. 1 H NMR(500MHz,DMSO-d6)δ 8.45(q,J=16 .7Hz,1H),6.92(t,J=7.9Hz,1H),6.65(d,J=7.8 Hz,1H), 6.48(d,J=8.0Hz,1H).
[0254] Potassium trifluoro(2-hydroxy-6-(trifluoromethyl)phenyl)borate Preparation of (Int-30) [ka]
[0255] (2-Hydroxy-6-(trifluoromethyl)phenyl)boronic acid (0.500g, 2 The reaction vessel was evacuated. The reactor was then filled with methanol (3.04 mL) and refilled with a nitrogen balloon three times. In a separate 40 mL vial, potassium bifluoride (0 The resulting fluoride (0.759 g, 9.71 mmol) and water (3.04 mL) were added. The product solution was added to the reaction vessel by flowing. The resulting mixture was stirred at 24°C for 16 hours. The product mixture was diluted with acetone (25 mL). The diluted product mixture was filtered. The filtrate was concentrated to dryness. The resulting residue was diluted with acetone (40 mL). The residue was diluted with acetone (3 mL) and then The solution was triturated with hexane (approximately 20 mL). The product was filtered. and trifluoro(2-hydroxy-6-(trifluoromethyl)phenyl) ) Potassium borate (Int-30) was obtained. 1 H NMR (500 MHz, DMSO-d 6)δ 8.60(q,J=16.7Hz,1H),7.12(t,J=7.9Hz,1 H),7.01(d,J=7.7Hz,1H),6.79(d,J=8.0Hz,1H) .
[0256] 2-chloro-6-(3,6-difluoro-2-hydroxyphenyl)-5-fluoronicotinamide Preparation of thiinonitrile (Int-31) [ka]
[0257] 2,6-Dichloro-5-fluoronicotinonitrile (0.382 g, 2.00 mmol) ), potassium (3,6-difluoro-2-hydroxyphenyl)trifluoroborate (0 0.472g, 2.00mmol), [1,1'-bis(diphenylphosphino)ferrocene [Phenol]dichloropalladium(II) (0.146 g, 0.200 mmol) and potassium acetate A 50 mL round-bottom flask was charged with 1000 mg of ammonium hydroxide (0.393 g, 4.00 mmol). The flask was purged with nitrogen three times. Dioxane (15.3 mL) and water (0.955 mL) were added. L) (15:1) was added. The reaction mixture was stirred at 60°C overnight. The reaction mixture was filtered. The crude product was purified by column chromatography using 10% to 20% ethyl acetate-hexane. Purified using up to 2-chloro-6-(3,6-difluoro-2-hydroxyphenyl) To give 5-fluoronicotinonitrile (Int-31), 1 H NMR (600 MHz, CDCl3)δ 7.94(d,J=7.8Hz,1H),7.83(d,J= 2.0Hz,1H),7.26(td,J=9.5,5.0Hz,1H),6.75(t d, J = 9.2, 3.7 Hz, 1 H).
[0258] 3-(3-amino-2-isopropylpyridin-4-yl)propan-1-ol (In Preparation of t-32 [ka]
[0259] 4-(3-((tert-butyldimethylsilyl)oxy)propyl)-2-isopropyl Contains pyridin-3-amine (Int-10c, 2.00 g, 6.48 mmol) Add THF (13 mL) to the flask, then add TBAF (19.5 mL, 19.5 mmol) , 1M in THF) was added. The mixture was heated to 50°C for 1 hour. After cooling to room temperature, The mixture was concentrated under reduced pressure, and the crude product was purified by column chromatography using hexane. Purify using 0 to 30% ethyl acetate in water to obtain 3-(3-amino-2-isopropyl) (Int-32)pyridin-4-ylpropan-1-ol was obtained. MS (ESI) m / z 195[M+H] +.
[0260] (R)-3-(3-amino-2-isopropylpyridin-4-yl)propan-1-ol Preparation of Int-33b [ka]
[0261] Step A: (R)-4-((1-(benzyloxy)propan-2-yl)oxy)-3- Nitro-2-(prop-1-en-2-yl)pyridine (Int-33a) (R)-1-(benzyloxy)propan-2-ol (0.178 mL, 1.10 mm ol) was dissolved in THF (2.98 mL) and cooled to 0°C. Slowly add ammonium hydroxide (0.044 g, 1.1 mmol, 60 wt % in mineral oil) and the reaction mixture The mixture was stirred at 0°C for 30 minutes. Then, 4-chloro-3-nitro-2-(prop-1-ene- 2-yl)pyridine (Int-10a, 0.199 g, 1.00 mmol) was added dropwise to the reaction mixture. The reaction mixture was stirred at this temperature for 2 hours until the starting material was consumed. It was quenched with ammonium chloride and diluted with ethyl acetate. The layers were separated and the aqueous layer was diluted with Et The combined organic layers were washed with water, brine, dried over sodium sulfate, and The crude product was purified by column chromatography to give (R)-4-((1 -(benzyloxy)propan-2-yl)oxy)-3-nitro-2-(prop-1- (2-en-yl)pyridine (Int-33a) was obtained. 1 H NMR (600 MHz, C DCl3)δ 8.47(d,J=5.8Hz,1H),7.40-7.29(m,5H ),6.98(d,J=5.8Hz,1H),5.36(dq,J=2.1,1.3Hz ,1H),5.30-5.22(m,1H),4.78(pd,J=6.5,3.9Hz ,1H),4.62-4.50(m,2H),3.66(dd,J=10.6,6.8H z,1H),3.62(dd,J=10.6,3.9Hz,1H),2.19(t,J= 1.2Hz,3H), 1.38(d,J=6.3Hz,3H). Step B: (R)-2-((3-amino-2-isopropylpyridin-4-yl)oxy) Propan-1-ol (Int-33b) (R)-4-((1-(benzyloxy)propan-2-yl)oxy)-3-nitro- 2-(prop-1-en-2-yl)pyridine (4 g, 12 mmol), AcOH (4 m L) and a mixture of Pd / C (2 g) and EtOH (40 mL) were heated at 30 °C overnight under H The reaction mixture was filtered and concentrated to give (R)-2-((3-amino-2-isopropyl) Pyrpyridin-4-yl)oxy)propan-1-ol (Int-33b) was obtained. 1 H NMR (400 MHz, methanol-d4) δ 7.78 (d, J = 5.6 Hz, 1 H),6.80(d,J=5.6Hz,1H),4.64-4.56(m,1H),3. 78-3.68(m,2H),3.19(s,1H),1.33(d,J=6.4Hz, 3H),1.25(dd,J=1.2,6.6Hz,6H).
[0262] (S)-3-(3-amino-2-isopropylpyridin-4-yl)propan-1-ol Preparation of Int-34c [ka]
[0263] Step A: (S)-4-((1-(benzyloxy)propan-2-yl)oxy)-3- Nitro-2-(prop-1-en-2-yl)pyridine (Int-34a) (S)-1-(benzyloxy)propan-2-ol (4.20 g, 25.3 mmol) ) in THF (40 mL) was added to a mixture of NaH (2.50 g, 63.3 mmol, 60 wt %) was added at 0° C. The mixture was stirred at room temperature for 1 h and then diluted with 10 mL of THF 4-Chloro-3-nitro-2-(prop-1-en-2-yl)pyridine (Int-10 a, 5.00 g, 25.3 mmol) was added. The reaction mixture was stirred at room temperature overnight. The above solution was poured into the NH4Cl solution. This solution was extracted with EtOAc (80 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The product was purified by column chromatography on silica gel (petroleum ether / EtOAc = 50:1). Purified by (S)-4-((1-(benzyloxy)propan-2-yl)oxy) )-3-nitro-2-(prop-1-en-2-yl)pyridine (Int-34a) Ta. 1 H NMR(400MHz,CDCl3)δ 8.47(d,J=5.6Hz,1 H),7.40-7.28(m,5H),6.97(d,J=6.0Hz,1H),5. 36-5.24(m,2H),4.81-4.75(m,1H),4.61-4.52( m,2H),3.69-3.57(m,2H),2.19(s,3H),1.38(d, J=6.4Hz,3H). Step B: (S)-2-((3-amino-2-isopropylpyridin-4-yl)oxy) Propan-1-ol (Int-34b) (S)-4-((1-(benzyloxy)propan-2-yl)oxy)-3-nitro- 2-(prop-1-en-2-yl)pyridine (4.0 g, 12 mmol), AcOH( 4 mL) and a mixture of Pd / C (2.0 g, 10 wt%) and EtOH (40 mL) were added to 3 The mixture was stirred under H2 at 0 °C overnight. The reaction mixture was filtered and concentrated to give (S)-2-((3- Amino-2-isopropylpyridin-4-yl)oxy)propan-1-ol (Int -34b) was obtained without further purification.
[0264] Step C: (S)-3-(3-amino-2-isopropylpyridin-4-yl)propane- 1-all (Int-34c) (S)-2-((3-amino-2-isopropylpyridin-4-yl)oxy)propane 1-methyl-1-ol (10.0 g, 47.6 mmol) and imidazole (6.50 g, 95 tert-Butylchlorodimethylsilane (0.2 mmol) was added to a mixture of tert-butylchlorodimethylsilane (0.001 mmol) and DCM (100 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was washed with water (20 mL) and concentrated. The crude product was purified by column chromatography on silica gel. The (S)-3-(3- Amino-2-isopropylpyridin-4-yl)propan-1-ol (Int-34c ) was obtained. MS (ESI) m / z 325 [M+H] + .
[0265] 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy-1,1,2,2- d4) Preparation of 2-isopropylpyridin-3-amine (Int-35c) [ka]
[0266] Step A: 2-((tert-butyldimethylsilyl)oxy)ethane-1,1,2,2- d4-1-ol (Int-35a) Ethane-d4-1,2-diol (5.0 g, 76 mmol) was placed in a 500 mL round-bottom flask. The reactor was evacuated and refilled with nitrogen three times. THF (1 00 mL) was added to the reaction vessel. Sodium hydride (3.0 g, 76 mmol) in mineral oil (6.0 mL) The resulting solution (0% suspension) was added to the reaction vessel in six equal portions over a period of 15 minutes at 24°C. The resulting mixture was stirred at 24°C for 1 hour. t-Butylchlorodimethylsilane (11.4 g, 76.0 mmol) in 30 mL of THF The resulting mixture was added dropwise to the reaction vessel via a cannula. HF (2 x 10 mL) was added to the bath containing the silyl chloride and the rinse was The resulting mixture was stirred at 24°C for 1 hour. The reaction mixture was quenched with aqueous ammonium chloride (20 mL). The extract was extracted three times with ether (3 x 50 mL). The combined organic layers were dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to dryness. The residue was purified by flash column chromatography. Purified by chromatography, eluting with 0 to 30% ethyl acetate-hexane. 2-((tert-butyldimethylsilyl)oxy)ethane-1,1,2,2-d4-1 -Ol (Int-35a) was obtained. 1 H NMR (500 MHz, CDCl3) δ 0 .93(s,9H),0.11(s,6H). Step B: 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy-1,1, 2,2-d4)-3-nitro-2-(prop-1-en-2-yl)pyridine (Int- 35b) 2-((tert-butyldimethylsilyl)oxy)ethane-1,1,2,2-d4- 1-ol (4.82 g, 26.7 mmol) was added to a 500 mL round-bottom flask. The reactor was evacuated and refilled with nitrogen three times. THF (50 mL) was added to the reactor. The resulting mixture was cooled to 0°C. Sodium hydride (1.12 g, 2 8.0 mmol) (60% suspension in mineral oil) was added in five equal portions over a 15 minute period. The mixture was stirred at 0°C for 30 minutes. -3-nitro-2-(prop-1-en-2-yl)pyridine (Int-10a, 5.0 5 g, 25.4 mmol) was dissolved in THF (25 mL) under nitrogen. was transferred dropwise via cannula to the reaction mixture at 0° C. The resulting mixture was heated at 0° C. The mixture was stirred for 2 hours. The product mixture was quenched with saturated aqueous ammonium chloride (10 mL). The quenched product mixture was extracted three times with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate. The dried solution was filtered, and the filtrate The resulting residue was purified by flash column chromatography to obtain a 0 to 40% Purification was carried out by elution with ethyl acetate-hexane up to 50% to obtain 4-(2-((tert-butyl) (dimethylsilyl)oxy)ethoxy-1,1,2,2-d4)-3-nitro-2-(propoxy) To give (propyl-1-en-2-yl)pyridine (Int-35b), 1 H NMR (500 MHz, acetonitrile-d3) δ 8.49 (d, J = 5.8 Hz, 1H), 7.13 (d,J=5.8Hz,1H),5.45-5.26(m,1H),5.21-4.97 (m,1H),2.11(s,3H),0.85(s,9H),0.04(s,6H). Step C: 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy-1,1, 2,2-d4)-2-Isopropylpyridin-3-amine (Int-35c) 4-(2-((tert-butyldimethylsilyl)oxy)ethoxy-1,1,2,2 -d4)-3-nitro-2-(prop-1-en-2-yl)pyridine (4.82 g, 1 4.1 mmol) was dissolved in EtOH (70 mL), degassed under nitrogen, and Pd-C (1 0 wt%, 0.300 g, 2.81 mmol) was added, degassed under nitrogen, and then placed under a hydrogen atmosphere. The reaction mixture was stirred at rt for 24 hours. The product mixture was thoroughly purged with nitrogen. The mixture was filtered through a Celite pad. The filtrate was concentrated to dryness. The resulting residue was extracted with ethyl acetate ( 20 mL) and filter the diluted product mixture through a syringe filter. The catalyst / activated carbon was further removed. The filtrate was concentrated to dryness and 4-(2-((tert-butyl Dimethylsilyl)oxy)ethoxy-1,1,2,2-d4)-2-isopropylpyridin To give benzophenone-3-amine (Int-35c), 1 H NMR (500 MHz, acetonitrile) Le-d3)δ 7.84(d,J=5.5Hz,1H),6.73(d,J=5.5Hz ,1H),4.03(s,2H),3.11(p,J=6.7Hz,1H),1.23( d,J=6.7Hz,6H),0.92(s,9H),0.11(s,6H).
[0267] 4-(3-((tert-butyldimethylsilyl)oxy)propyl)-6-isopropyl Preparation of pyrimidin-5-amine (Int-36c) [ka]
[0268] Step A: 4-[(1E)-3-[(tert-butyldimethylsilyl)oxy]prop- 1-en-1-yl]-6-chloropyrimidin-5-amine (Int-36a) A 5000 mL three-neck round-bottom flask purged with nitrogen and maintained under an inert atmosphere of nitrogen The contents were DME (2000 mL), H2O (400 mL), Na2CO3 (248 g, 23 43 mmol, 3.00 equivalents), tert-butyldimethyl [[(2E)-3-(4,4 ,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-ene
[0041] 4,6-di-[(2-yl)oxy]silane (233 g, 781 mmol, 1.00 equiv.), Chloropyrimidin-5-amine (128 g, 781 mmol, 1.00 equiv.), Pd(P Ph3)2Cl2 (47 g, 67 mmol, 0.10 equiv.) was added. The resulting solution was dissolved in water. The resulting solution was stirred in a bath at 80°C for 3 hours, cooled to room temperature, and diluted with 2 x 500 mL of vinegar. The organic layers were combined and concentrated in vacuo. The residue was purified by column chromatography. The product was purified using ethyl acetate / petroleum ether (1:1) to give 4-[(1E)-3 -[(tert-butyldimethylsilyl)oxy]prop-1-en-1-yl]-6- Chloropyrimidin-5-amine (Int-36a) was obtained. MS (ESI) m / z 30 0[M+H] + . Step B: 4-[(1E)-3-[(tert-butyldimethylsilyl)oxy]prop- 1-en-1-yl]-6-(prop-1-en-2-yl)pyrimidin-5-amine ( Int-36b) A 5000 mL three-neck round-bottom flask purged with nitrogen and maintained under an inert atmosphere of nitrogen The contents were DME (2000 mL), H2O (400 mL), Cs2CO3 (531 g, 16 30 mmol, 3 equivalents), 4-[(1E)-3-[(tert-butyldimethylsilyl) Oxy]prop-1-en-1-yl]-6-chloropyrimidin-5-amine (163g , 543 mmol, 1.00 equivalents), 4,4,5,5-tetramethyl-2-(prop-2 (91 g, 544 mmol, 1.0 0 equivalents) and Pd(PPh3)2Cl2 (38 g, 54 mmol, 0.1 equivalents). The resulting solution was stirred in an oil bath at 100°C for 12 hours. The resulting solution was cooled to room temperature. , Extract with 2 x 500 mL of ethyl acetate. The organic layers were combined and concentrated in vacuo. The residue was diluted with acetic acid. Purification by column chromatography using ethyl acetate / petroleum ether (1:1) 4-[(1E)-3-[(tert-butyldimethylsilyl)oxy]prop-1-ene -1-yl]-6-(prop-1-en-2-yl)pyrimidin-5-amine (Int- 36b) was obtained. MS(ESI) m / z 306[M+H] + . Step C: 4-[3-[(tert-butyldimethylsilyl)oxy]propyl]-6-isopropyl Isopropylpyrimidin-5-amine (Int-36c) A 3000 mL three-neck round-bottom flask purged with nitrogen and maintained under an inert atmosphere of nitrogen Ethanol (1500 mL), 4-[(1E)-3-[(tert-butyldimethyl Silyl)oxy]prop-1-en-1-yl]-6-(prop-1-en-2-yl) Pyrimidine-5-amine (107 g, 350 mmol, 1.00 equiv.) and Pd / C ( 3.73 g, 35.0 mmol, 0.1 equivalents) was added. H2 (gas) was introduced into the mixture. The resulting solution was stirred at 25°C for 12 hours. The solid matter was filtered off. The resulting mixture was The residue was purified by column chromatography (EtOAc:petroleum ether = 1:1). The product was purified by 4-[3-[(tert-butyldimethylsilyl)oxy]propyl]-6 -isopropylpyrimidin-5-amine (Int-36c) was obtained. 1 H-NMR (30 0MHz,DMSO-d6):δ 8.28(s,1H),5.00(s,2H),3. 66(t,J=6.5Hz,2H),3.29-3.12(m,1H),2.63(t, J=7.4Hz,2H),1.93-1.77(m,2H),1.14(d,J=6.6 Hz,6H),0.86(s,9H),0.02(s,6H).
[0269] 4-(4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-2-yl Preparation of isopropylpyridin-3-amine (Int-37d-1 and Int-37d-2) Made [ka]
[0270] Step A: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl) (I)but-3-en-1-ol (Int-37a) Pd(PhP) (4.01 g, 3.4 mL) was placed in a microwave vial containing a magnetic stir bar. 7mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2' 1,3,2-dioxaborolane (26.4 g, 104 mmol) was added. The vial was evacuated and backfilled with nitrogen three times. Toluene (24 mL) was added. After addition of but-3-yn-1-ol (6.08 g, 87 mmol) and acetic acid (4. 4 mL) was added. The reaction mixture was pre-stirred for 5 min and then heated in a microwave oven to 80 °C for 3 min. After cooling to room temperature, the mixture was concentrated in vacuo and the residue was columned on silica gel. The eluate was purified by column chromatography (petroleum ether: EtOAc = 50:1 to 20:1). Purified by 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- The reaction mixture was divided into four batches ( The weights were set at 1.52g each. 1 H NMR (500 MHz, CDCl3) δ 5.8 9(d,J=3.0Hz,1H),5.70(s,1H),3.67(t,J=6.0H z,2H),2.42(t,J=6.0Hz,2H),1.26(s,12H). Step B: tert-butyldimethyl ((3-(4,4,5,5-tetramethyl-1,3, 2-Dioxaborolan-2-yl)but-3-en-1-yl)oxy)silane (Int -37b) 3-(4,4,5,5-tetramethyl-1,3,2-dioxadibenzofuran) in DCM (260 mL) A stirred solution of (borolan-2-yl)but-3-en-1-ol (15 g, 76 mmol) tert-butylchlorodimethylsilane (17.1 g, 114 mmol) and imidazoline azole (10.3 g, 151 mmol) was added, and the mixture was stirred at 20°C for 16 h under a N2 atmosphere. The reaction mixture was quenched with water (200 mL) and diluted with dichloromethane The combined organic layers were washed with brine (180 mL) and extracted with N Dry over a2SO4, filter, and evaporate the solvent under reduced pressure. Column chromatography (petroleum ether:ethyl acetate = 60:1 to 30:1) Purified by tert-butyldimethyl ((3-(4,4,5,5-tetramethyl- 1,3,2-Dioxaborolan-2-yl)but-3-en-1-yl)oxy)silane (Int-37b) was obtained. 1 H NMR (400 MHz, CDCl3) δ 5.78 ( d,J=3.2Hz,1H),5.62(s,1H),3.61(t,J=7.2Hz, 2H),2.33(t,J=7.2Hz,2H),1.21(s,12H),0.84( s,9H),0.00(s,6H). Step C: 4-(4-((tert-butyldimethylsilyl)oxy)but-1-ene-2 -yl)-3-nitro-2-(prop-1-en-2-yl)pyridine (Int-37c ) 4-Chloro-3-nitro-2-(propan-1-yl)-1,2-dichloro-1,3-dichloro-2,4 ... 1-en-2-yl)pyridine (Int-10a, 4.00 g, 20.1 mmol) The solution was treated with cesium carbonate (13.1 g, 40.3 mmol), tert-butyldimethyl (( 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butanoate (3-en-1-yl)oxy)silane (9.44 g, 30.2 mmol) and bis( Triphenylphosphine)palladium(II) dichloride (0.707g, 1.01mm ol) and the resulting mixture was stirred at 70°C for 16 hours under a N2 balloon. The mixture was cooled, diluted with water (200 mL), extracted with EtOAc (2×300 mL), and added Na Drying over 2SO4, filtering, and evaporating the solvent under reduced pressure gave the crude product. The crude product was chromatographed on silica gel (EtOAc / petroleum ether, 1 Purified by 4-(4-((tert-butyldimethylsilyl)methylsilyl) (oxy)but-1-en-2-yl)-3-nitro-2-(prop-1-en-2-yl) (Int-37c) pyridine (Int-37c). MS (ESI) m / z 349 [M+H] + . 1 H NMR(400MHz,CDCl3)δ 8.58(d,J=5.2Hz,1H ),7.18(d,J=5.2Hz,1H),5.31(d,J=4.4Hz,2H), 5.15(d,J=11.2Hz,2H),3.69(t,J=6.4Hz,2H),2 .57(t,J=6.4Hz,2H),2.18(s,3H),0.86(s,9H), 0.00(s,6H). Step D: 4-(4-((tert-butyldimethylsilyl)oxy)butan-2-yl) -2-isopropylpyridin-3-amine (Int-37d-1 and Int-37d- 2) 4-(4-((tert-butyldimethylsilyl)oxy)butanol) in MeOH (50 mL) (1-en-2-yl)-3-nitro-2-(prop-1-en-2-yl)pyridine A stirred solution of Pd-C (1.22 g, 1.15 mmol) l) (10 wt%) was added under a nitrogen atmosphere and the mixture was degassed and purged with hydrogen three times. The resulting mixture was stirred under a hydrogen balloon (pressure: 15 psi) at 20°C for 4 hours. The mixture was filtered and the filter cake was washed with methanol (100 mL). The filtrate was concentrated in vacuo. and 4-(4-((tert-butyldimethylsilyl)oxy)butan-2-yl)-2 This racemic material was separated by preparative SFC column M, Conditions: 0.1% NH3H2O IPA, separated, 4-(4-((tert-butyl) (dimethylsilyl)oxy)butan-2-yl)-2-isopropylpyridin-3-amino Int-37d-1 was identified as peak 1. MS (ESI) m / z 323 [M+H] + year and 4-(4-((tert-butyldimethylsilyl)oxy)butan-2-yl )-2-isopropylpyridin-3-amine (Int-37d-2) was identified as peak 2. MS( ESI) m / z 323 [M+H] + was obtained as.
[0271] 4-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl Preparation of )methyl)-2-isopropylpyridin-3-amine (Int-38g) [ka]
[0272] Step A: 2-(((tert-butyldimethylsilyl)oxy)methyl)prop-2-ene Int-1-ol (Int-38a) NaH (60%) (8.85 g, 221 mmol) was dissolved in 2-methylpropional in THF (800 mL). Add to a solution of ethylenepropane-1,3-diol (15.0 g, 170 mmol) at 0°C After stirring at 0°C for 0.5 hours, tert-butylchlorodimethylsilane (26.9 g, 179 mmol) was added to the mixture at 0°C to give a white mixture. The mixture was stirred for an additional 2 hours at 0° C. Then, the reaction mixture was slowly poured into 200 mL of ice water. The resulting solution was extracted with ethyl acetate (2 x 300 mL) and the organic layers were combined. Washed with brine (500 mL), dried over Na2SO4, filtered, concentrated and the crude The product was obtained as an oil, which was purified by flash silica gel chromatography ( to 3% EtOAc / petroleum ether) and purified to give 2-(((tert-butyl) (dimethylsilyl)oxy)methyl)prop-2-en-1-ol (Int-38a) obtained. 1 H NMR(500MHz,CDCl3)δ 5.09(dd,J=0.8, 9.0Hz,2H),4.25(s,2H),4.17(d,J=5.8Hz,2H), 0.91(s,9H),0.09(s,6H). Step B: ((2-(bromomethyl)allyl)oxy)(tert-butyl)dimethylsilyl N (Int-38b) 2-(((tert-butyldimethylsilyl)oxy) in CH2Cl2 (500 mL) (methyl)prop-2-en-1-ol (33.0 g, 163 mmol) in a stirred solution at 0°C. Triphenylphosphine (51.3 g, 196 mmol) was added to the solution, and then perbromo Methane (64.9 g, 196 mmol) was added, and the solution was stirred at 15°C for 17 hours. The solution was filtered and the filtrate was concentrated in vacuo. The residue was chromatographed on silica gel. -treated (EtOAc / petroleum ether, gradient from 0:100 to 5:95), ((2- (Bromomethyl)allyl)oxy)(tert-butyl)dimethylsilane (Int-38 b) was obtained. 1 H NMR(500MHz,CDCl3)δ 5.27-5.21(m, 2H),4.27(s,2H),4.01(s,2H),0.92(s,9H),0.1 0(s,6H). Step C: tert-Butyldimethyl ((2-((4,4,5,5-tetramethyl-1,3 ,2-Dioxaborolan-2-yl)methyl)allyl)oxy)silane (Int-38c ) In a two-necked round-bottom flask equipped with a magnetic stir bar and a condenser, add magnesium (3.30 g, 1 The flask was charged with 36 mmol) and fitted with a rubber septum. The flask was purged with argon. Dry THF (500 mL) was added, followed by 4,4,5,5-tetramethyl-1,3,2-dichloromethane (1.5 mL). Oxaborolane (14.5 g, 113 mmol) was added to the reaction mixture. (Bromomethyl)allyl)oxy)(tert-butyl)dimethylsilane (30.0 g, 113 mmol) was added dropwise at 25°C under constant stirring. After stirring at 25°C for 90 minutes, The reaction mixture was diluted with hexane (200 mL) and quenched with saturated NH4Cl (50 mL). The combined organic phase was washed with brine (100 mL). ), dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and tert-butyldichloromethane. Methyl ((2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2 The resulting product was methyl-allyloxysilane (Int-38c). 1 H NMR(5 00MHz, CDCl3)δ 5.00(d,J=1.8Hz,1H),4.81(d, J=1.7Hz,1H),4.07(s,2H),1.67(s,2H),1.24(s ,12H),0.91(s,9H),0.06(s,6H). Step D: 4-Chloro-2-isopropyl-3-nitropyridine (Int-38d) 4-Chloro-3-nitro-2-((2-chloro-3-nitro-2-methyl ... Prop-1-en-2-yl)pyridine (Int-10a, 6.00 g, 30.2 mmol) To a stirred solution of 2.80 ml of tris(triphenylphosphine)rhodium(I) chloride g, 3.02 mmol) was added under a nitrogen atmosphere, and the mixture was degassed and purged with hydrogen three times. The resulting mixture was stirred under hydrogen (pressure: 50 psi) at 50°C for 6 hours. The mixture was concentrated in vacuo and the residue purified by flash silica gel chromatography (0 to 8% Purification by elution with a gradient of EtOAc / petroleum ether at 77°C gave 4-chloro-2-isopropyl ether. Propyl-3-nitropyridine (Int-38d) was obtained. 1 H NMR (400 MHz) ,CDCl3)δ 8.59(d,J=5.1Hz,1H),7.33(d,J=5.1 Hz,1H),3.12-3.01(m,1H),1.31(d,J=6.7Hz,6H ). Step E: 4-(2-(((tert-butyldimethylsilyl)oxy)methyl)allyl) -2-Isopropyl-3-nitropyridine (Int-38e) 4-Chloro-2-isopropyl-3-nitropyridine (4 To a stirred solution of 0.90 g, 24.4 mmol) of tert-butyldimethyl ((2-((4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)allyl )oxy)silane (22.9 g, 73.3 mmol), Cs2CO3 (16.3 mL, 4 8.8 mmol) (aqueous 3 M) and RuPhos Pd G3 (1.90 g, 2.44 (mmol) was added at 25 °C under N2 atmosphere, and the mixture was heated at 80 °C for 3 h under N2 atmosphere. The reaction mixture was quenched with water (30 mL) and ethyl acetate (100 mL) was added. The combined organic layers were washed with brine (2 x 20 mL) and extracted with Na2SO4 The mixture was dried at 77°C, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash silica gel chromatography. Purification by chromatography (eluent: 0 to 2% EtOAc / petroleum ether) and 4-(2-(((tert-butyldimethylsilyl)oxy)methyl)allyl)-2 3-Isopropyl-3-nitropyridine (Int-38e) was obtained. 1 H NMR (500 MHz, CDCl3)δ 8.59(d,J=4.9Hz,1H),7.19-7.12 (m,1H),5.23(s,1H),4.83(d,J=1.2Hz,1H),4.0 8-3.99(m,2H),3.40-3.31(m,2H),3.11-2.99(m ,1H),1.31(d,J=6.7Hz,6H),0.88(s,9H),0.05- 0.02(m,6H). Step F: 4-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclo Propyl)methyl)-2-isopropyl-3-nitropyridine (Int-38f) 4-(2-(((tert-butyldimethylsilyl)oxy)) in DCM (200 mL) Methyl)allyl)-2-isopropyl-3-nitropyridine (6.00g, 17.1mm A stirred solution of Pd(OAc)2 (0.192 g, 0.856 mmol) and Pd(OAc)2 (0.192 g, 0.856 mmol) was A solution of 1.03 L of ethanol (514 mmol) (approximately 0.5 M in EtO) was heated at -20°C for 3 hours. The mixture was filtered and the filter cake was washed with dichloromethane (50 mL). The filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography (0 to 100%). Purification by elution with 10% EtOAc / petroleum ether to give 4-((1-((( tert-Butyldimethylsilyl)oxy)methyl)cyclopropyl)methyl)-2-isopropyl Isopropyl-3-nitropyridine (Int-38f) was obtained. 1 H NMR (400MH z,CDCl3)δ 8.57(d,J=5.1Hz,1H),7.36(d,J=5. 1Hz,1H),3.39-3.29(m,2H),3.02(td,J=6.7,13 .4Hz,1H),2.77-2.67(m,2H),1.30(d,J=6.6Hz, 6H),0.86(s,9H),0.55-0.49(m,2H),0.48-0.43 (m,2H),0.00--0.05(m,6H). Step G: 4-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclo Propyl)methyl)-2-isopropylpyridin-3-amine (Int-38g) 4-((1-(((tert-butyldimethylsilyl)oxy) Methyl)cyclopropyl)methyl)-2-isopropyl-3-nitropyridine (2.60 To a stirred solution of zinc powder (3.73 g, 57.1 mmol) and Add ammonium chloride (6.10 mL, saturated aqueous solution) in water (5 mL) at 0°C and mix. The mixture was stirred for 2 h at 20° C. The mixture was filtered and the filter cake was diluted with EtOAc (100 mL The organic layer was washed with brine (30 mL) and sodium sulfate. The mixture was dried over sodium, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography. Purification by chromatography (eluent 0 to 20% EtOAc / petroleum ether) gave 4 -((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl) Methyl)-2-isopropylpyridin-3-amine (Int-38g) was obtained. 1 HN MR(400MHz,CDCl3)δ 7.92(d,J=4.9Hz,1H),6.7 5(d,J=4.9Hz,1H),4.23-4.08(s,2H),3.37(s,2 H),3.06(spt,J=6.7Hz,1H),2.71(s,2H),0.97( s,9H),0.91-0.82(m,6H),0.38(br d,J=3.4Hz, 4H), 0.03(s,6H). Step H: (1-((3-amino-2-chloropyridin-4-yl)ethynyl)cyclopropyl Pill) Methanol (Int-38h) 4-Bromo-2-chloropyridine-3-amine in TEA (5.4 mL, 39 mmol) In a flask containing 1-ethynylcyclopropyl Pill) methanol (0.25 g, 2.6 mmol), copper(I) iodide (21 mg, 0.1 1mmol) and bis(triphenylphosphine)palladium(II) dichloride (2 The flask was purged with nitrogen and then heated for 75 minutes. After 3 hours, the mixture was allowed to cool to room temperature and then further (1-ethyl) (Cyclopropyl)methanol (98 mg, 1.02 mmol) was added to the mixture. The mixture was heated to 75° C. for 1 hour. After 1 hour, the mixture was allowed to cool to room temperature and then concentrated under reduced pressure. Ethyl acetate and brine were added. The organic layer was separated and washed with water over anhydrous magnesium sulfate. The resulting residue was purified by silica gel column chromatography. - (a 3:1 mixture of hexane and ethyl acetate:ethanol) and purified by (1-(( 3-amino-2-chloropyridin-4-yl)ethynyl)cyclopropyl)methanol ( Int-38h) was obtained. MS (ESI) m / z 223 [M+H] + Step I: 4-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclo Propyl)ethynyl)-2-chloropyridin-3-amine (Int-38i) 1-((3-amino-2-chloro- Pyridin-4-yl)ethynyl)cyclopropyl)methanol (Int-38h, 0.3 A contaminating flask containing 8 g (1.7 mmol) of HCl was cooled to 0°C. tert-Butylchlorodimethylsilane (0.34 g, 2.2 mmol) and imidazoline 3.2 mmol) was added, and the mixture was allowed to warm to room temperature. After 3 hours, the mixture was concentrated under reduced pressure. Ethyl acetate and brine were added. The organic layer was separated, dried over magnesium sulfate, filtered, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate gradient in hexane). and purified as 4-((1-(((tert-butyldimethylsilyl)oxy)methyl)silyl To give (chloropropyl)ethynyl)-2-chloropyridin-3-amine (Int-38i), MS(ESI)m / z 337[M+H] + Step J: 4-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclo Propyl)ethynyl)-2-(prop-1-en-2-yl)pyridin-3-amine(I nt-38j) 4-((1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl (I)ethynyl)-2-chloropyridin-3-amine (Int-38i, 0.32 g, 0. 96 mmol), potassium isopropenyltrifluoroborate (0.17 g, 1.1 mm ol), PdCl2(dppf)-CH2Cl2 adduct (78 mg, 0.096 mmol ) and potassium carbonate (0.26 g, 1.9 mmol) in a vial containing dioxane. Aqueous ether (1.0 mL) and water (0.15 mL) were added. The vial was purged with nitrogen. The mixture was then heated to 90°C for 3 hours. After 3 hours, the mixture was allowed to cool to room temperature. The product was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography. (hexane and ethyl acetate:ethanol 3:1 mixture) and purified by 4-((1- (((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl)ethynyl) -2-(prop-1-en-2-yl)pyridin-3-amine (Int-38j) was obtained. MS(ESI)m / z 343[M+H] + Step K: 4-(2-(1-(((tert-butyldimethylsilyl)oxy)methyl)silyl (chloropropyl)ethyl)-2-isopropylpyridin-3-amine (Int-38k) 4-((1-(((tert-butyldimethylsilyl)silyl)methylsilyl)methylsilylsilyl)methylsilylsilyl 2-(prop-1-en-2-yl)pyroxymethyl)cyclopropylethynyl A flask containing din-3-amine (Int-38j, 0.32 g, 0.94 mmol) The LASCO was purged with nitrogen. Palladium on carbon (10% catalyst loading, 32 mg, 0.0 30 mmol) was added. The flask was then evacuated. e) and purged with hydrogen. The mixture was then stirred at room temperature for 1 hour. After 1 hour, the mixture The filtrate was filtered through Celite, and the resulting residue was purified by silica gel column chromatography. Purification by chromatography (hexane and a 3:1 mixture of ethyl acetate and ethanol) 4-(2-(1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl (p-ethyl)-2-isopropylpyridin-3-amine (Int-38k) was obtained. S(ESI) m / z 349[M+H] + .
[0273] (2R,5S)-4-(1-(4-(2-((tert-butyldimethylsilyl)oxy )Ethoxy)-2-isopropylpyridin-3-yl)-7-chloro-6-fluoro-2 -oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-di Preparation of tert-butyl methylpiperazine-1-carboxylate (Int-39c) [ka]
[0274] Step A: N-((4-(2-((tert-butyldimethylsilyl)oxy)ethoxy) -2-isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluoro Oronicotinamide (Int-39a) 2,6-dichloro-5-fluoronicotinamide (500 mg, 2.39 mmol) The reaction vessel was evacuated and a nitrogen balloon was used to add the solution to an 8 mL vial. The reaction vessel was refilled three times. THF (2.4 mL) was added to dissolve the starting material. A 2M solution of oxalyl chloride (1.44 mL, 2.87 mmol) was added dropwise to the reaction vessel. The resulting mixture was heated at 75°C for 1 hour. The intermediate solution was allowed to cool to room temperature. The intermediate solution was concentrated to half its volume. THF (200 μL) was added to the reaction vessel. The resulting mixture was cooled to 0°C. In a separate 4 mL vial, 4-(2-( (tert-Butyldimethylsilyl)oxy)ethoxy)-2-isopropylpyridine- 3-Amine (Int-10f, 743 mg, 2.39 mmol) in THF (200 μL) This amine solution was added dropwise to the reaction vessel, and the resulting mixture was stirred at 0°C for 1 hour. The product mixture was allowed to warm to room temperature and the reaction mixture was diluted with saturated aqueous sodium chloride. The mixture was quenched with 2 mL of a 1:1 mixture of acetic acid and aqueous ammonium chloride. The organic layers were combined and extracted with sodium sulfate three times (3×20 mL). The dried solution was filtered and the filtrate was concentrated to dryness. The residue was purified by flash column chromatography using 5% (ethyl acetate:ethanol, 3: 1, v / v)-dichloromethane to 50% (ethyl acetate:ethanol, 3:1, v / v )-dichloromethane to N-((4-(2-((tert-bromo-2-methyl-2-propanol) (ethyldimethylsilyl)oxy)ethoxy)-2-isopropylpyridin-3-yl)carboxamide bamoyl)-2,6-dichloro-5-fluoronicotinamide (Int-39a) was obtained. MS(ESI)m / z 545[M+H] + Step B: 1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)- 2-Isopropylpyridin-3-yl)-7-chloro-6-fluoropyridin [2,3-d ]pyrimidine-2,4(1H,3H)-dione (Int-39b-1) N-((4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2- Isopropylpyridin-3-yl)carbamoyl)-2,6-dichloro-5-fluorodiphenyl Cotinamide (830 mg, 1.52 mmol) was added to a 20 mL vial. The reaction vessel was evacuated and refilled with nitrogen three times. THF (3.0 mL) was added to the reaction vessel. The resulting mixture was cooled to 0°C. The resulting solution was added dropwise to the reaction vessel. The resulting mixture was stirred at 0°C for 1 hour. The product mixture was diluted with saturated aqueous ammonium bicarbonate (2 The resulting mixture was extracted three times with ethyl acetate (3 x 20 mL). The combined organic layers were dried over sodium sulfate. The dried solution was filtered and The filtrate was concentrated to dryness. The resulting residue was extracted with hexane to 66% (ethyl acetate-ethanol). The elution was carried out by flash column chromatography using hexane (3:1 v / v). The racemic material was purified by SFC column C, conditions: containing 0.05% diethylamine. Decomposed with MeOH, peak 1 was 1-(4-(2-((tert-butyldimethylsilyl) (2-isopropyl)oxy)ethoxy)-2-isopropylpyridin-3-yl)-7-chloro-6- Fluoropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Int-3 9b-1) was obtained. MS (ESI) m / z: 509 [M+H] + . Step C: (2R,5S)-4-(1-(4-(2-((tert-butyldimethylsilyl )Oxy)ethoxy)-2-isopropylpyridin-3-yl)-7-chloro-6-fluoro Oro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2 ,5-Dimethylpiperazine-1-carboxylate tert-butyl (Int-39c-1) 1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-isopropyl (isopropylpyridin-3-yl)-7-chloro-6-fluoropyrido[2,3-d]pyridin Myzine-2,4(1H,3H)-dione (Int-39b-1, 630 mg, 1.24 m mol) was added to a 20 mL vial. The reaction vessel was evacuated and filled with nitrogen for 3 minutes. The mixture was refilled twice. Acetonitrile (2.5 mL), N-ethyl-N-isopropylpropane -2-amine (330 μL, 1.86 mmol) and phosphoryl trichloride (150 μL, 1.601 mmol) was added to the reaction vessel, and the resulting mixture was heated at 80° C. for 1 hour. The mixture was concentrated to dryness. The resulting residue was dissolved in acetonitrile (1.3 mL) in a 20 mL vial. N-ethyl-N-isopropylpropan-2-amine (341 μL) was dissolved in L, 1.91 mmol) and (2R,5S)-2,5-dimethylpiperazine-1-carbohydrate Tert-butyl carboxylate (205 mg, 0.956 mmol) was added to the reaction vessel. The resulting mixture was stirred at 24°C for 1 hour. The product mixture was diluted with ethyl acetate (100 mL). The mixture was washed three times with saturated aqueous sodium bicarbonate (3 x 10 mL). The dried solution was filtered and the filtrate was concentrated to dryness. The resulting residue was extracted with hexane up to 66% (ethyl acetate-ethanol = 3:1 v / v) Purification by flash column chromatography eluting with hexane (2R,5 S)-4-(1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy )-2-Isopropylpyridin-3-yl)-7-chloro-6-fluoro-2-oxo- 1,2-Dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperidine tert-Butyl tetraazine-1-carboxylate (Int-39c-1) was obtained. MS (ESI ) m / z 706[M+H] + .
[0275] Intermediates Int-40-1 to Int-48 were synthesized in the same manner as intermediate Int-39c-1. Prepared using appropriate starting materials. [Table 6] TIFF0007595127000082.tif226170TIFF0007595127000083.tif125170
[0276] 17,20-difluoro-6-(propan-2-yl)-11,12-dihydro-2H, 10H-1,18-Ethenopyrido[4,3-e]pyrimido[1,6-g][1,7,9] Preparation of benzoxadiazacyclododecine-2,4(3H)-dione (Int-49d) [ka]
[0277] Step A: (3S)-4-(1-(4-(3-((tert-butyldimethylsilyl)oxy)methyl)methyl) 6-fluoro-7-(2-isopropyl)propyl-2-isopropylpyridin-3-yl (fluoro-6-hydroxyphenyl)-2-oxo-1,2-dihydropyrido[2,3-d ]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate tert-butyl ( Int-49a-1) (S)-4-(1-(4-(3 -((tert-butyldimethylsilyl)oxy)propyl)-2-isopropylpyridin benzo-3-yl)-7-chloro-6-fluoro-2-oxo-1,2-dihydropyrido[2 ,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid tert- Butyl (Int-43-1, 10.5 g, 15.2 mmol), potassium acetate (7.47 g, 76.0 mmol) and 1,1'-bis(diphenylphosphinoferrocene-para Stirring of dium(II) dichloride dichloromethane complex (0.62 g, 0.76 mmol) The solution was diluted with 3-fluoro-2-( Trifluoro-l4-boraneyl)phenol, potassium salt (4.98g, 22.8mm ol) was added at 90°C under N2 atmosphere, and the mixture was stirred at 90°C for 2 hours under N2 atmosphere. The reaction mixture was extracted with ethyl acetate (2 x 100 mL). Wash with ethanol (100 mL), dry over Na2SO4, filter, and evaporate the solvent under reduced pressure. The residue was purified by flash silica gel chromatography from 0 to 50% Purification by elution with EtOAc / petroleum ether gave (3S)-4-(1-(4-(3 -((tert-butyldimethylsilyl)oxy)propyl)-2-isopropylpyridin phenyl-3-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-2- Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpyridin Tert-butyl perazine-1-carboxylate (Int-49a-1) was obtained. MS (ES I) m / z 765 [M+H] + . Step B: (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl) )-1-(4-(3-hydroxypropyl)-2-isopropylpyridin-3-yl)- 2-Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methyl tert-Butyl 1-piperazine carboxylate (Int-49b-1) (3S)-4-(1-(4-(3-((tert-butyldimethyl (silyl)oxy)propyl)-2-isopropylpyridin-3-yl)-6-fluoro 2-(2-fluoro-6-hydroxyphenyl)-2-oxo-1,2-dihydropyridin Lido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylic acid TE A stirred solution of rt-butyl ether (Int-49a-1, 8.90 g, 11.6 mmol) was added to TBF. AF (34.9 mL, 34.9 mmol) (1 M in THF) was added and the mixture was stirred at 20°C. The mixture was stirred for 16 hours under N2 atmosphere. The residue was purified by flash silica gel chromatography. and purified using an eluent of 0 to 8% MeOH / DCM to give (3S)-4-( 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-(3-hydroxyphenyl)- (2-(2-hydroxypropyl)pyridin-3-yl)-2-oxo-1,2-dihydroxypropyl Dropirido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carbo tert-Butyl phosphate (Int-49b-1) was obtained. MS (ESI) m / z 651 M+H] + . Process C: Int-49c-1 (3S)-4-(6-fluoro-7-(2-fluoro-6-hydroxybenzoate) in THF (350 mL) hydroxyphenyl)-1-(4-(3-hydroxypropyl)-2-isopropylpyridin (3-phenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine-4- tert-Butyl)-3-methylpiperazine-1-carboxylate (Int-49b-1 To a stirred solution of triphenylphosphine (7.15 g, 27.3 mmol) was added and the mixture was stirred at 65 °C under N2 atmosphere, followed by DIA D (4.24 mL, 21.8 mmol) was added, and the reaction mixture was stirred at 65° C. for 10 minutes. The reaction mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography to give 0. Purification by elution with 10% to 10% CH2Cl2 / MeOH afforded Int-49c-1 MS(ESI)m / z 633[M+H] + . Step D: 17,20-difluoro-6-(propan-2-yl)-11,12-dihydro -2H,10H-1,18-ethenopyrido[4,3-e]pyrimido[1,6-g][1, 7,9]benzoxadiazacyclododecine-2,4(3H)-dione (Int-49d -1) Int-49c-1 (3.50 g, 5.53 mmol) was dissolved in MeOH (50 mL). Then, KOH (0.93 g, 16.6 mmol) was added to the mixture, and the mixture was heated to 40°C. The reaction mixture was stirred at 40°C for 15 hours. The mixture was cooled to room temperature and Quench with 1 mL of saturated ammonium chloride, dilute with 150 mL of EtOAc, and combine. The combined organics were washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography using 0 to 60% EtOAc. Purified with 17,20-difluoro-6-(propane-2 -yl)-11,12-dihydro-2H,10H-1,18-ethenopyrido[4,3-e ]pyrimido[1,6-g][1,7,9]benzoxadiazacyclododecine-2,4( 3H)-dione (Int-49d-1). MS (ESI) m / z 451 [M+H ] + .
[0278] Example 50: (5aS a ,17aR a )-20-chloro-2-[(2S,5R)-2,5 -Dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-14,17-difluoro Fluoro-6-(propan-2-yl)-11,12-dihydro-4H-1,18-(ethoxy)- (Benzylidene)pyrido[4,3-e]pyrimido[1,6-g][1,4,7,9]benzo Dioxadiazacyclododecin-4-one [ka]
[0279] Step A: N-((4-(2-((tert-butyldimethylsilyl)oxy)ethoxy) -2-isopropylpyridin-3-yl)carbamoyl)-2,5,6-trichloronicotinic acid Chinamide (Int-50a) 2,5,6-trichloronicotinamide (1.09 g, 4.83 mmol) was dissolved in 100 ml The reaction vessel was evacuated and a nitrogen balloon was used to add the solution. It was recharged three times. THF (4.83 mL) was added to the reaction vessel to dissolve the starting material. A 2M solution of oxalyl dichloride (2.90 mL, 5.80 mmol) was added dropwise to the reaction vessel. The resulting mixture was heated at 75°C for 1 hour. The intermediate solution was allowed to cool to room temperature. The resulting intermediate solution was concentrated to dryness. The resulting residue was dried under vacuum for 1 hour. The reactor was then purged with nitrogen. The reaction vessel was refilled with a balloon, and THF (10 mL) was added to the reaction vessel. was cooled to 0° C. In a separate 25 mL flask, 4-(2-((tert-butyl Dimethylsilyl)oxy)ethoxy)-2-isopropylpyridin-3-amine (Int -10f (1.50 g, 4.83 mmol) was dissolved in THF (9.3 mL). The amine solution was added dropwise to the reaction vessel, and the resulting mixture was stirred at 0°C for 1 hour. The reaction was carefully quenched by the addition of pH 7 buffer (10 mL). The resulting product mixture was extracted three times with ethyl acetate (3 x 20 mL). The organic layers were combined and The combined organic layer was dried over sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The resulting residue was purified by flash column chromatography on a silica gel column. First, 5% (ethyl acetate:ethanol, 3:1, v / v)-dichloromethane, linear gradient A gradient of (ethyl acetate:ethanol, 3:1, v / v)-dichloromethane up to 50% Purification was carried out by elution with N-((4-(2-((tert-butyldimethylsilyl)isopropyl)methyl)methylsilyl)methylsilyl ethoxy)-2-isopropylpyridin-3-yl)carbamoyl)-2,5,6 -trichloronicotinamide (Int-50a) was obtained. MS(ESI) m / z 563 [M+H] + . Process B: 5aS a -1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethoxy (2-isopropylpyridin-3-yl)-6,7-dichloropyrido[2,3- d] Pyrimidine-2,4(1H,3H)-dione (Int-50b-1) N-((4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2- Isopropylpyridin-3-yl)carbamoyl)-2,5,6-trichloronicotinic acid Add the amide (Int-50a, 2.00 g, 3.56 mmol) to a 100 mL flask. The reactor was evacuated and refilled with a nitrogen balloon three times. (7.1 mL) was added to the reaction vessel. The resulting mixture was cooled to 0°C. 1M THF solution of bis(trimethylsilyl)amide (7.12 mL, 7.12 mmol) The resulting mixture was stirred at 0°C for 30 minutes. The mixture was quenched with aqueous ammonium bicarbonate (25 mL). The mixture was extracted three times with ethyl acetate (3 x 100 mL). The organic layer was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to dryness. The resulting residue was purified by silica gel column chromatography. Flash column chromatography, initially hexane, linear gradient up to 66% Purified by elution with (ethyl acetate-ethanol=3:1 v / v)-hexane, and 1- (4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-isopropyl Pyridine-3-yl)-6,7-dichloropyrido[2,3-d]pyrimidine-2,4 The (1H,3H)-dione was obtained. The racemic material was purified by SFC column K, conditions: 0.1% NH Decomposition with MeOH containing 4OH yields peak 1 5aS a -1-(4-(2-((te rt-Butyldimethylsilyl)oxy)ethoxy)-2-isopropylpyridin-3-yl (1H,3H)-6,7-dichloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dichloropyrido[2,3-d]pyrimidine The compound (Int-50b-1) was obtained as a single conformer. 1 H-NMR (400 MHz) ,CDCl3)δ:8.62(d,J=5.6Hz,1H),8.50(s,1H), 6.87(d,J=6.0Hz,1H),4.06-4.09(m,2H),3.75- 3.79(m,2H),2.74-2.81(m,1H),1.23(d,J=5.2H z,3H),1.18(d,J=6.8Hz,3H),0.76(s,9H),0.07 (s,3H),0.11(s,3H). Step C: (2R,5S)-4-(1-(4-(2-((tert-butyldimethylsilyl )Oxy)ethoxy)-2-isopropylpyridin-3-yl)-6,7-dichloro-2 -oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-di tert-Butyl methylpiperazine-1-carboxylate (Int-50c-1) 5aS a -1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy )-2-Isopropylpyridin-3-yl)-6,7-dichloropyrido[2,3-d]pyridin Rimidine-2,4(1H,3H)-dione (Int-50b-1,800mg, 1.52 The reaction vessel was evacuated and nitrogen was introduced into a 20 mL vial. The mixture was refilled three times using a run. Acetonitrile (3.0 mL), N-ethyl-N-isothiazolinone (1.0 mL), Propylpropan-2-amine (407 μL, 2.28 mmol) and phosphoric acid trichloride The resulting mixture was heated to 80°C. Heat for 1 hour. Cool the product mixture to room temperature. Concentrate the cooled product mixture to dryness. The residue was dissolved in acetonitrile (3.04 mL) in a 20 mL vial. N-Ethyl-N-isopropylpropan-2-amine (812 μL, 4.56 mmol) and (2R,5S)-2,5-dimethylpiperazine-1-carboxylate tert-butyl (489 mg, 2.28 mmol) was added to the reaction vessel. The resulting mixture was stirred at 24°C for 1 The mixture was stirred for 1 hour. The product mixture was diluted with ethyl acetate (100 mL). The mixture was washed three times with saturated aqueous sodium bicarbonate (3 x 10 mL). The dried solution was filtered and the filtrate was concentrated to dryness. The residue was purified by flash column chromatography on a silica gel column, first with hexane, then with hexane, A gradient of 3:1 v / v ethyl acetate-hexane was used to obtain a 66% gradient. Purified by elution with (2R,5S)-4-(1-(4-(2-((tert-butyl Dimethylsilyl)oxy)ethoxy)-2-isopropylpyridin-3-yl)-6,7 -Dichloro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl )-2,5-dimethylpiperazine-1-carboxylate tert-butyl (Int-50c- 1) was obtained. 1 H-NMR(400MHz,DMSO-d6)δ:8.48(s,1H) ,8.43(s,1 H),7.07(d,J=5.6Hz,1H),4.75(s,1 H),4.34(s,1H),4.00-4.04(m,3H),3.95(s,1H) ,3.64-3.67(m,3H),2.63-2.69(m,1H),1.44(s, 9H),1.29(d,J=6.4Hz,3H),1.13(d,J=4.4Hz,3H ),1.07(d,J=6.8Hz,3H),1.02(d,J=6.4Hz,3H), 0.68(s,9H),0.17(s,6H). Step D: (2R,5S)-4-(1-(4-(2-((tert-butyldimethylsilyl )oxy)ethoxy)-2-isopropylpyridin-3-yl)-6-chloro-7-(3 ,6-difluoro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyrido[ 2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylic acid ert-Butyl (Int-50d-1) (2R,5S)-4-(1-(4-(2 -((tert-butyldimethylsilyl)oxy)ethoxy)-2-isopropylpyridin 2,3-diphenyl-3-yl)-6,7-dichloro-2-oxo-1,2-dihydropyrido[2,3-d ]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylic acid tert-butyl To a stirred solution of ethyl acetate (Int-50c-1, 12.0 g, 16.6 mmol), (6.53 g, 66.5 mmol) and [1,1'-bis(diphenylphosphino)fluorene] [Erocene]dichloropalladium(II) complex with dichloromethane (1.35 g, 1.6 6 mmol) was added at 25°C, and the mixture was stirred at 90°C for 5 minutes under a N2 atmosphere. Then, (3,6-difluoro-2-methyl ... -hydroxyphenyl) potassium trifluoroborate (Int-23c, 6.50 g, 2 7.5 mmol) was added to the above mixture, and the mixture was stirred at 90°C for 30 minutes. The mixture was quenched with brine (50 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, and After filtration, the solvent was evaporated under reduced pressure. The residue was purified by flash silica gel chromatography. Purification was carried out by elution with 0 to 100% EtOAc / petroleum ether ( 2R,5S)-4-(1-(4-(2-((tert-butyldimethylsilyl)oxy) Ethoxy)-2-isopropylpyridin-3-yl)-6-chloro-7-(3,6-difluoromethyl)-2-isopropylpyridin-3-yl (fluoro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyrido[2,3-d ]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylic acid tert-butyl Chill (Int-50d-1) was obtained. 1 H NMR (400MHz, methanol-d4) δ 8.44-8.32(m,2H),7.10(dt,J=5.3,9.7Hz,1H ),6.99(d,J=5.9Hz,1H),6.55(dt,J=3.4,8.8Hz ,1H),4.92-4.86(m,1H),4.59-4.38(m,2H),4.0 9-4.04(m,1H),4.00-3.93(m,1H),3.91-3.79(m ,2H),3.77-3.69(m,1H),3.68-3.61(m,1H),3.5 9-3.39(m,1H),2.93(td,J=6.5,13.3Hz,1H),1. 57-1.49(m,12H),1.36(d,J=6.8Hz,3H),1.23-1 .20(m,3H),1.07(d,J=6.6Hz,3H),0.78(s,9H), -0.11(d,J=5.6Hz,6H). Step E: (2R,5S)-4-(6-chloro-7-(3,6-difluoro-2-hydroxybenzoyl) (4-(2-hydroxyethoxy)-2-isopropylpyridine-3-phenyl) -yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl) tert-Butyl 2,5-dimethylpiperazine-1-carboxylate (Int-50e-1 ) (2R,5S)-4-(1-(4-(2-((tert-butyl))) in DCM (200 mL) (dimethylsilyl)oxy)ethoxy)-2-isopropylpyridin-3-yl)-6- Chloro-7-(3,6-difluoro-2-hydroxyphenyl)-2-oxo-1,2- Dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine- 1-tert-Butyl carboxylate (Int-50d-1, 17.0 g, 20.9 mmol) ) to a stirred solution of triethylamine trihydrofluoride (10.2 mL, 62.5 mmol) was added at 20° C. and the mixture was stirred at 20° C. for 2 hours. The reaction mixture was diluted with 300 mL of DCM and quenched with aqueous sodium bicarbonate (saturated, 200 mL) and dichloromethane. Extraction with methane (200 mL) was performed. The combined organic layers were washed with brine (200 mL). Dry over Na2SO4, filter, and evaporate the solvent under reduced pressure to give (2R,5S)- 4-(6-chloro-7-(3,6-difluoro-2-hydroxyphenyl)-1-(4- (2-hydroxyethoxy)-2-isopropylpyridin-3-yl)-2-oxo-1 ,2-Dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpipera tert-Butyl methyldiamine-1-carboxylate (Int-50e-1) was obtained. 1 H NMR( 400MHz, methanol-d4) δ 8.45-8.33(m,2H), 7.06(d t,J=5.4,9.7Hz,1H),7.00(d,J=5.9Hz,1H),6.5 8-6.39(m,1H),4.97-4.88(m,1H),4.55-4.31(m ,2H),4.17-4.08(m,1H),3.98(td,J=4.9,10.1H z,1H),3.94-3.79(m,2H),3.66-3.46(m,3H),2. 98-2.84(m,1H),1.51(s,12H),1.31(br d,J=6. 4Hz,3H),1.23-1.18(m,3H),1.07(d,J=6.8Hz,3 H). Process F:Int-50f-1 (2R,5S)-4-(6-chloro-7-(3,6-difluoromethyl)-2-(2-methyl-2-propanol)-2-one in DCM (750 mL) 1-(4-(2-hydroxyethoxy)-2-isopropyl)-2-isopropyl (pyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin tert-Butyl (I)-2,5-dimethylpiperazine-1-carboxylate nt-50e-1, 14.0 g, 20.0 mmol) and triphenylphosphine (1 To a stirred solution of DIAD (8.07 g, 39.9 mmol) The resulting mixture was stirred at 40°C for 30 minutes under a nitrogen atmosphere. The reaction mixture was concentrated in vacuo, and the residue was purified by flash silica gel chromatography to obtain a 0 to 0 Purification by elution with MeOH / DCM up to 0.5% gave Int-50f-1. 1 H NMR (400 MHz, methanol-d4) δ 8.41 (d, J = 5.9 Hz, 1 H),8.33(s,1H),7.30(ddd,J=5.1,9.4,11.0Hz, 1H),7.05(d,J=5.9Hz,1H),6.95(dt,J=3.5,8.8 Hz,1H),4.83-4.60(m,4H),4.59-4.45(m,1H),4 .39-4.28(m,1H),4.17-4.08(m,1H),3.87(d,J= 13.7Hz,1H),3.70-3.61(m,1H),3.51-3.33(m,1 H),3.10(td,J=6.9,13.5Hz,1H),1.60(br d,J= 5.9Hz,3H),1.52(br d,J=5.5Hz,9H),1.40(br d,J=6.3Hz,3H),1.29(d,J=7.0Hz,3H),1.05(d, J = 7.0 Hz, 3H). Process G:Int-50g-1 Int-50f-1 (11.0g, 16.1mmol) in CH2Cl2 (100mL) To the solution was added TFA (50 mL) and the mixture was stirred at 20° C. for 30 minutes. The residue was concentrated in vacuo to give Int-50g-1. MS (ESI) m / z 583 [M+H] + . Process H:(5aS a ,17aR a )-20-chloro-2-[(2S,5R)-2,5-di Methyl-4-(prop-2-enoyl)piperazin-1-yl]-14,17-difluoro 6-(propan-2-yl)-11,12-dihydro-4H-1,18-(ethanediyl)- Ylidene)pyrido[4,3-e]pyrimido[1,6-g][1,4,7,9]benzodioxide Hexadiazacyclododecin-4-one (Example 50) In CH2Cl2 (200mL) (Int-50g-1,16.4g,20.5mmol A stirred solution of acryloyl chloride (2 0.42 g, 26.7 mmol) was added dropwise and the mixture was stirred at 20° C. for 30 minutes. The mixture was washed with water (50 mL) and the aqueous layer was extracted with DCM (100 mL). The residue was diluted with 0 to 10% MeO. Flash silica gel chromatography using an eluent of OH / DCM followed by preparative HPLC (column: YMC Triart C18 250 mm * 50mm, 7μm; water ( 0.04% NH3H2O + 10 mM NH4HCO3) - MeOH Start B 25, End 60; Gradient time (min): 20; 100%B Retention time (min): 3; Flow rate (mL / min The product was purified by preparative SFC column E, conditions: 0.1% NH3·H2 O MeOH, start B 25%, end B 25%; flow rate (mL / min): 200; injector Further purification was performed by (5aS a ,17aR a )-20-chloro -2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazine -1-yl]-14,17-difluoro-6-(propan-2-yl)-11,12-di Hydro-4H-1,18-(ethanediylidene)pyrido[4,3-e]pyrimido[1,6 -g][1,4,7,9]benzodioxadiazacyclododecin-4-one (Example 50 ) was obtained as a single conformer. MS(ESI) m / z 637[M+H] + . 1 H NMR (500 MHz, methanol-d4) δ 8.41 (d, J = 5.8 Hz, 1H) ,8.33(d,J=17.9Hz,1H),7.30(ddd,J=5.1,9.4, 10.8Hz,1H),7.05(d,J=6.0Hz,1H),6.95(dt,J= 3.4,8.8Hz,1H),6.92-6.74(m,1H),6.34-6.25( m,1H),5.86-5.79(m,1H),5.06-4.88(m,1H),4. 83(br d,J=10.8Hz,1H),4.78-4.27(m,5H),4.1 8-4.09(m,1H),3.95-3.72(m,1H),3.66(br d,J =14.0Hz,1H),3.10(qd,J=6.8,10.5Hz,1H),1.5 9(br dd,J=7.0,9.2Hz,3H),1.47(dd,J=6.7,19 .2Hz,3H),1.29(d,J=6.7Hz,3H),1.05(dd,J=3. 4,6.8Hz,3H).
[0280] Example 51-1: (5aS a ,17aR a )-20-chloro-2-[(2S,5R)-2 ,5-Dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-14,17- Difluoro-6-(propan-2-yl)-11,12-di[( 2 H) Hydro] (11, 12- 2 H2)-4H-1,18-(ethanediylidene)pyrido[4,3-e]pyrimido [1,6-g][1,4,7,9]benzodioxadiazacyclododecin-4-one [ka]
[0281] Step A: N-((4-(2-((tert-butyldimethylsilyl)oxy)ethoxy- 1,1,2,2-d4)-2-isopropylpyridin-3-yl)carbamoyl)-2, 5,6-Trichloronicotinamide (Int-51a) 2,5,6-trichloronicotinamide (1.72 g, 7.63 mmol) was added to a reflux condenser. The reaction vessel was placed in a 100 mL round-bottom flask equipped with a condenser. The solution was evacuated and refilled three times with a nitrogen balloon. THF (7.6 mL) was added. A 2M solution of oxalyl dichloride (4.58 mL) was added to the reaction vessel to dissolve the starting material. , 9.16 mmol) was added dropwise to the reaction vessel, and the resulting mixture was heated at 75°C for 1 hour. The intermediate solution was allowed to cool to room temperature. The cooled intermediate solution was concentrated until its volume was reduced to half. THF (3.8 mL) was added to the reaction vessel, and the resulting mixture was cooled to 0°C. In a separate 20 mL vial, add 4-(2-((tert-butyldimethylsilyl)methyl)methyl)methylsilyl. oxy)ethoxy-1,1,2,2-d4)-2-isopropylpyridin-3-amine(I nt-35c (2.40 g, 7.63 mmol) was dissolved in THF (3.8 mL). The amine solution was added dropwise to the reaction vessel, and the resulting mixture was stirred at 0°C for 1 hour. The mixture was allowed to warm to room temperature. The warmed product mixture was diluted with 20 mL of pH 7 solution. The quenched product mixture was extracted three times with ethyl acetate (3 x 20 mL). The organic layers were combined and the combined organic layers were dried over sodium sulfate. The solution was filtered, and the filtrate was concentrated to dryness. The resulting residue was purified by flash filtration on a silica gel column. Column chromatography, initially 5% (ethyl acetate:ethanol, 3:1, v / v) -dichloromethane, linear gradient up to 50% (ethyl acetate:ethanol, 3:1, Purified by elution with (v / v)-dichloromethane, and N-((4-(2-((tert- Butyldimethylsilyl)oxy)ethoxy-1,1,2,2-d4)-2-isopropyl (Pyridin-3-yl)carbamoyl)-2,5,6-trichloronicotinamide (Int -51a) was obtained. MS(ESI) m / z 567[M+H] + . Step B: 1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy-1 ,1,2,2-d4)-2-isopropylpyridin-3-yl)-6,7-dichloropyridine Do[2,3-d]pyrimidine-2,4(1H,3H)-dione (Int-51b) N-((4-(2-((tert-butyldimethylsilyl)oxy)ethoxy-1,1 ,2,2-d4)-2-isopropylpyridin-3-yl)carbamoyl)-2,5,6 -Trichloronicotinamide (3.35 g, 5.92 mmol) was placed in a 100 mL flask. The reactor was evacuated and refilled with a nitrogen balloon three times. THF (11.8 mL) was added to the reaction vessel, and the resulting mixture was cooled to 0°C. 1M THF solution of sodium bis(trimethylsilyl)amide (11.8 mL, 11.8 m mol) was added dropwise to the reaction vessel. The resulting mixture was stirred at 0°C for 30 minutes. The mixture was quenched with saturated aqueous ammonium bicarbonate (25 mL). The residue was extracted three times with ethyl acetate (3 x 100 mL). The organic layer was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to dryness. The resulting residue was Flash column chromatography in hexane, initially with a linear gradient to 66% Purified by elution with a gradient of (ethyl acetate-ethanol = 3:1 v / v)-hexane and 1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy-1,1 ,2,2-d4)-2-isopropylpyridin-3-yl)-6,7-dichloropyridin [ 2,3-d]pyrimidine-2,4(1H,3H)-dione (Int-51b) was obtained. S(ESI) m / z 529[M+H] + . Step C: (2R,5S)-4-(1-(4-(2-((tert-butyldimethylsilyl )oxy)ethoxy-1,1,2,2-d4)-2-isopropylpyridin-3-yl) -6,7-dichloro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine- tert-Butyl (Int-4-yl)-2,5-dimethylpiperazine-1-carboxylate 51c) 1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy-1,1, 2,2-d4)-2-isopropylpyridin-3-yl)-6,7-dichloropyridin [2 ,3-d]pyrimidine-2,4(1H,3H)-dione (2.95 g, 5.57 mmol) ) was added to a 20 mL vial. The reaction vessel was evacuated and a nitrogen balloon was inserted. The column was recharged three times with acetonitrile (11.1 mL), N-ethyl-N-isopropyl Dipropan-2-amine (1.49 mL, 8.36 mmol) and phosphoryl trichloride ( 0.67 mL, 7.2 mmol) was added to the reaction vessel, and the resulting mixture was heated to 80°C for 1 hour. The resulting mixture was cooled to 0°C. Benzene-2-amine (2.98 mL, 16.7 mmol) and (2R,5S)-2,5-diamine tert-Butyl methylpiperazine-1-carboxylate (1.79 g, 8.36 mmol) was added to the reaction mixture, and the resulting mixture was stirred at 0° C. for 30 minutes. The diluted product mixture was diluted with saturated aqueous sodium bicarbonate (200 mL). The organic layer was washed three times (3 x 50 mL) with the solution. The organic layer was dried over sodium sulfate. The resulting solution was filtered, and the filtrate was concentrated to dryness. The resulting residue was then passed through an 80 g silica gel column. Flash column chromatography in DCM, initially with a linear gradient up to 50% The (2R,5S)- 4-(1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy-1, 1,2,2-d4)-2-isopropylpyridin-3-yl)-6,7-dichloro-2- Oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethyl tert-Butyl ethylpiperazine-1-carboxylate (Int-51c) was obtained. MS (E SI) m / z 725 [M+H] + . Step D: (2R,5S)-4-(6-chloro-7-(3,6-difluoro-2-hydroxybenzoyl) (4-(2-hydroxyethoxy-1,1,2,2-d4)-2-phenyl)- Isopropylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d] Pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylic acid tert-butyl Lu (Int-51d) (2R,5S)-4-(1-(4-(2-((tert-butyldimethylsilyl)oxy )Ethoxy-1,1,2,2-d4)-2-isopropylpyridin-3-yl)-6,7 -Dichloro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl )-2,5-dimethylpiperazine-1-carboxylate tert-butyl (1.00 g, 1. 38mmol), (3,6-difluoro-2-hydroxyphenyl)trifluoroboric acid Potassium (Int-23c, 0.421 g, 1.79 mmol), potassium acetate (0.5 40g, 5.51mmol), 1,1'-bis(diphenylphosphino)ferrocene- Radium(II) dichloride dichloromethane complex (0.113 g, 0.138 mmol) The solution was added to a 20 mL scintillation vial equipped with a magnetic stir bar and degassed under nitrogen. The mixture was degassed three times under nitrogen, and then dioxane (5.9 mL) / water (0.98 mL) was added. The reaction was heated to 90° C. for 1 hour. The reaction was cooled to 24° C. and 10 mL of 1:1 water / saturated fatty acid solution was added. Quench with sodium carbonate, extract with 2 x 25 mL of EtOAc, and wash with brine. The crude residue was dissolved in 10 mL of THF and treated with 1 M TBF in THF. An AF solution (3.44 mL, 3.44 mmol) was added, and the mixture was stirred at 24°C for 1.5 hours. The reaction was quenched with saturated NH4Cl, extracted once with EtOAc, and washed with brine. The extract was dried over sodium sulfate, filtered, concentrated in vacuo, and then washed with silica gel from 0 to 100%. The (2R,5S)-4-(6- Chloro-7-(3,6-difluoro-2-hydroxyphenyl)-1-(4-(2-hydroxyphenyl)- 2-isopropylpyridin-3-yl)-2-(2-isopropyl-2-ethoxyethoxy)-1,1,2,2-d4 -oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-di Methylpiperazine-1-carboxylate tert-butyl ester (Int-51d) was obtained. MS( ESI) m / z 705 [M+H] + . Process E:Int-51e (2R,5S)-4-(6-chloro-7-(3,6-difluoro-2-hydroxyphenyl) 1-(4-(2-hydroxyethoxy-1,1,2,2-d4)-2-isopropyl (pyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin tert-Butyl 2,5-dimethylpiperazine-1-carboxylate (80 2 mg, 1.14 mmol) was added to a 100 mL flask equipped with a reflux condenser. The reactor was evacuated and refilled with a nitrogen balloon three times. Toluene (4 5.5 mL) and cyanomethylenetributylphosphorane (1.0 M in toluene, 2.3 The resulting mixture was heated to 60°C for 24 hours. The product mixture was concentrated to dryness, and the resulting residue was flash-filtered on a silica gel column. Column chromatography, initially hexane, linear gradient to 100% ethyl acetate Purification by elution with ethanol:ethanol 3:1 gave Int-51e. ) m / z 687[M+H] + . Process F:Int-51f Int-51e (2.21 g, 0.322 mmol) was dissolved in DCM (3.2 mL) under nitrogen Trifluoroacetic acid (1.23 mL, 16.1 mmol) was added to the reaction vessel. The resulting mixture was stirred for 1 hour and the product mixture was concentrated to dryness. The resulting residue containing was used directly in the next step without purification.
[0282] Process G:(5aS a ,17aR a )-20-chloro-2-[(2S,5R)-2,5-di Methyl-4-(prop-2-enoyl)piperazin-1-yl]-14,17-difluoro 6-(propan-2-yl)-11,12-di[( 2 H)hydro](11,12- 2 H2)-4H-1,18-(ethanediylidene)pyrido[4,3-e]pyrimido[1,6 -g][1,4,7,9]benzodioxadiazacyclododecin-4-one (Example 51 -1) Int-51f (299 mg, 322 μmol) was added to a 20 mL vial. The resulting mixture was dissolved in DCM (1.6 mL). The resulting solution was cooled to 0°C. After cooling, N-ethyl-N-isopropylpropan-2-amine (287 μL, 1.61 HCl (39 μL, 0.48 mmol) and acryloyl chloride (39 μL, 0.48 mmol) were added to the reaction vessel. The reaction mixture was stirred at 0°C for 1 hour. The product mixture was dissolved in saturated aqueous ammonium bicarbonate solution. The resulting mixture was quenched with ethyl acetate three times (3×20 mL). The organic layer was dried over sodium sulfate. The dried solution was filtered and The liquid was concentrated to dryness. The racemic material was separated by SFC column G, conditions: containing 0.25% DMEA Decomposed with MeOH, peak 1 (5aS a ,17aR a )-20-chloro-2-[( 2S,5R)-2,5-Dimethyl-4-(prop-2-enoyl)piperazin-1-yl ]-14,17-difluoro-6-(propan-2-yl)-11,12-di[( 2 H) Hydro](11,12- 2 H2)-4H-1,18-(ethanediylidene)pyrido[4, 3-e]pyrimido[1,6-g][1,4,7,9]benzodioxadiazacyclododecyl Benzene-4-one (Example 51-1) was obtained as a single conformer. MS (ESI) m / z 641[M+H] + . 1 H NMR (500 MHz, DMSO-d6) δ 8.41 ( d,J=5.7Hz,1H),8.23(d,J=19.9Hz,1H),7.50(d dd,J=11.1,9.3,5.2Hz,1H),7.34-7.09(m,2H), 6.84(ddd,J=50.1,16.7,10.5Hz,1H),6.19(ddd ,J=16.8,8.1,2.4Hz,1H),5.76(ddd,J=10.4,4. 9,2.3Hz,1H),4.88(s,0.5H),4.74(s,0.5H),4. 69-4.49(m,2H),4.21(d,J=13.8Hz,0.5H),3.85 (d,J=14.1Hz,0.5H),3.77-3.58(m,0.5H),3.52 (t,J=15.8Hz,1H),3.25(dd,J=13.9,3.9Hz,0.5 ),3.05(q,J=6.4Hz,1H),1.46(t,J=7.8Hz,3H), 1.40-1.32(m,3H),1.17(dd,J=6.8,2.0Hz,3H), 0.98 (dd, J = 6.7, 4.1 Hz, 3H).
[0283] Example 52: (5aR a ,18aR a )-2-[(2S,5R)-2,5-dimethyl-4 -(prop-2-enoyl)piperazin-1-yl]-12,12,18,21-tetra Fluoro-6-(propan-2-yl)-10,11,12,13-tetrahydro-4H -1,19-(ethanediylidene)pyrido[4,3-f]pyrimido[1,6-h][1, 8,10]Benzoxadiazacyclotridecin-4-one [ka] TIFF0007595127000088.tif83158
[0284] Step A: 1-(benzyloxy)but-3-yn-2-ol (Int-52a) 2-(benzyloxy)acetaldehyde (6.20 g, 41.3 mmol) in 250 The reaction vessel was evacuated and a nitrogen balloon was used to add the solution. The reaction vessel was refilled three times with 103 mL of THF. The resulting mixture was then cooled to 0°C. Ethynylmagnesium bromide (0.50 M in THF, 100 mL, 49 The product mixture was added dropwise to a solution of saturated ammonium chloride and stirred at 0°C for 2 hours. The quenched product mixture was diluted with ethyl acetate and quenched with 30 mL of aqueous ethanol. The organic layer was dried over sodium sulfate, filtered, and The solution was concentrated to dryness, and the resulting residue was purified by flash column chromatography on a silica gel column. Elution with hexane initially, followed by a linear gradient to 30% ethyl acetate-hexane The product was purified by the method described above to give 1-(benzyloxy)but-3-yn-2-ol. -52a). 1 H NMR(500MHz,CDCl3):δ 7.41-7.28(m ,5H),4.69-4.58(m,2H),3.67(dd,J=9.8,3.6Hz ,1H),3.59(dd,J=9.8,7.1Hz,1H),2.46(d,J=2. 2Hz,1H). Step B: 1-(benzyloxy)but-3-yn-2-one (Int-52b) 1-(benzyloxy)but-3-yn-2-ol (Int-52a, 7.10 g, 40.3 mmol) in DCM (water saturated) (101 mL) in a 250 mL round-bottom flask Dess-Martin periodinane (20.5 g, 48.4 mmol) was dissolved in 5 The resulting mixture was stirred for 30 minutes. The diluted product mixture was diluted with saturated aqueous sodium bicarbonate (100 mL). solution (50 mL) and quenched with saturated aqueous sodium thiosulfate (50 mL). The quenched mixture was extracted three times with ether (3 x 100 mL). The organic layer was washed with sulfuric acid. The dried solution was filtered and the filtrate was concentrated to dryness. The resulting residue was purified by flash column chromatography on a silica gel column, first with hexane, Purify twice by eluting with a linear gradient of ethyl acetate-hexane up to 25% and (Benzyloxy)but-3-yn-2-one (Int-52b) was obtained. 1 H NMR (500MHz, CDCl3):δ 7.54-7.30(m,5H),4.67(s, 2H), 4.27(s,2H), 3.34(s,1H). Step C: 2,2-difluorobut-3-yn-1-yl)oxy)methyl)benzene (I nt-52c) Diethylamino(difluoro)sulfanium tetrafluoroborate (13.0g, (56.8 mmol) was added to a 100 mL plastic tube. Aqueous fluoride trihydrofluoride (12.3 mL, 76.0 mmol) was added to the reaction vessel. The mixture was stirred for 5 minutes. In a separate vial, 1-(benzyloxy)but-3-yl Int-52b (6.60 g, 37.9 mmol) in DCM (30 mL) The starting material solution was added dropwise to the reaction mixture using a plastic pipette. The reactor was rinsed twice with DCM (2 x 4 mL). The rinse was added to the reactor. The resulting mixture was stirred at 24°C for 16 hours. The product mixture was cooled to 0°C. Saturated aqueous sodium bicarbonate solution (10 mL) was added to the reaction vessel. The resulting two-phase mixture Drop into chilled (0°C) supersaturated sodium bicarbonate solution (100 mL + 20 g solid). The resulting mixture was stirred for 30 minutes. The resulting mixture was extracted three times with ether (3 x 200 mL). The organic layer was washed with sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to dryness. Two flash column chromatography runs on a gel column, first with hexane, followed by a linear gradient The product was purified by elution with a gradient of ethyl acetate-hexane up to 20% (((2,2- Difluorobut-3-yn-1-yl)oxy)methyl)benzene (Int-52c) Got it. 1 H NMR(500MHz,CDCl3):δ 7.52-7.30(m,5H ),4.74(s,2H),3.81(t,J=12.1Hz,2H),2.85(t, J=5.1Hz,1H). Step D: (E)-(4-(benzyloxy)-3,3-difluorobut-1-ene-1- Potassium trifluoroborate (Int-52d) 2,5-Dimethylhexa-2,4-diene (26.0 mL, 182 mmol) in 500 mL The reaction mixture was placed in a 100 mL round-bottom flask under nitrogen. THF (14.3 mL) was ad...
Claims
1. In the manufacture of a medicament for use in a method for treating cancer, 【Chemistry 1】 Use of a compound selected from the group consisting of: wherein the cancer is mediated by KRAS G12C mutation. The above uses.
2. The method of treating cancer further comprises administering to the subject an additional active agent; The use of claim 1 , wherein the further active agent is an anti-cancer agent.
3. The use of claim 2, wherein the anti-cancer agent is selected from an EGFR inhibitor, an anti-PD-1 agent, an SHP2 inhibitor, and an ERK inhibitor.
4. The use according to claim 3, wherein the anticancer drug is an EGFR inhibitor.
5. The use of claim 3, wherein the anti-cancer agent is an anti-PD-1 agent.
6. The use of claim 5, wherein the anti-PD-1 agent is pembrolizumab.
7. The use according to claim 3, wherein the anticancer agent is an SHP2 inhibitor.
8. The use according to claim 3, wherein the anti-cancer agent is an ERK inhibitor.
9. The use of claim 1 , wherein the cancer is selected from pancreatic cancer, colorectal cancer, and lung cancer.
10. The use according to claim 3, wherein the cancer is selected from pancreatic cancer, colorectal cancer, and lung cancer.
11. The use according to claim 1, wherein the subject is a human.
12. 12. The use according to claim 11, wherein the compound or a pharma- ceutically acceptable salt thereof is administered orally.
13. In the manufacture of a medicament for use in a method for treating cancer, 【Chemistry 2】 16. Use of a compound having the formula: wherein the cancer is mediated by KRAS G12C mutation.
14. In the manufacture of a medicament for use in a method for treating cancer, 【Chemistry 3】 16. Use of a compound having the formula: wherein the cancer is mediated by KRAS G12C mutation.
15. In the manufacture of a medicament for use in a method for treating cancer, 【Chemistry 4】 16. Use of a compound having the formula: wherein the cancer is mediated by KRAS G12C mutation.
16. In the manufacture of a medicament for use in a method for treating cancer, 【Chemistry 5】 16. Use of a compound having the formula: wherein the cancer is mediated by KRAS G12C mutation.
17. In the manufacture of a medicament for use in a method for treating cancer, 【Chemistry 6】 16. Use of a compound having the formula: wherein the cancer is mediated by KRAS G12C mutation.
18. In the manufacture of a medicament for use in a method for inhibiting KRAS G12C protein, 【Chemistry 7】 11. The use of a compound selected from the group consisting of:
19. The compound is 【Chemistry 8】 20. The use according to claim 18, wherein
20. The compound is 【Chemistry 9】 20. The use according to claim 18, wherein
21. The compound is 【Chemistry 10】 20. The use according to claim 18, wherein
22. The compound is 【Chemistry 11】 20. The use according to claim 18, wherein
23. The compound is 【Chemistry 12】 20. The use according to claim 18, wherein
24. 1. A pharmaceutical composition for use in treating cancer, comprising: 【Chemistry 13】 or a pharma- ceutically acceptable salt thereof, wherein the cancer is mediated by KRAS G12C mutation.
25. 1. A pharmaceutical composition for use in inhibiting a KRAS G12C protein, comprising: 【Chemistry 14】 A pharmaceutical composition comprising a compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
Citation Information
Patent Citations
Small molecule inhibitors of KRAS G12C mutations
JP2022553994A
Inhibitors of KRAS g12c mutant proteins
WO2018064510A1
KRAS g12c inhibitors and methods of using the same
WO2018119183A2
KRAS g12c inhibitors and methods of using the same
WO2018217651A1
KRAS g12c inhibitors and methods of using the same
WO2020050890A2
